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To identify determinants of clinical outcomes following primary percutaneous coronary 
intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI). 
Background: 
Although PPCI is currently the gold-standard guideline-indicated care for STEMI in the UK, 
factors associated with important clinical outcomes are still being explored and discovered. 
The purpose of this study and the analyses within this study, is to identify factors that were 
either previously unreported or variably reported. 
Methods: 
Baseline and procedural data of all consecutive patients undergoing PPCI between 01-01-
2009 and 31-12-2011, and between 01-01-2013 and 31-12-2013 in Leeds General Infirmary 
UK were collected prospectively in the West Yorkshire Primary Percutaneous Coronary 
Intervention (WY-PPCI) research and audit databases. Patients were followed up to a 
minimum of 12-months following index-PPCI. 
Five analyses were undertaken to assess the association between the following factors and 
clinical outcomes in PPCI: gender, ethnicity, P2Y12-receptor inhibitor, individual operator 
PPCI volume, glycoprotein IIb/IIIa inhibitor (GPI) use according to arterial access site. 
Multivariable analysis was undertaken to adjust for potential confounders. Clinical 
endpoints (depending on analyses) were: major adverse cardiovascular events (MACE; 
defined as all-cause mortality, myocardial infarction (MI), and repeat target and non-target 




Gender: Although women were older than men at presentation (median age 69 vs 60yr, p 
<0.01), mortality and MACE were not statistically significantly higher in women after 
stratification into age groups (<60, 60-79, and ≥80yr) alone, and also after multivariable 
analysis. Age was most strongly associated with adverse outcomes. 
Ethnicity: Univariable and multivariable analysis both revealed no significant differences in 
MACE and mortality between South Asian and White patients, despite South Asian patients 
being significantly younger than White patients. 
P2Y12-receptor inhibitor therapy: After multivariable analysis, both ticagrelor and prasugrel 
were associated with lower recurrent MI compared to clopidogrel. However, only prasugrel 
was associated with reduced mortality, both in comparison with clopidogrel and ticagrelor. 
There was no difference in bleeding between the three drugs. 
Annual operator PPCI volume: Low annual operator-volume (<55 PPCI cases per year) was 
independently associated with 30-day mortality compared to high operator-volume (≥110 
PPCI per year), suggesting a volume-outcome relationship at a significantly higher threshold 
than the AHA/ACC/SCAI recommendation of ≥11 PPCI cases per year. 
GPI-use: In transfemoral PPCI, GPI use was independently associated with higher 30-day 
bleeding (particularly access-site bleeding) and mortality compared to no GPI-use. In 





This study has identified important factors associated with outcomes following in the real-
world, in a large, contemporary “all-comers” registry. Analyses from this study should lead 
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1.1. Acute coronary syndrome 
Acute coronary syndrome (ACS) refers to the clinical spectrum describing acute coronary 
ischaemia – unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI) 
and the most severe end of this spectrum, ST-segment elevation myocardial infarction 
(STEMI). Myocardial infarction (MI) can be distinguished from UA by the presence of 
elevated levels of cardiac biomarkers (Troponin I or T).  
When this syndrome exists without ST-segment elevation on a 12-lead electrocardiogram 
(ECG), it is considered a NSTEMI. Acute cardiac ischaemic chest pains, with or without ST-
segment deviation, and with no elevation in plasma concentration of cardiac biomarkers 
(Troponin I or Troponin T), would constitute UA. 
 
1.1.1. Epidemiology 
Cardiovascular disease (CVD) is the leading cause of death worldwide. In 2012, 17.5 million 
people died from CVD, 7.4 million of whom died from coronary artery disease (CAD)1. In the 
United Kingdom (UK), CAD is the leading single cause of death, accounting for 15% of male 
deaths and 10% of female deaths in 2014, accounting for 69,000 deaths2. CAD was the most 
common cause of premature death in men (defined as individuals under the age of 75 
years), accounting for 16,800 (15%) deaths, while in women, CAD accounted for 5,500 (7%) 
premature deaths3. 
There has been a significant decline in death from CAD in the UK since 1975. In 1975, the 
age-standardised death rates for men and women from CAD were 668 and 337 deaths per 
100,000 population per annum respectively. This has improved steadily over the years, and 
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in 2013, the age-standardised death rates in men and women in the UK were 177 and 86 
deaths per 100,000 population respectively, accounting for a 73% improvement over this 
period of time. Similar improvements have been recorded in premature deaths secondary to 




Atherosclerosis refers to the presence of intimal plaques. These plaques are lipid-rich 
lesions covered by fibrous caps. Plaque rupture can then expose the necrotic core of these 
lipid-rich plaques, promoting platelet aggregation and activation, which in turn releases 
serotonin, thromboxane A2 and Adenosine Diphosphate (ADP) that can cause coronary 
vasospasm and further platelet aggregation4. Thrombus formation and distal embolization 
following coronary artery atherosclerotic plaque disruption can cause ACS5,6. STEMI typically 
occurs when a coronary vessel is completely occluded by thrombus. 
 
Ischaemia-driven myocardial cellular injury 
There are numerous mechanisms that contribute towards cellular damage in myocardial 
infarction4. Acute ischaemia causes a reduction of mitochondrial oxidative phosphorylation. 
This in turn leads to a reduction in Adenosine Triphosphate (ATP), which contains the high-
energy phosphate required for cellular metabolism. Plasma membrane sodium pumps are 
ATP-dependent. Therefore, a reduction in ATP causes intracellular sodium accumulation and 
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potassium efflux. This is accompanied by osmotic migration of water into the injured cell, 
causing cellular oedema.  
Reperfusion of ischaemic tissue can also cause cellular injury. Oxygen-dependent free 
radicals are generated from infiltrating leucocytes as well as endothelial and parenchymal 
cells. When reperfusion increases the amount of available oxygen, the concentration of 
free-radicals may increase. Another postulated mechanism involves the complement 
activation which can cause cellular injury, mediated by leucocyte influx. 
 
1.2 Diagnosis of STEMI 
STEMI can be characterised by the presence of ≥2mm ST-segment elevation in two or more 
contiguous chest leads, or ≥1mm ST-segment elevation in two or more contiguous limb 
leads, or presumed new left bundle branch block (LBBB) on a 12-lead electrocardiogram 
(ECG), in the context of acute cardiac ischaemic chest pain of at least 20 minutes in 
duration7. 
A variety of presentations have been described for patients presenting with STEMI. Patients 
typically present with central heavy or “crushing” chest pain, which can radiate to the jaw, 
arms or to the back. This is commonly accompanied by diaphoresis and nausea. In elderly 
patients, patients with diabetes mellitus and in patients with cognitive impairment, the 
symptoms at presentation are not always typical. In addition to atypical symptoms, diabetic 
patients are known to suffer with “silent MI”, which refers to the absence of chest pain, or 
other angina-equivalent symptoms during myocardial infarction. This is due to possible 
neuropathy affecting the transmission of cardiac pain signals. 
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1.3 Treatment of STEMI 
1.3.1. Non-invasive treatment of STEMI 
Since the 1970s, there has been a progressive evolution in the treatment of ACS. The role of 
acetyl-salicylic acid (aspirin) in the management of CAD gained prominence in the late 
1970s, with growing evidence suggesting improved outcomes in patients with CAD treated 
with aspirin rather than placebo8,9. Beta-adrenergic receptor blockers (beta-blockers) were 
then shown to be beneficial post-MI in both ISIS-1 and COMMIT10,11. The benefits of 
additional fibrinolytic therapy over standard therapy with aspirin alone were then described 
in key studies12,13. This formed the basis of the “old” treatment of myocardial infarction, 
with aspirin, beta-blockers, and the subsequent introduction of intravenous fibrinolysis. 
However, it was estimated that approximately 15%-50% of patients who received 
intravenous fibrinolysis did not achieve satisfactory reperfusion within 90 minutes of 
therapy13–16, which led to the assessment of emergency percutaneous coronary intervention 
(PCI), either following fibrinolysis (facilitated PCI) or without fibrinolysis (primary PCI (PPCI)) 
as superior options to fibrinolysis. 
 
1.3.2. Primary percutaneous coronary intervention 
PPCI refers to emergency balloon angioplasty (with or without coronary stent deployment) 
as the primary method of achieving reperfusion, without prior administration of fibrinolytic 
therapy. 
In March of 1993, two major studies were published in the New England Journal of 
Medicine, both showing immediate angioplasty to be advantageous over fibrinolysis. Zijlstra 
et al demonstrated with only 142 patients presenting with acute MI that immediate 
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coronary balloon angioplasty was superior to intravenous streptokinase in reducing 
recurrent ischaemia, residual stenosis and in improving left ventricular systolic function17. 
Grines et al showed that immediate coronary angioplasty reduced recurrent myocardial 
infarction and death, with mortality benefits particularly significant in the high-risk 
population (age over 70 years at presentation, anterior MI and heart rate of above 100 
beats per minute at presentation)18. 
In 2003, Keeley et al published their landmark meta-analysis comparing primary angioplasty 
with intravenous fibrinolysis, concluding that primary angioplasty was superior to 
intravenous fibrinolysis19. In 2008, the UK national roll-out for 24/7 PPCI commenced, with 
Leeds General Infirmary being one of the pilot sites. Since then, there has been a steady 
temporal rise in the uptake of PPCI in England, Wales and Northern Ireland. In 2011, 81% of 
patients presenting with STEMI received PPCI. This had increased to 98.4% of patients in 
201620. 
 
1.3.2.1. Evolution of technologies and techniques in PPCI 
There has been significant progress in technique and technology associated with PPCI. The 
main progress in technique has been the move from transfemoral PPCI to transradial PPCI, 
informed by several large studies, and subsequent reviews21–39. At the time of the national 
rollout of PPCI, transradial PCI was only undertaken in 34.7% of all PCI cases. By 2014, the 
proportion of patients undergoing transradial PCI had more than doubled to 75.3%40. 
There have been numerous advances in technology in PPCI. Stent technology has 
progressed rapidly over the last 9 years. In 2008, only 57% of patients underwent drug-
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eluting stent (DES) implantation. This had risen significantly over the following years to 
85.7% in 2014, signalling a shift from bare-metal-stent (BMS) implantation to DES 
implantation, driven by evidence of lower target vessel revascularisation and mortality in 
newer generation zotaralimus-eluting stents (ZES) and everolimus-eluting stents (EES) in 
comparison with BMS and older generation sirolimus-eluting stents (SES) and paclitaxel-
eluting stents (PES)41–45. 
Sirker et al showed from their analysis of data from the British Cardiovascular Intervention 
Society (BCIS) database that thrombus aspiration had increased in utilisation from 18% in 
2008 to 48% in 2013, following the publication of the TASTE and TAPAS trials46–48. However, 
their analysis revealed no significant advantages in the utilisation of thrombus aspiration 
over PCI alone. Their study was published soon after the TOTAL trial which also had shown 
no significant reduction in primary endpoints with routine thrombus aspiration, with a 
paradoxical rise in the risk of stroke noted in the thrombus aspiration group49. The effect of 
these two studies showing no significant benefit with a possible increased risk of stroke with 
thrombus aspiration on current practice has yet to be determined, but it is possible that the 
use of thrombus aspiration may have reduced since the publication of these studies. 
1.3.2.2. Factors influencing clinical outcomes following PPCI 
Traditional risk factors for CAD that can influence outcomes following PPCI include arterial 
hypertension, elevated low-density lipoprotein (LDL) and total cholesterol levels, low high-
density lipoprotein (HDL) levels, cigarette smoking, advancing age, diabetes mellitus, family 
history of premature coronary artery disease and central obesity 50–55. Other well-
established predictors of adverse outcomes following PPCI include increasing age at 
presentation, femoral artery access instead of radial artery access, cardiogenic shock, pre-
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procedural cardiac arrest, renal dysfunction, balloon angioplasty (with no stent), bleeding, 
morbidity (with advanced Charlson Comorbidity Index (CCI)), and unprotected left-main 
coronary artery intervention56–58.  
1.3.2.3. Other factors associated with outcomes following PPCI 
Whilst some of the aforementioned risk factors are also established predictors of poor 
outcomes following PPCI, other less-established factors have been proposed as predictors of 
poor clinical outcomes following PPCI, with conflicting evidence presented over the last two 
decades. The examination and the report of the association of these less frequently-
reported factors, which are outlined in the following sections, form the basis of this thesis. 
Identification and clarification of factors that can influence or are associated with improved 
or adverse outcomes following PPCI could potentially improve the service provided, if 







Although data pertaining to the influence of gender on clinical outcomes following PPCI have 
been published in the past, data of patients undergoing PPCI in the contemporary era of PPCI 
are limited. The progress in technique, pharmacotherapy and in equipment in PPCI, along 
with progress in secondary prevention therapy could have all further contributed to improved 
clinical outcomes following PPCI in relation to gender. Studies over the last two decades have 
reported increased risk of major adverse cardiovascular events (MACE) and mortality in 
women compared to men in PPCI59–64. However, it remains unclear whether there are true 
sex-related differences in therapeutic efficacy of PPCI, or if differences in baseline 
characteristics, especially age, and differences in treatment received contribute to poorer 
outcomes observed in women60,64–74. 
Earlier studies had indicated that gender was an independent predictor of poor clinical 
outcomes following PPCI59–64,68,70,75. However, other studies have shown that adjustment for 
confounding factors eliminates this excess risk in women. Studies comparing outcomes 
following PPCI in men and women have found that women present at an older age 
compared to men60,61,63,67–71,73–79. This is likely to be due to the cardio-protective effects of 
endogenous oestrogen80. However these studies also highlighted the fact that along with 
age at presentation with STEMI, women were more likely to have systemic hypertension, 
which has been shown to confer a higher hazard ratio for CAD in women compared to 
men81. There were also numerous procedural biases that favoured men. Pre-hospital and/or 
in-hospital delays to reperfusion, known predictors of adverse clinical outcomes following 
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STEMI, were more pronounced in women in most of these studies82–87. Women were less 
likely to undergo transradial PPCI, which has been shown to be superior to transfemoral 
PPCI by reducing major bleeding and all-cause mortality39,88,89. Women were also less likely 
to receive glycoprotein IIb/IIIa inhibitors (GPI) although the reason for this could be their 
lower pre-procedural TIMI 0 flow in the infarct-related artery (IRA). Other proposed 
confounders were reduced body surface area, coronary artery diameter and renal 
function63. 
1.4.1.2. Literature review strategy 
Literature search of articles between 1st of January 2000 and 30th of September 2016 was 
conducted using PubMed in September 2016, and then repeated in July 2017 to include 
studies published between 30th of September 2016 and 16th of July 2017. The following 
search of titles and abstracts on PubMed: “((((((((gender) OR sex) OR female) OR male)) AND 
((((outcomes) OR mortality) OR survival) OR death)) AND ((((primary percutaneous coronary 
intervention) OR primary PCI) OR emergency coronary angioplasty) OR primary transluminal 
coronary angioplasty))) AND ((((((ST segment elevation myocardial infarction) OR ST 
elevation myocardial infarction) OR STEMI) OR ST segment elevation acute coronary 
syndrome) OR ST elevation acute coronary syndrome) OR Acute myocardial infarction)” 
returned 4176 studies. Review of titles of these studies, followed by abstracts if the titles 
included the following terms: (gender/sex/female/male) and (myocardial infarction and/or 
percutaneous coronary intervention and/or angioplasty), were undertaken. This strategy 
revealed 17 studies that were relevant (published in English, in full-text, which included 




1.4.1.2.1. Review of relevant studies 
In their analysis of 109,708 patients (male: n=74,137; female: n=35,571) whom underwent 
PCI for all indications between January 1994 and January 1998, Petersen et al found that 
although unadjusted procedural mortality was higher for women (1.8% vs 1.0%, p<0.001), 
adjustment for baseline risk factors eliminated the excess risk in women (Odds Ratio (OR) 
1.07 (95% Confidence interval (CI) 0.92-1.24))71. They concluded that body-surface area 
(BSA) was a more important predictor of clinical outcomes following PCI compared to 
gender, showing a direct relationship between increasing BSA and survival following PCI. 
However, mortality data for this study was limited to in-hospital mortality. Importantly also, 
the data from this study describe outcomes in all PCI, not specifically PPCI for STEMI. This 
study also predated the routine use of intracoronary stents, and secondary prevention with 
DAPT. 
Vakili et al then published data of all patients (n=1044; male: n=727; female: n=317) 
undergoing PPCI for STEMI in New York State in 199559. In their analysis, both unadjusted 
(7.9% vs 2.3%, p<0.001) and adjusted (for age, hypertension, diabetes mellitus, peripheral or 
cerebrovascular disease, cardiogenic shock or haemodynamic instability and time to 
treatment – all of which were significantly different between genders) in-hospital mortality 
(OR 2.33 (95% CI 1.20-4.60)) was higher in women compared to men. Once again, patients 
in this study underwent PCI at a time that preceded the routine use of intracoronary stents 
or secondary prevention with DAPT. Abrupt vessel closure occurred in 4% of women and 2% 
of men, which is significantly higher than patients undergoing PPCI in the contemporary era, 
since the routine use of intracoronary stents in PPCI was advocated. 
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Conversely, in 2002, Mehilli et al published one-year mortality of 1937 patients (male: 
n=1435; female: n=502) who underwent PCI for STEMI in a single tertiary referral centre 
between 1995 and 2000 in Germany90. Although unadjusted mortality (Hazard Ratio (HR) 
1.06 (95% CI 0.80-1.39); p=0.70) was not significantly different in women, after adjustment 
for potential confounding factors (age, hypertension, diabetes mellitus, smoking, previous 
MI, previous coronary artery bypass grafting (CABG), previous PCI, anterior MI, and time to 
admission), women actually had lower mortality compared to men (HR 0.67 (95% CI 0.50-
0.91); p=0.01). They concluded that if treatment (both acute and secondary prevention) 
between genders did not vary, clinical outcomes in women were not adverse compared to 
men, and when further adjusted for baseline characteristics, the female sex was an 
independent predictor of lower one-year mortality. 
Cheng et al published 30-day mortality from their single-centre analysis of 1032 patients 
(male: n= 874; female: n=158) who underwent PPCI for STEMI between May 1993 and April 
200267. In their study, unadjusted mortality was almost two-fold (14.6% vs 7.4%; p<0.01) in 
women. However, adjustment for age and other variables (not specified) revealed no 
statistically significant difference in mortality between women and men (OR 1.06 (95% CI 
0.53-2.14)). Reperfusion time was significantly longer in women in their study, and the 
effect of this was observed in the presence of New York Heart Association (NYHA) III-IV 
heart failure in 29.1% of women compared to 18.5% of men, and in the presence of 
myocardial free wall rupture (3.80% in women vs 0.23% in men). However, it was not clear if 
this was adjusted for in their analysis. Only 50% of patients in their study received stents, 
and P2Y12 receptor inhibitor therapy was only given up to two weeks post-PPCI. These 
factors have progressed significantly since and it is possible that outcomes could be 
different with higher stent usage and better secondary prevention. 
29 
 
In 2007, Milcent et al published their analysis of data of 74389 patients hospitalised for AMI 
in France in 1999, concluding that both unadjusted (OR 1.37 (95% CI 1.30-1.46)) and 
adjusted (OR 2.65 (95% CI 2.52-2.79)) in-hospital mortality were higher in women compared 
to men91. However, there was a significant disparity between the treatment received by 
men and women, with men more likely to undergo interventional procedures (which as a 
factor, was independently associated with lower mortality in their study), and when the 
expected probability of death was re-calculated assuming equal treatment strategies, excess 
mortality was no longer significant in women. However, this is unlikely to be a significant 
factor at present time, which has seen the rapid growth and acceptance of PPCI as the 
default treatment for STEMI, with approximately 99% of patients with STEMI receiving PPCI 
as their main strategy of treatment in England20. 
Analysis of data from 20,290 patients (male: n=14657; female: n=5633) from the AMI Plus 
registry in Switzerland, that included patients who were admitted with ACS between 1997 
and 2006 once again showed higher unadjusted in-hospital mortality in women (10.7% vs 
6.3%; p<0.001)61. However, this study, in keeping with most prior studies, showed that after 
adjustment for confounders, women were not significantly more likely to have in-hospital 
mortality compared to men (OR 1.09 (95% CI 0.95-1.25)). They were however, 
independently less likely to undergo PCI (OR 0.67 (95% CI 0.64-0.76)), suggesting a 
treatment bias favouring men. This, once again, is unlikely to be a significant factor at 
present time in the UK with PPCI being the default guideline-recommended therapy for all 
patients with STEMI. 
In 2008, Jneid et al published data from 78,254 patients (male: n=47556; female: n=30698) 
who were diagnosed with AMI across 420 American hospitals between 2001 and 200660. In 
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their STEMI subgroup (male: n=25353; female: n=16694), unadjusted analyses revealed 
significantly higher in-hospital mortality in women (10.5% vs 5.5%). In contrast with previous 
studies, adjustment for baseline characteristics did not eliminate excess mortality in women 
(OR 1.12 (95% CI 1.02-1.23)). However, significant differences were observed in the 
treatment received by women in comparison to men. Women had longer time to 
reperfusion compared to men, were 23% less likely to receive any reperfusion compared to 
men, and were also less likely to receive aspirin and beta-blocker therapy compared to men. 
These factors, however, were not adjusted for, and the differences observed in outcomes 
were likely to be due to the differences in treatment received between genders, rather than 
gender itself contributing to poor outcomes following STEMI. 
Berger et al published their analysis of 102004 patients (male: n=75972; female: n=26032) 
with STEMI from 11 ACS trials78. Although these were not real-world data, it was important 
to note that their findings were in keeping with prior real-world registry studies, showing an 
increase in unadjusted mortality in women (OR 1.15 (95% CI 1.06-1.24)) compared to men. 
However, as with most observational studies, once baseline characteristics and in addition, 
angiographic disease severity were adjusted for, mortality was no longer statistically 
significantly different between genders. As this was a pooled analysis of RCT data, treatment 
differences between genders were unlikely. This further contributed to the opinion that 
female gender per se was not an independent predictor of adverse outcomes. 
In 2009, data analysed from the American College of Cardiology – National Cardiovascular 
Data Registry (ACC-NCDR), of 42038 patients (male: n=29703; female: n=12335) who 
underwent PPCI for STEMI revealed higher unadjusted mortality (2.2% vs 1.4%) in women64. 
However, as with most prior observational studies, risk-adjusted mortality was not 
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significantly higher in women compared to men (OR 0.97 (95% CI 0.88-1.07)), despite other 
adverse post-PCI outcomes (cardiogenic shock and bleeding) being significantly higher in 
women. Once again, there were differences in treatment given to women, as women were 
noted to have lower rates of stent implantation or and were less likely to have been 
discharged on aspirin and statin at compared to men. These differences were not adjusted 
for. Interestingly, despite that, mortality was not statistically significantly different between 
genders; suggesting, once again, that gender per se was not an independent predictor of 
mortality. 
In 2010, Sjauw et al reported data from their analysis of 3277 consecutive patients (male: 
n=2367; female n=910) who underwent PPCI for STEMI between 1995 and 200692. 
Unadjusted 30-day (9.2% vs 8.1%), 12-month (10.5% vs. 12.2%), and three-year (13.8% vs. 
15.6%) mortality were not statistically significantly higher in women. They had found that 
30-day (HR 1.09 (95% CI 0.77-1-53)), 12-month (HR 1.03 (95% CI 3.76*(presumably 0.76)-
1.34) and 3-year (HR 1.10 (95% CI 0.76-1.49)) risk-adjusted mortality were also not 
statistically significantly different between genders despite longer onset-of-symptom to call-
time, further adding to the evidence-base that the female gender in itself is not an 
independent predictor of mortality. 
Duvernoy et al analysed outcomes in 8771 patients (male: n=6229; female: n=2542) 
undergoing PPCI for STEMI in multiple centres in Michigan, USA between 2003 and 200879. 
Once again, despite observing higher unadjusted in-hospital mortality in women compared 
to men (OR 1.79 (95% CI 1.45-2.22)), when propensity-matched, despite higher rates of 
vascular complications and blood transfusions, women did not have significantly higher 
mortality compared to men (OR 1.30 (95% CI 0.98-1.72)). Prior to that, they presented their 
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analysis of 22725 patients (male: n=14848; female: n=7877) who underwent PCI for all 
indications between 2002 and 200363. Although data specific to PPCI were not presented 
then, they found that when adjusted for differences in baseline characteristics (excluding 
BSA and renal function), women had higher post-PCI mortality (OR 1.52 (95% CI 1.16-2.01)) 
compared to men. However, when BSA and renal function were corrected for in addition to 
other baseline characteristics, mortality in women was not significantly higher compared to 
men (OR 1.25 (95% CI 0.90-1.74)). This is despite significant differences in secondary 
prevention that were not corrected for (women were less likely to receive aspirin, statin, 
ACE-inhibitors and beta-adrenergic receptor blockers). They therefore concluded that 
baseline renal function and BSA contributed to differences in outcomes observed between 
genders. 
Benamer et al analysed data from 16760 patients (male: n=13096; female: n=3664) in Paris 
who were treated with PCI for STEMI within 24-hours of onset68. They found that when 
adjusted for age, diabetes mellitus, cardiogenic shock, left main stem PCI, and number of 
diseased coronary arteries, female gender was independently associated with adverse 
outcomes (OR 1.38 (95% CI 1.16-1.63)). However, unlike other studies, other risk factors 
(prior MI, renal function, prior coronary revascularisation, hypertension, prior stroke or 
peripheral vascular disease) were not presented or corrected for. Differences in secondary 
prevention were also not presented. These factors could all have contributed to differences 
in outcomes observed between genders in their analysis. 
A smaller analysis of 240 patients (male: n = 181; female n = 59) who underwent PPCI for 
STEMI between 2002 and 2004 in Turin, Italy, revealed significantly higher rate of 
unadjusted death (20.0% vs 8.1%; p=0.029)76. They also concluded that when adjusted for 
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confounders, the female sex was still associated with a significantly higher rate of death 
compared to the male sex. However, if their rates of death were 12 females (20% of 59 
patients) and 15 males (8.1% of 181 patients), it is unlikely that adequate multivariable 
adjustment would have been conducted. Therefore, it is quite likely that the difference 
observed in adjusted mortality is likely to be more aligned with the unadjusted difference 
quoted. 
In 2013, Wijnbergen et al presented 2-year outcome data of 870 patients (male: n=668; 
female: n=202) who underwent PPCI for STEMI between 2006 and 2008 in Eindhoven, The 
Netherlands93. As with previous studies, women had significantly more adverse risk-factor 
profiles compared to men. Unadjusted death was lower in men (Relative risk (RR) 0.31 (95% 
CI 0.16-0.62)). However, when adjusted for age, hypertension, smoking status, diameter of 
stent, and time to reperfusion, men no longer had lower mortality compared to women (HR 
0.69 (95% CI 0.30-1.59)), a finding that was in keeping with  other studies published prior to 
theirs. 
More recently, in 2013, Otten et al presented their analysis of 6746 patients (male: n=4991; 
female: n=1755) who underwent PPCI for STEMI between 1998 and 2008 in The 
Netherlands70. Data were analysed according to age (<65 years vs ≥65 years), and gender. 
Variables included in their Cox Proportional Hazards (Cox PH) models were age, 
hypertension, Killip class and multivessel disease. However, time to reperfusion was not 
corrected for despite being significantly longer in women (218 minutes vs 200 minutes in 
patients under 65; 237 minutes vs 220 minutes in patients aged 65 and over; p<0.01 for 
both), and neither were history of cigarette-smoking and family history of CAD, both of 
which were significantly higher in women.  They had found that unadjusted 30-day death 
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was higher in women in both age groups compared to men. Unadjusted one-year death was 
higher in women under 65 years of age, but was not significantly higher in the older age 
group. However, in contrast with other previous studies, it was found that younger women 
had higher adjusted one-year mortality compared to men (HR 1.687 (95% CI 1.108-2.569)). 
It is important to note that renal function was not presented or corrected for, and ACE-
inhibitor therapy (which is prognostically important following MI) was lower in women at 1 
year (49% vs 53%; p=0.05). It is possible that differences in baseline characteristics that 
were not presented and in post-MI care (as reflected by lower use of ACE-inhibitors) could 
account for the difference in adjusted one-year mortality in younger women. 
Birkemeyer et al published their analysis of 1104 patients (male: n=823; women: n=281) 
who underwent PPCI for STEMI in two STEMI networks in Germany between 2001 and 2003 
(network 1), and between 2005 and 2007 (network 2)94. Unadjusted 12-month mortality 
was significantly higher in women (14.9% vs 6.9%; p<0.01). However, propensity-matched, 
multivariable adjustment revealed no significant difference in mortality (OR 1.13 (95% CI 
0.61-2.11)) despite lower use of aspirin, clopidogrel, beta-adrenergic receptor blocker and 
lipid-lowering therapy at discharge in women (p≤0.05 for all medications). 
Most recently, Brogan et al presented 5-year mortality data for all patients undergoing PPCI 
for STEMI in England and Wales between 2005 and 2013 (n=88188; male: n=65178)56. Their 
survival analysis was based on expected survival of comparable UK population, rather than 
using patients within the PPCI groups as their denominators, and were quoted as excess 
mortality risk ratio (EMRR). They found that females had a higher ongoing risk of mortality 
(EMRR 1.33 (95% CI 1.26-1.41)), suggesting mode of presentation, differences in secondary 
prevention and multimorbidity as potential causes for the differences noted. However, 
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differences in access sites, medications, stent use, time to reperfusion, age and other 
baseline characteristics according to gender were not presented for each group, and rather, 
some of these factors were presented for the entire cohort of patients. These could all 
account for differences observed in long-term outcomes. 
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Table 1.1: Summary of studies examining the association between gender and outcomes in PPCI. 
Authors Study design Country Data-collection 
years 









Adjusted ORb 1.07 (95% CIf 0.92-1.24) 
in women. 
Body surface area more important 
predictor of outcomes compared to 
gender. 




Adjusted ORb 2.33 (95% CI 1.20-4.60) 
in women. 
Mehilli et al90 Observational Germany 1995-2000 1937 1435 502 Cox regression 12-month 
mortality 
Adjusted HRc 0.67 (95% CI 0.50-0.91) 
in women. 




Adjusted ORb 1.06 (95% CI 0.53-2.14) 
in women. 




Adjusted ORb 2.65 (95% CI.52-2.79) in 
women, but women received less 
invasive procedures compared to 
men – not matched or adjusted for.  
Radovanovic 
et al61 




Adjusted ORb 1.09 (95% CI 0.95-1.25) 
in women. 




Adjusted ORb 1.12 (95% CI 1.02-1.23) 
in women with significant disparity in 
treatment received (not adjusted for). 
Berger et al78 Collated RCT
d 
data 




Adjusted ORb 1.23 (95% CI 0.96-1.57) 
in women, once angiographically 
matched. 




Adjusted ORb 0.97 (95% CI 0.88-1.07) 
in women. 
Sjauw et al92 Observational The 
Netherlands 




Adjusted HRc in women: 
30-day – 1.09 (95% CI 0.77-1-53). 
12-month – 1.03 (95% CI 0.76-1.34). 
3-year – 1.10 (95% CI 0.76-1.49). 
Duvernoy et 
al79 














Adjusted ORb 1.38 (95% CI 1.16-1.63) 
in women; significant risk factors and 
differences in treatment not 
presented or adjusted for. 
D’Ascenzo et 
al76 
Observational Italy 2002-2004 240 181 59 Not described 53-58 
months 
No exact ORb/HRc given, but stated 
that there was a difference in 






2006-2008 870 668 202 Cox regression 2-years Adjusted HRc 0.69 (95% CI 0.30-1.59) 
in women. 
Otten et al70 Observational The 
Netherlands 
1998-2008 6746 4991 1755 Cox regression 12-month 
mortality 
Adjusted HRc 1.687 (95% CI 1.108-
2.569) in women <65 years. Adjusted 
HRc 1.022 (95% CI 0.762-1.370) in 
women ≥65 years. Time to 
reperfusion not corrected for despite 
being longer in women. 
Birkemeyer et 
al94 
Observational Germany 2001-2003; 
2005-2007 




Adjusted ORb 1.13 (95% CI 0.61-2.11) 
in women. 









EMRRe 1.33 (95% CI 1.26-1.41) in 
women; secondary prevention and 
other co-morbidities not adjusted for. 
aPCI: Percutaneous coronary intervention;  bOR: Odds ratio;  cHR: Hazard ratio;  dRCT: Randomised controlled trial;  eEMRR: Excess mortality  




All but two of the relevant studies identified were derived from observational data from 
“all-comers” registries. Only one of these studies, by Brogan et al, included patients who 
underwent PPCI after 2008, which was when PPCI was rolled out nationally in the UK56. 
Most of these studies were spread over a long period of time, one of which by Berger et al 
involved patients whom underwent PPCI between 1993 and 200678. Most studies involved 
patients undergoing PPCI both before and after the landmark publication by Keeley et al 
showing that PPCI was superior to fibrinolysis in the treatment of STEMI19. 
All of the studies identified employed multivariable analysis to adjust for confounding 
variables. This was mainly undertaken with logistic regression analysis, although four of the 
studies employed Cox regression analysis. The reason behind employing logistic regression 
over Cox regression in these studies were unclear, but it was noted that the largest dataset 
to employ Cox regression involved analysis of 6746 patients. Larger datasets could have 
presented significant difficulties in satisfying proportional hazards assumptions, and this 
could have led to the use of logistic regression analysis. This is especially important 
considering the fact that in all of these studies, women were older at presentation, were 
more likely to be hypertensive and were subjected to longer time to reperfusion. Some 
studies also identified significant differences in treatment strategy and secondary 
prevention in women. However, these important differences that included differences in 
prescription of aspirin, P2Y12-receptor inhibitor therapy, statins, beta-adrenergic receptor 
blockers and ACE-inhibitors, were in most studies, not adjusted for. These may reflect the 
difference in morbidity between men and women at presentation, but treatment bias 
cannot be excluded. Time to reperfusion was also significantly longer in women in most of 
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these studies. Time to reperfusion has been shown to be an important predictor of infarct 
size and mortality, and it has been shown to be longer in women95. Whilst some of these 
delays were due to longer symptom-onset-to-call-for-help time (patient delay), differences 
were also noted in call-to-reperfusion time, suggesting gender differences in time to 
reperfusion within the STEMI pathway. Whilst patient delay may be an important factor in 
explaining the differences in symptom-onset-to-balloon time (total ischaemic time), 
including this variable in a regression model may not necessarily be appropriate, as possible 
differences in characterisation of symptoms and pain thresholds may be inherently different 
between genders, and as such, may be consequences of differences in genders rather than 
confounders. 
In terms of outcomes, only two studies, by Mehilli et al and Sjauw et al, revealed no 
difference in unadjusted mortality between men and women following PPCI90,92. All other 
relevant studies showed significant differences in unadjusted outcomes in women 
compared to men. Most of the studies also showed that once baseline characteristics had 
been adjusted for by multivariable analysis, mortality was no longer different between 
genders. This is despite significant disparity in secondary prevention between genders that 
was not adjusted for. The most recent of the studies identified, by Otten et al and by Brogan 
et al, suggested that adjusted differences in outcomes exist between men and women. 
Otten et al concluded that women <65 years of age had more adverse outcomes compared 
to men <65 years of age, and Brogan et al concluded that although adjusted outcomes may 
differ between men and women, they could be related to differences in morbidity and 
secondary prevention, rather than the acute treatment of STEMI. 
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Considering the heterogeneity in outcomes noted between genders, and the fact that only 
one of these studies were undertaken following the UK national roll-out of PPCI for the 
treatment of STEMI, the association between gender and outcomes following PPCI in STEMI 




South Asian individuals made up 7.5% of the population in England and Wales in the 2011 
national census96. They are known to have a higher prevalence of insulin resistance and 
diabetes mellitus compared to other ethnic groups97. This is thought to be due to a 
combination of factors. Higher levels of carbohydrate consumption in South Asian 
individuals is thought to be a contributing factor to their higher prevalence of diabetes 
mellitus97. However, they are also known to have altered levels of adipokines and pro-
diabetic inflammatory mediators compared to White individuals98–108. In addition to their 
higher prevalence of diabetes mellitus, South Asian patients also have a higher prevalence 
of systemic hypertension, hypercholesterolaemia and pre-existing CAD at presentation with 
STEMI, despite their younger age at presentation2,104,105,109–111. In most of these studies, 
South Asians were however, less likely to be cigarette smokers. Due to their adverse risk-
factor profile, South Asian patients tend to present at an earlier age with 
CAD2,98,102,105,106,109,112–116. When they undergo coronary revascularisation, either 
percutaneous or surgical, MACE has been reported to be higher in this group, despite their 
younger age at presentation105,109. However, more recent studies suggested that once CAD 
is manifest, South Asian patients have lower mortality compared to White patients, with age 
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at presentation playing a key role2,117. The wide variability in outcomes reported in studies, 
of which only one included patients who underwent PPCI following the UK roll-out in 2008, 
suggests further investigation into this association is required. 
1.4.2.2. Literature review strategy 
Literature search of studies published between 1st of January 2000 and 30th of September 
2016 was undertaken on 30th of September 2016. This search was then repeated in July 
2017 to include articles published between 30th September 2016 and 16th July 2017, and 
between 1st of January 1995 and 31st of December 1999, due to the small number of studies 
initially identified. The following search term was used to identify relevant articles in 
PubMed: (((((south asian) OR ethnicity OR race)) AND (((outcome$) OR mortality OR death) 
OR survival)) AND myocardial infarction) AND (((percutaneous coronary intervention) OR 
coronary angioplasty) OR emergency angioplasty). Given the paucity of data available in this 
review, a more inclusive search protocol (compared to the search undertaken for the 
identification of relevant studies pertaining to the association between gender and 
outcomes in PPCI) to identify studies pertaining to MI and PCI were utilised. This returned 
259 studies. Review of the titles of these studies, followed by abstracts if the titles included 
the following terms: ((South Asian) and/or (ethnicity or race) and (myocardial infarction 
and/or percutaneous coronary intervention and/or angioplasty)), were undertaken. This 
strategy revealed 6 publications that were determined relevant (published in English, in full-




1.4.2.2.1. Review of relevant studies 
The earliest published study within the search period was by Wilkinson et al who published 
six-month mortality data of 462 patients (white: n=313; South Asian: n=149) who were 
admitted to Newham General Hospital in London between 1988 and 1992 with acute MI 
(89% STEMI)102. In their study, South Asian patients were younger at presentation, were less 
likely to be current cigarette-smokers (but more likely to have previously smoked 
cigarettes), had a four-fold greater prevalence of diabetes mellitus, and were more likely to 
be treated with aspirin and thrombolysis (despite differences in regional ST-elevation being 
statistically insignificant). Unadjusted outcomes were not statistically significantly different. 
When adjusted for age, gender, previous MI, treatment received and diabetes mellitus, 
outcomes remained comparable (HR 1.26 (95% CI 0.68-2.33) in South Asian patients). When 
diabetes mellitus was not adjusted for, mortality was significantly higher in South Asian 
patients (HR 2.02 (95% CI 1.14-3.56)). This suggested that diabetes mellitus played a key role 
in the outcomes of South Asian patients in comparison with white patients. The applicability 
of this study to current practice however, is debatable as details of invasive management, if 
at all undertaken, were not presented, and therefore, this study could reflect outcomes 
observed in the “old” medical treatment of STEMI. 
In 2002, Gupta et al analysed in-hospital mortality of 1106 patients (White: n=553, South 
Asian: n=553), matched by age, gender, hospital of admission and discharge date, who were 
admitted hospitals in Toronto, Canada with STEMI between 1994 and 1999118. South Asian 
patients were more likely to have diabetes, but were less likely to be cigarette-smokers, 
hypercholesterolaemic or suffer with peripheral vascular disease. South Asian patients had 
longer symptom-onset to presentation time (patient delay). This could be due to the 
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phenomena of “silent ischaemia” and atypical presentation associated with diabetes 
mellitus, which in this cohort of patients, was almost two-fold in South Asians. Management 
of MI was not different according to ethnicity. Unadjusted in-hospital mortality was not 
statistically significantly different in South Asian patients (9.6% vs 7.8%; p=0.27). However, 
multivariable adjustment to correct for confounders was not undertaken. Nevertheless, this 
study suggested that South Asian ethnicity was not a predictor of mortality following AMI, 
albeit in the thrombolysis era (approximately 6.3% of patients underwent coronary 
revascularisation of any description for index MI). 
Khan et al then published their analysis of one-year mortality of 41625 patients (white: 
n=38479; South Asian: n=2190; Chinese: n=946) who were admitted to hospital in Alberta, 
Canada between 1994 and 2003 with MI (according to International Classification of 
Diseases Code 410 which could have included NSTEMI)110. South Asian patients in their 
study were more likely to be male, younger, diabetic and hypertensive compared to white 
patients. In terms of treatment received, rates of PCI within 30 days of admission were not 
significantly different (OR 1.06 (95% CI 0.9-1.24) in South Asians). Although adjusted 30-day 
mortality was not statistically significantly different (OR 0.88 (95% CI 0.75–1.03) in South 
Asian patients), long-term mortality (events/1000 patient-years) was statistically 
significantly lower in South Asian patients (OR 0.65 (95% CI 0.57–0.72) in South Asian 
patients). In their study, South Asian patients were more likely to receive diagnostic 
coronary angiography compared to white patients, but not necessarily revascularisation (as 
described earlier). They speculated that this could be due to physicians’ perception of 
cardiovascular risk in this cohort, and therefore the earlier employment of invasive 
approach. Differences in secondary prevention, and the adherence to it, were not 
described, and neither were use of stents and additional pharmacotherapy. They had 
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however, corrected for age, and still found that longer-term mortality was significantly 
lower in South Asian patients compared to white patients. They had postulated that other 
non-cardiac causes of death could have been lower in the South Asian patients, a finding 
that had been described in the past, which is plausible in this comparison as 30-day 
outcomes were not significantly different between the ethnic groups119. 
Albarak et al then investigated the association between South Asian ethnicity and 30-day 
and long-term (mean follow-up 4.2 years) mortality in their cohort of 7135 patients (white: 
n=6648; South Asian: n=487) between 20 and 55 years of age who were admitted to 
hospital with MI (according to International Classification of Diseases Code 410 which 
included both NSTEMI and STEMI)in British Columbia, Canada, between 1995 and 2002115. 
In this subgroup of younger patients (≤ 55 years), age was not significantly different 
between white patients and South Asian patients. Despite this, South Asian patients still had 
two-fold greater prevalence of diabetes mellitus compared to white patients. They were 
also significantly more likely to be low-income earners compared to white patients. Similar 
to the study by Khan et al112, despite higher proportions of South Asian patients undergoing 
cardiac catheterisation procedures, rates of coronary revascularisation were not 
significantly different between ethnic groups. Unadjusted short-term (HR 0.83 (95% CI 0.37-
1.90)) and long-term (HR 1.14 (95% CI 0.76-1.74)) mortality were not statistically 
significantly different between white patients and South Asian patients. When adjusted for 
confounding variables, 30-day (HR 0.90 (95% CI 0.38-2.10)) and long-term (HR 0.81 (95% CI 
0.53-1.26)) mortality were still not significantly different between the two groups. 
Interestingly, amongst diabetic patients, adjusted rate of recurrent MI were significantly 
higher in South Asian patients (HR 1.48 (95% CI 1.04-2.11)), suggesting additional social or 
metabolic factors that could contribute to adverse outcomes in South Asian patients. 
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Analysis of 4729 patients (White: n=4219; South Asian: n=371) who underwent PCI for MI 
(once again according to International Classification of Diseases Code 410) in British 
Columbia, Canada between 1999 and 2003 once again revealed differences in age at 
presentation and prevalence of diabetes mellitus between white patients and South Asian 
patients109. Adjusted 30-day (OR 1.63 (95% CI 0.83-3.20) for South Asians) and 12-month 
mortality (HR 0.77 (95% CI 0.43-1.40) for South Asians) revealed no significant association 
between ethnicity and outcomes in this particular comparison. However, recurrent MI (HR 
1.34 (95% CI 1.08-1.67)) and heart failure (HR 1.81 (95% CI 1.00-3.29)) following index event 
were both higher in South Asian patients. 
The most recent study to examine the association between South Asian ethnicity and long-
term mortality (median 2.8 years) was published in 20142. Jones et al analysed data from 
279256 (White: n=259318; South Asian: n=19938) patients who had undergone PCI in 
England and Wales between 2004 and 2011. Of these patients, 36396 White patients and 
3047 South Asian patients underwent PPCI for STEMI. In the PPCI subgroup, only mortality 
was presented, not MACE (as was the case with all PCI). Although unadjusted mortality was 
lower in South Asian patients (Kaplan-Meier log-rank p=0.0025), adjustment for age and 
other confounders including diabetes eliminated this difference (HR/OR not quoted). Age 
was felt to be the strongest factor in differences in outcomes noted in South Asian patients, 
as adjustment for age alone meant South Asian patients had conversely higher long-term 




Table 1.2: Summary of studies examining the association between South Asian ethnicity and outcomes in PPCI. 
Authors Study design Country Data-
collection 
years 




Analysis Endpoints Findings 
Wilkinson 
et al102 






Adjusted HRa 1.26 (95% CIe 0.68-2.33) in 
South Asians. HR 2.02 (95% CI 1.14-3.56) in 











Mortality (9.6% in South Asians vs 7.8% in 
White patients; p=0.27) not significantly 









30-day and 1 
year 
mortality. 
Adjusted 30-day mortality ((ORb 0.88 (95% 
CI 0.75–1.03) in South Asians) not 
significantly different, but 12-month 
mortality (OR 0.65 (95% CI 0.57–0.72)) 
lower in South Asian patients.  
Albarak et 
al115 







No significant difference in adjusted 30-day 
(HR 0.90 (95% CI 0.38-2.10)) and long-term 
(HR 0.81 (95% CI 0.53-1.26)) mortality. 
Recurrent MIc higher in diabetic South 
Asians compared to diabetic white patients 
(HR 1.48 (95% CI 1.04-2.11)). 
Gasevic et 
al109 









MI and HF. 
Adjusted 30-day (OR 1.63 (95% CI 0.83-
3.20)) and 12-month (HR 0.77 (95% CI 0.43-
1.40)) mortality not significantly different. 
Recurrent MI (HR 1.34 (95% CI 1.08-1.67)) 
and HFd (HR 1.81 (95% CI 1.00-3.29)) higher 
in South Asians. 
Jones et 
al2 






Unadjusted mortality lower in South Asians 
(Log-rank p=0.0025). Adjusted mortality not 
significantly different (OR/HR not quoted). 




All of the relevant studies were observational studies from registry data. Only one of the 
studies by Jones et al was undertaken at the time that PPCI was the guideline-
recommended therapy in the relevant country, and that too, for only half the recruitment 
period. 
As with most analyses of the association of gender with clinical outcomes (as described in 
the previous section), multivariable analysis was undertaken to adjust for confounders to 
obtain adjusted HR or OR, depending on the regression analysis employed. Logistic 
regression analysis was the most commonly used multivariable analysis model, followed by 
Cox regression analysis. Once again, this could be due to violation of proportional hazards 
assumptions, but reasons for the employment of logistic regression analysis were not 
specified. Most studies had corrected for major confounders, which in this comparison were 
age, diabetes mellitus, smoking and socioeconomic status (where appropriate). Acute 
treatment was not significantly different and hence, this was not corrected for. However, 
none of the studies assessed details of other secondary prevention, such as aspirin, P2Y12-
receptor inhibitors or GPI. 
Identification of ethnicity was done by two distinct methods. Four of the 7 studies were 
from Canadian registries and in these registries, ethnicity was not recorded at the time of 
procedure/admission. Instead, it was derived from surnames using Nam Pehcan computer 
software, the use of which has been analysed in the past, showing good sensitivity (90.5%) 
but poor positive predictive value (63.2%) in identifying South Asian names120. This could in 
theory lead to the ethnicity of significant number of patients being mis-labelled. Surname 
changes following marriage for instance may not have been picked up. The UK studies 
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however had directly recorded ethnicity at the time of admission/cardiac catheterisation, 
which in most cases were recorded following direct questioning of the patient. This is likely 
to be more reliable. However, although the authors of the Canadian papers have stated that 
the likelihood of significant discrepancies were low, this important potential source of error 
cannot be completely discounted, as it forms the very basis of the comparison of one ethnic 
group with another. 
In terms of outcomes, one study had shown that adjusted 12-month mortality was lower in 
South Asians112, a finding that no other study observed. Their study was undertaken prior to 
the acceptance of PPCI as the gold-standard therapy in STEMI. The proportion of patients in 
their study who had undergone PCI during index admission was less than 20% in both ethnic 
groups, which is very different compared to the treatment of MI at present time. The 
applicability of the results of that study to current practice therefore is unclear. All other 
studies had shown that South Asian ethnicity is not independently associated with mortality. 
However, South Asian ethnicity was found to be independently associated with recurrent 
MI, TLR and heart failure (HF)105,109. Other metabolic or social factors, in addition to diabetes 
mellitus and age, could contribute to these differences. 
With the advances in PPCI technique and pharmacotherapy, and the advances in the 
monitoring and treatment of diabetes mellitus (including the acute treatment of patients 
with diabetes mellitus presenting with MI), which is a significant factor in the association 
between South Asian ethnicity and adverse outcomes, re-examination of the association 





1.4.3. Oral P2Y12-receptor inhibitor therapy 
1.4.3.1. Background  
The role of aspirin in the secondary prevention of CAD has been well-established121–123. The 
publication of the CURE, COMMIT and CLARITY-TIMI 28 trials heralded the era of dual-
antiplatelet therapy with aspirin and clopidogrel in acute coronary syndromes124–126. As 
stent technology and PCI techniques progressed, a newer-generation of more potent P2Y12-
receptor inhibitor therapy emerged. The first of these drugs was prasugrel. The TRITON-TIMI 
38 trial showed a reduction in ischaemic endpoints with a rise in bleeding complications 
when prasugrel was used instead of clopidogrel in ACS with scheduled PCI127. The STEMI 
subgroup analysis by Udell et al demonstrated a reduction in the composite endpoint of 
cardiovascular death, non-procedural MI or stroke at 30 days with the use of prasugrel over 
clopidogrel in patients presenting with STEMI who underwent PCI, with no reduction noted 
in mortality alone128. This had led to the National Institute of Clinical Excellence (NICE) UK 
recommendation that prasugrel should be used within its marketing authorisation in the 
treatment of patients undergoing PPCI129. The PLATO investigators then published their 
analysis of 18624 patients with ACS randomised to either ticagrelor or clopidogrel, showing 
that patients treated with ticagrelor had reduced rates of recurrent MI, vascular mortality 
and importantly, all-cause mortality compared to those treated with clopidogrel130. The 
NICE guidelines were then updated, with ticagrelor replacing prasugrel as the recommended 
P2Y12-receptor inhibitor therapy, given its survival benefits observed in PLATO131. However, 
there are no available RCTs comparing clinical outcomes of patients treated with ticagrelor 
and prasugrel. The PRAGUE-18 trial comparing these agents was terminated early due to 
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futility, and the ISAR-REACT trial is ongoing132,133. Therefore, there are little available data to 
guide clinicians when it comes to choosing between prasugrel and ticagrelor. 
1.4.3.2. Literature review strategy 
Literature search of studies published between 2000 and 2016 was conducted in September 
2016, and then repeated in July 2017 to include studies published in 2017. The following 
search was undertaken in Pubmed: (((((((((antiplatelet$) OR P2Y12) OR Prasugrel) OR 
Ticagrelor) OR Clopidogrel)) AND myocardial infarction) AND ((((primary percutaneous 
coronary intervention) OR primary angioplasty) OR emergency angioplasty) OR 
percutaneous coronary intervention))) AND ((((((outcome) OR mortality) OR survival) OR 
death) OR reinfarction$) OR event$), returning 2071 results. Review of titles of these 
studies, followed by abstracts if the titles included the following terms: ((ticagrelor or 
prasugrel or clopidogrel or P2Y12) and (myocardial infarction and/or percutaneous coronary 
intervention and/or angioplasty)), were undertaken, returning 8 studies that were 
determined to be relevant to this study (published in English, in full-text, which included 
patients undergoing PPCI for STEMI). 
1.4.3.2.1. Review of relevant studies 
The TRITON TIMI 38 trial published in 2007 assessed the efficacy of prasugrel in comparison 
with clopidogrel in 13608 patients (prasugrel: n=6813; clopidogrel: n=6795) who presented 
between 2004 and 2007 with high-risk ACS127. Clopidogrel was at the time, following the 
publication of the COMMIT trial, the default P2Y12-receptor inhibitor used in acute 
coronary syndromes in conjunction with aspirin134. This study found that treatment with 
prasugrel in patients with acute coronary syndrome with scheduled PCI was associated with 
reduced ischaemic endpoints at 15 months, but not mortality. In their STEMI subgroup 
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analysis128, amongst patients who underwent PPCI (n=2340) the composite endpoint of 
cardiovascular death, recurrent MI or stroke was lower at 30 days in patients receiving 
prasugrel (n=1152) compared to patients receiving clopidogrel (n=1188)(HR 0.53 (95% CI 
0.34-0.81)). At 15 months, this was no longer statistically significant (HR 0.76 (95% CI 0.56-
1.03)). However, the core group of patients who benefited from treatment with prasugrel 
were patients under 75 years of age with no prior history of cerebrovascular disease, who 
weighed ≥60kg135. Therefore, this left a two-drug prescription system, with patients aged 75 
years and above or weighing <60kg prescribed clopidogrel, and others being prescribed 
prasugrel. 
In 2009, the PLATO investigators published their study comparing ticagrelor with clopidogrel 
in 18624 patients (ticagrelor: n=9333; clopidogrel: n=9291) recruited between 2006 and 
2008, concluding that ticagrelor was associated with reduction in the composite endpoint of 
vascular death, recurrent MI or stroke (HR 0.84 (95% CI 0.77–0.92)), and importantly, a 
reduction in all-cause mortality (HR 0.78 (95% CI 0.69–0.89)) compared to clopidogrel, with 
no significant difference in TIMI-major bleeding (HR 1.03 (95% CI 0.93–1.15))136. The 
incidence of fatal intracranial bleeding in patients treated with ticagrelor was however, ten-
fold (0.1% vs 0.01%; p=0.02) compared to clopidogrel. They then published their STEMI 
subgroup analysis in 2010 (total n=7544; ticagrelor: n=3752; clopidogrel: n=3792), 
concluding that ticagrelor was associated with lower composite of cardiovascular death, MI 
and stroke (HR 0.85 (95% CI 0.74-0.97)) and all-cause mortality (HR 0.82 (95% CI 0.67-1.00)). 
Recurrent MI was also lower in patients receiving ticagrelor (HR 0.80 (95% CI 0.65–0.98)). 




In 2014, Koshy et al published their observational analysis of 1688 patients (prasugrel: 
n=822; clopidogrel: n=866) who underwent PPCI for STEMI between 2008 and 2009 in 
Newcastle, UK137. Although the difference in unadjusted 12-month mortality was not 
statistically significant, adjusted all-cause mortality was lower in patients receiving prasugrel 
(HR 0.472 (95% CI 0.253–0.881)). In their cohort of patients, potentially due to the temporal 
trends in the use of prasugrel in comparison with clopidogrel, transradial PPCI was 
significantly higher in the prasugrel group (78% vs 61.4%; p<0.001). As described in previous 
sections, transradial PPCI is independently associated with lower short and long-term 
mortality, as well as bleeding, compared to transfemoral PPCI. Crucially in this study, arterial 
access site was not included in their Cox regression analysis and thus, could have 
significantly confounded their findings. 
Serebruany et al then published their meta-analysis of 10 RCTs and one retrospective 
registry, with a total of 26658 patients with STEMI (ticagrelor: n=3719; prasugrel: n=2591; 
clopidogrel: n=6892) included in their analysis138. They found in their analysis of pooled 
data, prasugrel (OR 0.63 (95% CI 0.46-0.86)) was associated with lower 30-day 
cardiovascular mortality compared to clopidogrel, ticagrelor was not (OR 0.94 (95% CI 0.76-
1.17)). The main limitation in this study is that all-cause mortality was not assessed. Whilst 
10 out of the 11 sources of data were RCT data, the remaining source was the observational 
study by Koshy et al, which as described in the previous paragraph, could have a significant 
unadjusted confounding factor, transradial PPCI. Importantly, only two of the 10 RCTs they 
identified involved direct comparisons between two oral P2Y12-receptor inhibitors, the 
PLATO and TRITON-TIMI 38 trials that have been both critically appraised in this review. 
53 
 
The first study comparing ticagrelor with prasugrel was presented by Larmore et al, who had 
assessed 30-day clinical outcomes of 5322 propensity-matched patients (prasugrel: n=2661; 
ticagrelor: n=2661) who were admitted to a single centre in USA between 2011 and 2013 
with ACS and managed by PCI, of whom approximately 40% underwent PPCI for STEMI139. 
Thirty-day MACE (composite of all-cause mortality and cardiovascular events) was 
significantly lower in patients treated with prasugrel (RR 0.80 (95% CI 0.64-0.98)), as was 
recurrent MI (0.39 (95% CI 0.21–0.75)) and bleeding (0.65 (95% CI 0.45–0.95)). At 90 days, 
reduction in recurrent MI, but not other endpoints, was still statistically significant in 
patients treated with prasugrel (RR 0.53 (95% CI 0.34–0.81)). There were significant 
limitations with this study. The number of patients in each group with cardiogenic shock 
and/or cardiac arrest were not presented. Temporal trends in the use of ticagrelor and 
prasugrel were not presented, and neither were arterial access site choice in each group. 
Propensity matching was undertaken based on baseline characteristics, and other 
differences, such as GPI use, concomitant use of clopidogrel and bivalirudin, all of which 
were higher in the ticagrelor group, were not matched or adjusted for. Outcomes specific to 
patients undergoing PPCI, where the use of prasugrel has been shown to be most beneficial 
(in comparison with clopidogrel), were not presented. 
In 2016, results from the PRAGUE-18 study was published, having terminated early due to 
interim analysis suggesting futility132. This was the first RCT to attempt to compare clinical 
outcomes (composite of mortality, recurrent MI, urgent target vessel revascularisation, 
stroke, or major bleeding) in patients treated with prasugrel with those treated with 
ticagrelor. Initial power calculations suggesting a sample size of 1250 patients in each arm to 
show a difference of 2.5% with a two-sided alpha of 0.05 and a statistical power of 80%. 
However, interim analysis after recruitment of 1230 patients suggested no significant 
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difference in outcomes in patients treated with prasugrel compared to ticagrelor (OR 0.98 
(95% CI 0.55-1.73)) at 30 days. This led to the decision of the study group to terminate the 
study early, suggesting that a much larger study may be required to assess this in a trial. 
In 2017, Gosling et al published 12-month mortality and stent thrombosis of 3920 patients 
(prasugrel: n=1136; clopidogrel: n=1130; ticagrelor: n=1654) who had undergone PPCI for 
STEMI in Sheffield, UK between 2009 and 2015140. They found that adjusted 12-month 
mortality was lower with both ticagrelor (HR 0.70 (95% CI 0.61-0.99)) and prasugrel (95% CI 
0.65 (0.48-0.89)) compared to clopidogrel. No significant difference was observed with 
prasugrel (HR 0.81 (95% CI 0.61-1.10)) compared to ticagrelor. The variables included in 
their Cox regression model for STEMI patients were not described. Importantly, choice of 
arterial access site in each subgroup were not presented or adjusted for, and no attempts 
were made to adjust for potentially unidentified confounders as a result of a significant 
temporal trend in the choice of P2Y12-receptor inhibitor therapy. 
The most recent relevant study was published by Vercellino et al in 2017, which included 
401 patients (ticagrelor: n=142; clopidogrel: n=259) presenting with STEMI between 2011 
and 2013 in Sanremo, Italy141. Their main positive finding was that ticagrelor was 
independently associated with lower 12-month mortality after propensity scoring (HR 0.29 
(95% CI 0.08–0.99)) compared to clopidogrel. This was the only study amongst the studies 
identified that had employed propensity scoring analysis, rather than Cox regression or 
logistic regression analysis. Although they found numerical differences in baseline 
characteristics, most of these did not reach statistical significance, probably due to the small 
number of patients studied. Nevertheless, their finding was not particularly controversial, 
considering its alignment with the PLATO sub-study finding.  
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2340 1188 1152 - Clopidogrel vs 
prasugrel 
RCT 30-day and 15 month 
composite endpoints 
and bleeding 
Composite endpoints were lower with prasugrel at 30 
days (HRb 0.53 (95% CIf 0.34-0.81)) but not at 15 months. 








7544 3792 - 3752 Clopidogrel vs 
Ticagrelor 
RCT 12-month composite 
endpoints and bleeding 
Composite endpoints lower with ticagrelor (HR 0.85 
(95% CI 0.74-0.97)). All-cause mortality lower (HR 0.82 































Prasugrel was associated with lower 30-day 
cardiovascular mortality compared to clopidogrel (ORd 
0.63 (95% CI 0.46-0.86)). Ticagrelor was not associated 











30-day and 90-day 
composite events, and 
bleeding (not according 
to 
TIMI/HORIZONS/BARC) 
30-day MACEe (RR 0.80 (95% CI 0.64-0.98)), recurrent MI 
(0.39 (95% CI 0.21–0.75)) and bleeding (0.65 (95% CI 
0.45–0.95)) were lower with prasugrel. 90-day MI lower 


















30-day composite endpoint in prasugrel was not 
statistically significantly different compared to ticagrelor 















12-month mortality and 
stent thrombosis 
12-month mortality lower with ticagrelor (HR 0.70 (95% 
CI 0.61-0.99)) and prasugrel (HR 0.65 (95% CI 0.48-0.89)) 
compared to clopidogrel. No significant difference 












12-month mortality 12-month mortality lower with ticagrelor (HR 0.29 (95% 
CI 0.08–0.99)) compared to clopidogrel. 





The studies identified in the literature review included a mix of established RCTs and 
observational studies. One study was a meta-analysis of two of the RCTs included in this 
review, and one of the observational studies. For the observational studies, the analyses 
used were varied as well, with two using Cox regression, one using propensity matching and 
one using a relatively less frequently-used propensity scoring analysis. 
All studies had shown that the third-generation P2Y12-receptor inhibitors were associated 
with lower ischaemic events compared to clopidogrel, at both 30 days and at 12 months 
with no significant increase in the risk of bleeding in the newer agents. Twelve-month 
mortality was also shown to be lower in ticagrelor and prasugrel compared to clopidogrel by 
Koshy et al and Gosling et al. The only head-to-head comparison of ticagrelor and prasugrel 
specifically in STEMI by Gosling et al failed to show a difference in mortality between the 
two newer drugs. One study that had shown a difference was not specific for STEMI, and 
therefore its relevance to PPCI remains unclear. 
The observational studies all had limitations. Besides the study by Vercellino et al, none of 
the other studies had presented or adjusted for arterial access site differences, and none of 
them addressed the potential confounding factor which is time, as choice of P2Y12 receptor 
inhibitor in all the observational studies were subject to significant temporal trends. 
Changes over the period of time of recruitment for these observational registries could have 
included rates of implantation of DES and its generation, aspiration thrombectomy, 
procedural anticoagulant, and differences in secondary prevention, including primary 
prevention implantable cardioverter-defibrillator devices (ICD)142. However, adjustment for 
year of admission was not undertaken in any of these studies, and therefore, results quoted 
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in these studies, where a temporal trend was significant, could have been confounded by 
other unidentified factors. Another important limitation is the inability to determine 
switching between P2Y12-receptor inhibitors within the timelines specified for clinical 
endpoints. Most analyses were conducted based on either procedural or discharge P2Y12-
receptor inhibitor and yet in PLATO, premature discontinuation of study drugs occurred 
over 20% of patients136. Therefore, discontinuation or switching between drugs could have 
occurred over the specified time period, possibly due to adverse events including bleeding 
that might not have been accounted for. 
As at present there are no available real-world studies assessing clinical outcomes according 
to P2Y12-receptor inhibitor therapy, adjusting for temporal changes in practice and 
technique, and also importantly, adjusting for choice of arterial access site, the association 






1.4.4. Individual operator PPCI volume 
1.4.4.1. Background 
Individual operator volumes in PCI for all indications have previously been shown to be 
independently and directly associated with survival in numerous studies143–148. However, 
studies examining individual operator volumes of PPCI for STEMI are limited. PPCI for STEMI 
can be associated with significant challenges, such as recurrent cardiac arrest, active 
coronary ischaemia, cardiogenic shock, thrombus, acute pulmonary oedema as well as the 
ability of an operator to perform at a high level in the middle of the night, when PPCI is 
undertaken on a 24/7 basis. Published studies pre-date the contemporary era of PPCI which 
is signified by high proportions of transradial PPCI and use of DES. These studies had also 
assessed only in-hospital outcomes, rather than 30-day or 12-month clinical outcomes. The 
American Heart Association (AHA) has recommended a minimum operator volume of 11 
PPCI per year to maintain procedural standards, based on a single study of the New York PCI 
registry which analysed outcomes of patients presenting between the years 2000 and 
2002148,149. Therefore, the relevance of the cut-off of 11 PPCI per year when there has been 
evidence of a significant temporal trend in the uptake of PPCI, and advances in both 
procedural technique, technology and pharmacotherapy (all of which were previously 
described), between 2002 and the current time, is debatable and one which should be re-
examined. At present, there are no published data available to assess the association 
between individual operator annual PPCI volume and 30-day and 12-month mortality in the 




1.4.4.2. Literature review strategy 
Literature search using the PubMed database was undertaken in April 2017, and then 
repeated in July 2017 to retrieve all relevant studies published between 2000 and 2017. The 
following search term was used: (((((((operator$) OR physician$) OR interventionist$) OR 
cardiologist$)) AND (((volume$) OR experience) OR number$)) AND (((primary percutaneous 
coronary intervention$) OR primary angioplasty) OR emergency angioplasty)) AND ((((((ST 
segment elevation myocardial infarction$) OR ST elevation myocardial infarction$) OR 
myocardial infarction$) OR ST segment elevation acute coronary syndrome$) OR ST 
elevation acute coronary syndrome$)); returning 196 results. Review of titles of these 
studies, followed by abstracts if the titles included the following terms: (volume OR number 
OR experience) and (myocardial infarction and/or percutaneous coronary intervention 
and/or angioplasty), were undertaken. Only two studies analysing outcomes according to 
annual operator PPCI volume were identified. 
1.4.4.2.1. Review of relevant studies 
The first of the two relevant studies was undertaken by Vakili et al, who in 2001 published 
their analysis of 1342 patients who had undergone PPCI in New York, USA in 1995144. They 
divided operator volumes into tertiles (Tertile 1: 1-2 PPCI/year who had performed 65 PPCIs 
in total; Tertile 2: 2-10 PPCI/year who had performed 300 PPCIs in total; Tertile 3: ≥11 PPCI 
per year who had performed 977 PPCIs in total). They had combined tertile 1 and 2 to 
define low-volume operators. The remaining operators (tertile 3) were defined as high-
volume operators. They found that PPCI undertaken by high-volume operators in high-
volume centres (≥57 PPCI/year) was independently associated with lower in-hospital 
mortality compared to PPCI performed by low-volume operators in low-volume centres (OR 
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0.51 (95% CI 0.26-0.99)). The overall comparison of in-hospital mortality of PPCI performed 
by high-volume operator with low-volume operators (regardless of institutional volume) 
showed that high operator-volume was independently associated with lower in-hospital 
mortality (OR 0.43 (95% CI 0.21–0.83)). This was an important study that informed the 
aforementioned AHA Guideline. However, the relevance of this study in this day and age is 
unclear. As described in previous sections, the uptake of PPCI, the techniques (transradial 
PPCI), technology (aspiration thrombectomy, DES, use of intravascular imaging, use of 
adjunct devices such as Guideliner) and the evolution of secondary prevention (DAPT, ICD) 
since 1995 has been significant. In essence, although this was an important study at the 
time in suggesting optimal operator volumes in PPCI, the applicability of the volumes used 
to define high-volume operators and low-volume operators especially in England and Wales 
where at present, >90% of patients with a first diagnosis of STEMI are treated with PPCI, is 
debatable, as those volumes were derived at a time when PPCI was not yet the standard of 
care for patients with STEMI, and therefore, numbers were likely to be low compared to 
current time. 
The more recent analysis by Srinivas et al, who had analysed in-hospital mortality of 7321 
patients undergoing PPCI between 2000 and 2002 in New York had once again suggested a 
volume-outcome relationship between annual operator PPCI volume and in-hospital 
mortality148. They had found that PPCI performed by operators who undertook >10PPCI per 
year (as per AHA Guidelines) was independently associated with lower in-hospital mortality 
than PPCI performed by operators who undertook ≤10 PPCI per year (OR 0.66 (95% CI 0.48-
0.92)). When the threshold was increased to >20 PPCI per year, high operator-volume was 
still independently associated with in-hospital mortality compared to low operator-volume 
(OR 0.63 (95% CI 0.44–0.91)). No difference was observed at a threshold of 30PPCI per year. 
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This study reaffirmed the findings of Vakili et al that an operator volume-outcome 
relationship specific to PPCI exists, and once again, the patients included in this study 
underwent PPCI in an era when PPCI was not necessarily the standard of care, prior to the 
landmark analysis by Keeley et al in 2003 confirming the superiority of PPCI over 
intravenous fibrinolysis. It was also almost a decade prior to the national rollout of PPCI in 
the UK, before the era of transradial PPCI, DES and newer P2Y12-receptor inhibitors and 




Table 1.4: Summary of studies examining the association between individual operator PPCI volumes and outcomes. 
Authors Study design Country Data-collection years Number Analysis Endpoints Findings 
Vakili et 
al144 




High operator volume (>10PPCIa/year) was 
independently associated with lower in-hospital 
mortality (ORb 0.43 (95% CI 0.21–0.83)).  
Srinivas et 
al148 




Operator volume of >10 PPCI/year was associated 
with lower in hospital mortality (OR 0.66 (95% CI 0.48-
0.92)) compared to operator volume of ≤10 PPCI/year. 
Operator volume of >20 PPCI/year was associated 
with lower in-hospital mortality compared to operator 
volume of ≤20 PPCI/year (OR 0.63 (95% CI 0.44–0.91)). 




The current AHA Guideline pertaining to annual operator PPCI volume is informed by only 
two studies, both from New York, and both prior to the acceptance of PPCI as the standard 
of care for STEMI. Both studies were observational studies, as is expected for this specific 
question of operator volumes and outcomes. Both studies utilised logistic regression 
analysis. Both studies confirmed and operator-volume-outcome relationship specific to 
PPCI, which had not been reported prior to that, and has not been reported since, in USA or 
in Europe. 
Whilst it is possible to ascertain individual operator PPCI volume and outcomes in larger 
databases in current time, no study has yet been published. The most recent study by 
Fanaroff et al examining the operator-volume-outcome relationship (not specific to PPCI) in 
patients undergoing PCI between 2009 and 2015 (from the NCDR database in USA) had 
shown that in STEMI (627501 patients), low annual PCI volume (<50 PCI/year) was 
associated with higher adjusted probability of in-hospital mortality compared to high annual 
PCI volume (>100 PCI/year) (OR 1.13 (95% CI 1.08–1.19))150. This study was relevant to 
current practice as it was conducted in the contemporary era of PCI, with 73.5% of patients 
receiving DES, albeit with only 15.2% of patients undergoing transradial PCI. 
Hence, the association between individual operator annual volume of PPCI and clinical 
outcomes in contemporary PPCI is currently unknown, with current guideline-
recommendations being based on data from an era of PPCI that may not necessarily reflect 
current practice and volumes, and therefore outcomes. This therefore warrants further 




1.4.5. Glycoprotein IIb/IIIa inhibitor therapy according to arterial access site 
1.4.5.1. Background 
The evolution from transfemoral PPCI to transradial PPCI has revolutionised PPCI technique 
and technology. The evidence-base for the use of transradial PCI over transfemoral PCI is 
extensive, with the benefit of transradial PCI proven in reducing key endpoints of mortality 
and bleeding. As previously described, there has been a gradual and steady temporal trend 
in the utilisation of the radial artery as the primary arterial access site for PCI in the UK. 
Although not objectively proven, it is possible that with the current practice of using the 
radial artery for access by default, and reverting to transfemoral access if transradial access 
is not possible, there may be an element of de-skilling in transfemoral PCI over time, 
especially in more junior operators who may not have necessarily performed as many 
transfemoral PCIs as their more senior counterparts due to the change in attitudes towards 
transfemoral PCI. This could in theory widen the gap between outcomes observed in 
patients undergoing transradial PCI compared to those undergoing transfemoral PCI. The 
impact of arterial access site is particularly significant in PPCI, as periprocedural 
pharmacological agents could further increase the possibility of bleeding, particularly access 
–site bleeding in transfemoral PPCI. 
Glycoprotein IIb/IIIa-receptor inhibitor (GPI) therapy, especially abciximab, has been shown 
in RCTs to reduce re-infarction and target-vessel revascularisation151. However, none of 
these trials were conducted in the era of transradial PPCI, and none of the patients enrolled 
in these trials received third generation P2Y12-receptor inhibitor therapy.  
What is currently not known is the association between GPI use and outcomes according to 
arterial access sites. It is possible that in the era of transradial PPCI, the use of GPI in 
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transfemoral PPCI may be associated with increased bleeding complications, particularly 
arterial access site bleeding. However, this has not been assessed in either trials or real-
world data. 
1.4.5.2. Literature review strategy 
The search term “((((((primary percutaneous coronary intervention$) OR primary 
angioplasty) OR emergency angioplasty)) AND ((((((ST segment elevation myocardial 
infarction$) OR ST elevation myocardial infarction$) OR myocardial infarction$) OR ST 
segment elevation acute coronary syndrome$) OR ST elevation acute coronary 
syndrome$))) AND ((((glycoprotein) OR abciximab) OR tirofiban) OR eptifibatide)) AND 
(((mortality) OR death) OR bleeding)” of studies between 2000 and 2017 returned 956  
results in July 2017. Review of the titles of these studies, followed by abstracts if the titles 
included the following terms: (glycoprotein or tirofiban or abciximab) and (myocardial 
infarction and/or percutaneous coronary intervention and/or angioplasty), returned 5 
relevant studies (published in English, in full-text, which included patients undergoing PPCI 
for STEMI). 
1.4.5.2.1. Review of relevant studies 
The ADMIRAL study published in 2001 was a RCT that had randomised 300 patients 
between 1997 and 1998 to either abciximab or placebo in the setting of STEMI prior to 
coronary intervention (before arterial sheath insertion), and found that abciximab was 
associated lower incidence of the composite endpoint of mortality, re-infarction or urgent 
TLR at 30 days (RR 0.41 (95% CI 0.18–0.93)) and at 6 months (RR 0.46 (95% CI 0.22–0.93))151. 
Although TIMI-major bleeding was not statistically significantly higher in the abciximab 
group, there was an increased incidence of minor bleeding (RR 3.65 (95% CI 1.32–10.08)), 
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groin haematoma (RR 9.12 (95% CI 1.14–72.89)) and thrombocytopaenia (RR 3.55 (95% CI 
0.72–17.35)) with the use of abciximab. This study was undertaken in the early days of PPCI, 
before it was routinely used as the primary method of reperfusion. All patients who were 
included in this study were also likely to have undergone transfemoral PPCI (access site not 
presented, presumably because this study predated the era of transradial PPCI), and 
therefore, there would not have been the element of de-skilling with transfemoral PPCI. 
This study was also conducted with patients receiving aspirin and ticlopidine, rather than 
the newer and more potent P2Y12-receptor inhibitors. There were also numerous exclusion 
criteria, such that the patients with the highest risk, such as unconscious patients following 
cardiac arrest or cardiogenic shock, or patients with cognitive difficulties (long-term due to 
dementia or temporary due to opiates) who were unable to provide written informed 
consent were excluded. Therefore, whilst this RCT supported the use of abciximab in PPCI, 
its applicability in the real-world remains under-examined. 
The secondary analysis of the CADILLAC trial published in 2003, assessed the performance of 
abciximab in 2082 patients undergoing PPCI randomised to either abciximab (n=1052) or no 
abciximab (n=1030)152. Patients were randomised to either PTCA alone, PTCA + abciximab, 
stenting alone, or stenting + abciximab (the primary CADILLAC trial compared primary 
stenting against primary PTCA153). Both 30-day and 12-month endpoints were presented. 
Abciximab was associated with lower 30-day target vessel revascularisation (TVR) and stent 
thrombosis, with no significant difference observed at 12-months. There were no observed 
differences in 30-day and 120-month mortality. Patients in this study were likely to have 
undergone transfemoral PPCI (access site was not presented, likely because this study 
predated routine transradial PPCI). Only approximately 56% of patients received 
intracoronary stents, which were BMS rather than DES. In patients who received stents, 
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ischaemic TVR was 3.2% with stenting alone, and 1.6% with stenting + abciximab (P=0.004). 
Ticlopidine was given for 4 weeks in stented patients, and was optional for patients who 
underwent PTCA alone. Patients receiving abciximab were designated to either “low-risk” 
group, or “high-risk” group, and had potentially longer in-hospital stay. Patients presenting 
with cardiogenic shock, vein graft occlusion, vessel <2.5mm in diameter, lesion >64mm in 
length or those needing urgent CABG were excluded from this trial. The main findings of this 
study could be difficult to replicate in current practice. Higher proportion of stenting, the 
use of DES, longer periods of DAPT with more potent P2Y12-receptor inhibitor therapy, and 
other improvements in secondary prevention could all reduce TVR following PPCI, and thus, 
in current practice in the real-world, these differences may not be observed. 
Most recently, the BRAVE-3 trial compared abciximab with placebo in 800 patients 
undergoing PPCI between 2003 and 2008. No significant difference in mortality, infarct size 
or major bleeding was observed between the two groups, suggesting that with adequate 
P2Y12-loading, the effect of abciximab may not necessarily reflect CADILLAC or ADMIRAL154. 
All patients in this study received clopidogrel, for a minimum of 30 days following index 
event. Maintenance dose of aspirin was 200mg/day. Only 44% of patients received DES. 
Arterial access site were not specified. Considering their recruitment period, it is possible 
that patients could have undergone either transfemoral or transradial PPCI, and if this was 
not adjusted for, it could have confounded their analysis. The exclusion criteria were 
extensive: fibrinolytic therapy, bleeding diathesis or bleeding, previous cerebrovascular 
accident (CVA), major surgery or trauma within one month of index event, oral 
anticoagulant therapy within 7 days of PPCI, use of GPI within 14 days of PPCI, systolic blood 
pressure exceeding 180mmHg resistant to therapy, haematological abnormalities, 
cardiogenic shock, prolonged cardiopulmonary resuscitation (CPR – and thus, possibly a 
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significant proportion of ventilated patients), age >80 or <18, known or suspected 
pregnancy and allergy to study drugs; essentially excluding patients at the highest risk of 
adverse events following PPCI. The important finding of this study was that there was no 
significant difference in outcomes in patients receiving GPI, in comparison with CADILLAC 
and ADMIRAL, suggesting an attenuation in the effect of GPI in the presence of more potent 
P2Y12-receptor inhibitor therapy. 
Real-world studies examining this association are limited. In 2006, Heer et al published their 
analysis of 2184 patients undergoing PPCI between 2000 and 2002 from the Acute Coronary 
Syndrome (ACOS) registry in Germany155. They found that treatment with abciximab (n=946) 
was associated with improved mid-term (median follow-up 375 days) survival compared to 
control (n=1238) (HR 0.65 (95% CI 0.49-0.95)). Increased bleeding was noted in patients >75 
years of age. Interestingly, in-hospital mortality was not significantly different, and the 
Kaplan-Meier curves were essentially identical for the first 30-days, diverging thereafter. 
Therefore, it is unlikely that differences observed in survival were due to abciximab. Patients 
who received abciximab were more likely to receive aspirin (95% vs 89.3%; p<0.01) and 
clopidogrel (86.7% vs 75.4%; p<0.01) compared to control, suggesting that patients 
receiving abciximab were inherently “selected” based on lower bleeding risk, and that these 
secondary prevention differences could have contributed to differences in outcomes, 
especially the late divergence in survival. 
Most recently, data of 2935 patients undergoing PPCI in Copenhagen, Denmark between 
2003 and 2008 were published, showing that the use of GPI (n=1193) was associated with 
improved mortality in patients with complex lesions (HR 0.62 (95% CI 0.42-0.91))156. 
However, GPI was associated with increased mortality in patients with simple lesions (HR 
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1.72 (95% CI 1.14-2.58)). Arterial access site were not presented or corrected for in their 
analysis, and it is possible that some of their patients, especially in the latter years of 
recruitment, underwent transradial PPCI. However, importantly, in contrast with RCTs, they 
found that GPI was not beneficial to all patients who underwent PPCI and that certain 









Number GPI used Access site P2Y12-receptor 
inhibitor 




RCTa France 1997-1998 300 Abciximab Not 
described 
Ticlopidine for 30 
days 




abciximab at 30 days 




RCT Multicentre 1997-1999 2082 Abciximab Not 
described 
Ticlopidine for 4 
weeks if stented 
RCT Death, MI, 
stroke, TVRd 
Reduced composite 





RCT Germany 2003-2008 800 Abciximab Not 
described 
Clopidogrel for a 
minimum of 30 
days 









Heer et al155 Observ
ational 
Germany 2000-2002 2184 Abciximab Not 
described 




Lower mortality with 
abciximab but 
survival curves only 
diverge after 30-






Denmark 2003-2008 2935 Abciximab Not 
described 
Clopidogrel Cox regression 12-month 
mortality 
Abciximab associated 
with lower mortality 
in patients with 
complex lesions, but 
higher mortality in 
patients with simple 
lesions 





The landmark RCTs that showed potential benefit in the use of GPI were conducted with 
abciximab. The main studies, ADMIRAL and CADILLAC, were both most likely conducted on 
patients undergoing transfemoral PPCI. In these studies, choice of P2Y12-receptor inhibitor 
therapy (ticlopidine) and its duration (30 days) and type of stent (BMS) were at the time, 
contemporary. However, with the evolution of P2Y12-receptor inhibitors, and its duration of 
use following MI, and the increase in the use of DES, especially newer generation DES, the 
main endpoints that were reduced in these studies, reduced TLR and reduced TVR, may not 
be relevant in current practice. 
There has been a gradual shift away from transfemoral PPCI, as evidenced by the National 
Institute of Cardiovascular Outcomes Research (NICOR) report in 2014157. In their report, in 
2014, only approximately 25% of PPCIs were performed via the femoral artery. It is very 
likely that this has reduced further over the following years as multiple studies have, as 
previously described, shown a benefit in transradial PPCI over transfemoral PPCI with 
reduction in access site or retroperitoneal bleeding and mortality (possibly secondary to the 
reduction in bleeding). 
In this age of transradial PPCI, it is possible that when transfemoral PPCI is undertaken, the 
risk of access site bleeding could be significant, especially with the use of more potent 
P2Y12-receptor inhibitors. This could further be compounded by possible de-skilling in 
transfemoral PPCI, especially amongst more junior operators, who unlike their more senior 
colleagues, may not have undertaken significant volumes of transfemoral PPCI or even 
transfemoral PCI. This could potentially lead to increased complications due to lack of 
familiarity and technique. In this circumstance, using GPI, especially when its use with more 
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potent P2Y12-receptor inhibitors has been shown to be of no significant benefit, could lead 
to increased bleeding complications, particularly access site bleeding. The association 
between the real-world use of GPI and access site bleeding, specifically in transfemoral PPCI, 
requires further examination. 
1.5. Hypothesis 
The hypothesis of this study was that retrospective analysis of a bespoke regional registry of 
consecutive patients undergoing PPCI in a single tertiary referral centre would enable 
analyses of variables associated with outcomes beyond what is typically available from the 
interrogation of larger national datasets. 
1.6. Aims 
The aim of this study was to identify patient, systemic, and treatment variables associated 
with clinical outcomes in contemporary PPCI. 
The first patient characteristic investigated was the association between gender and 
outcomes following PPCI. This is because the association between gender and outcomes in 
PPCI continues to be reported with differing results and conclusions. The second patient 
characteristic investigated was the association between the South Asian ethnicity and 
outcomes following PPCI. This is because data analysing this association in contemporary 
PPCI are significantly limited in the number of studies and the era in which the studies were 
undertaken. 
The systemic variable investigated in this study was the association between annual 
operator PPCI volume and outcomes. This is because the current AHA recommendation that 
individual operators undertake >10 PPCI per year was based on two non-contemporary 
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studies in the USA. The association between total PCI volumes and outcomes as well as 
institutional volumes and outcomes have been reported in contemporary studies. 
The first treatment variable investigated was the association between oral P2Y12-receptor 
inhibitor and outcomes in contemporary PPCI. As described in the literature review, there 
are little available data to facilitate the comparison of prasugrel with ticagrelor in PPCI. The 
second treatment variable investigation was the use of GPI according to arterial access site. 
This is because studies that inform the guideline recommendations were undertaken prior 
to the routine use of transradial PPCI and third-generation P2Y12-receptor inhibitors. It was 
therefore possible that in the current era, the use of GPI may not reflect the findings of the 













2.1. The West Yorkshire PPCI Outcome Study 
The West Yorkshire PPCI Outcome Study was set up as a prospective, observational study to 
ascertain procedural and demographic characteristics, and clinical outcomes in all patients 
undergoing PPCI for STEMI at Leeds General Infirmary (LGI), United Kingdom. LGI is the largest 
regional single-centre PPCI centre by volume in the UK, providing a 24/7 PPCI service to a 
catchment population of 3.2 million people, achieving 100% population coverage, according 
to NICOR158. The period of recruitment was 1st of January 2009 until 31st of December 2011, 
and 1st of January 2013 until 31st of December 2013 (4 calendar years). Patients who 
presented for PPCI between 1st of January 2012 and 31st of December 2012 were excluded 
from this registry, as limited research staff availability did not allow for patient follow-up and 
data input in 2012. UK National Research Ethics Service approval (0911-11311/60) and NHS 
institutional approvals from each hospital within the West Yorkshire region were obtained 
prior to commencement of this registry (Appendix). 
 
2.2 Patient selection 
All patients who presented to the cardiac catheter laboratory at LGI for PPCI for STEMI 
(diagnosed according to standard criteria - with chest pain consistent with myocardial 
ischaemia for a minimum of 20 minutes with ST-segment elevation of ≥1mm in contiguous 
limb leads and/or ≥2mm in contiguous chest leads, or with presumed new left bundle-branch 
block on a 12-lead electrocardiogram) within the specified recruitment period were included 
in this study. STEMI was usually diagnosed by paramedics in the pre-hospital setting, and 
when diagnosed patients were transferred directly to the cardiac catheter laboratory at LGI 
for treatment, with a telephone referral en-route159. In the event of cardiovascular instability 
due to ongoing or refractory cardiac arrest, the patients were taken to the nearest Emergency 
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Department for emergency treatment, and were transferred to LGI when they were 
determined to be stable for inter-hospital transfer. Upon arrival at the cardiac catheter 
laboratory, patients were handed over to either the cardiac catheter laboratory team which 
includes the interventionist undertaking the procedure, or to the Coronary Care Unit (CCU) 
team, if out-of-hours and the patient arrived at LGI before the cardiac catheter laboratory 
team. All ECGs of the patient, with time documented, and a written ambulance transfer sheet 
that included symptom-onset time, call-for-help time, time of paramedic’s arrival at patient’s 
location, vital observations of the patient, arrival time at LGI and emergency treatment 
received prior to arrival at hospital, were provided to the cardiac catheter laboratory team. 
Informed consent was then obtained from patients for PPCI, either in written or verbal 
format. In patients who were unable to provide informed consent for any reason, PPCI was 
undertaken based on their best interest. 
 
2.3 Treatment 
Emergency diagnostic coronary angiography with (if indicated) follow-on PPCI was 
undertaken if patients presented within 12 hours of symptom-onset. Oral aspirin 300mg was 
typically given in the pre-hospital setting at the point of first medical contact, and either 
600mg clopidogrel, 60mg prasugrel or 180mg oral ticagrelor were administered upon arrival 
at the cardiac catheter laboratory, depending on guideline recommendations at the time of 
index PPCI131,160,161. Either bivalirudin or unfractionated heparin (± bail-out glycoprotein 
IIb/IIIa antagonist) were administered during PPCI. Arterial access site, decision to implant 
stents and the choice of stent (DES or BMS) and aspiration or mechanical thrombectomy, 
insertion of intra-aortic balloon pump (IABP) or temporary pacing wires were performed 
according to the operator’s experience and discretion based on the clinical condition of the 
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patient, informed by guideline recommendations. Thrombolysis in Myocardial Infarction 
(TIMI) classification was used to grade pre-procedure and post-procedure flow in the IRA. 
Call-for-help time (call time) and time of patient arrival at LGI (door time) were obtained from 
ambulance reports, if patients were admitted by ambulance. Emergency Department triage 
notes were used to ascertain call time and door time if patients self-presented. Time of first 
interventional device (balloon time) was obtained from the electronic cardiac catheter 
laboratory report (as part of the national audit dataset). From these recorded times, call-to-
balloon (CTB) and door-to-balloon (DTB) times were ascertained. Patients were typically 
observed on CCU post-PPCI for a minimum of 24 hours, and remained in hospital for a 
minimum of 72 hours post-PPCI. Patients whose local hospitals were not LGI were observed 
on CCU at LGI for a minimum of 6 hours post-PPCI, after which they were transferred to their 
local CCU depending on availability of beds. Dual antiplatelet therapy (DAPT) for 12 months 
followed by indefinite aspirin monotherapy, statin therapy, beta-adrenergic receptor 
blockers, Angiotensin-converting enzyme inhibitors (or angiotensin II receptor blockers) and 
(if indicated) mineralo-corticoid receptor antagonists were prescribed according to guideline 
recommendations at the time. Primary prevention ICDs were implanted according to 




2.4 Data collection and follow up strategy 
Data were initially recorded in a bespoke Microsoft Access-developed interface. This was 
later replaced with a custom-built web interface built in ASP.net, with a Microsoft SQL 
backend. All data are held in Leeds Teaching Hospitals NHS Trust, on a central SQL cluster 
that is managed by the Trust IT services. Individuals with access to the database were: the 
data manager (employed by Leeds Teaching Hospitals NHS Trust), the Principal 
Investigators, research nurses involved in data collection, administration support team, and 
Fellows involved in data analysis and publication. The database was populated via manual 
data input, with the option of importing relevant data directly from the Trust’s BCIS and 
MINAP modules. Data were then downloaded in .xslx format, for access in Microsoft Excel 
and statistical packages. 
 
Written and electronic case notes were reviewed at the time of discharge to ascertain 
patient characteristics, procedural variables, and in-hospital outcomes. Where possible, 
patient information leaflets were provided to patients either prior to discharge from LGI or 
prior to repatriation to their local hospital (Appendix 1). Drug therapy and adverse events 
were identified up to 12 months following index PPCI by a combination of patient telephone 
contact, accessing clinical information via written or electronic hospital records, or from the 
responsible Primary Care physician. In patients whose local hospital was LGI, this was done 
in Leeds. For patients whose local hospitals were other regional hospitals (Calderdale Royal 
Hospital, Airedale General Hospital, Huddersfield Royal Infirmary, Bradford Royal Infirmary, 
Mid-Yorkshire Hospitals NHS Trust (comprising of Pinderfields General Hospital and 
Dewsbury District Hospital), York Hospital and Harrogate and District Hospital), 
departmental and Research and Development clearance was obtained by research nurses 
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(KS and NBW) to work on-site at those hospitals to extract relevant data. Mortality data up 
to a minimum of 12 months post-PPCI were obtained from the Office of National Statistics 
and central NHS records. The Myocardial Infarction National Audit Project (MINAP) database 
was used to identify MIs. Review of hospital discharge and clinic letters, and hospital 
electronic pathology servers for rises in Creatinine Kinase and/or Troponin were undertaken 
to verify MIs. Identification of repeat coronary revascularisation procedures up to a 
minimum of 12 months post-PPCI was undertaken by reviewing all regional cardiac catheter 
laboratory databases and the cardiothoracic surgical database at LGI (which was the tertiary 
referral centre for CABG in West Yorkshire). Data adjudication was undertaken by blinded 
clinicians in consensus, to verify logged outcome events at 30 days and at 12 months. Data-
checking and validation was undertaken to ensure accuracy and validity of values obtained, 
and summary statistics were generated. 
 
2.5. Why use local registry data? 
Registry data are important sources of information for both performance assessment and 
for research purposes. Whilst RCT data are useful is assessing the efficacy of a particular 
treatment in any given population, the stringent inclusion and exclusion criteria usually 
associated with RCTs mean that a substantial proportion of patients are excluded from 
analyses. Usually, these are the sickest patients with the most adverse pre-morbid status. As 
a result, translating the findings of RCTs into clinical practice on a day-to-day basis can be 
tricky, as in the real-world, when such treatments are reassessed for efficacy and safety, 
they are not always achievable. 
This is where data from “all-comers” registry can be useful. There are usually no selection 
criteria for inclusion in registry, besides the very purpose of the registry. Important data 
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have been derived in the past from registries. The Swedish Coronary Angiogram and 
Angioplasty Register (SCAAR) for instance had facilitated a RCT with a registry-based follow-
up for the TASTE study which provided an interesting perspective about thrombus 
aspiration46. 
Registry interrogation also allows for the examination of a particular factor on a broader 
population than that of a RCT. This is usually seen when RCT demographics are compared to 
real-world registries. An example of this is the comparison of baseline characteristics of 
HORIZONS-AMI, which was a multicentre RCT with multiple exclusion criteria, some of 
which would have excluded the patients with the highest bleeding risk162. In comparison, 
HEAT-PPCI, which was a RCT, but randomised in an “all-comers” manner, revealed a 
completely different result, when bivalirudin was compared to heparin163. Patients in 
HORIZONS (median age 60 years) were significantly younger than the patients in the UK 
presenting with STEMI, which according to MINAP data, were 64 years old at 
presentation164. This has subsequently lead to the re-evaluation of the use of Bivalirudin in 
PPCI, which according to the most recent publication by Brogan et al, was only 13%56. 
In addition to this, some factors can only be determined from registry data. Factors such as 
institutional PPCI volumes, operator PPCI volumes, factors associated with centres such as 
the number of cardiologists and the provision of a 24/7 service, and the association 
between bleeding or renal failure with outcomes have all been determined with 
observational data from registries, as these are factors that cannot be assessed using clinical 
trials. With adequate statistical advice and analyses, important analyses can be undertaken 
using registry data. 
This was the reason that the West-Yorkshire Primary Percutaneous Coronary Intervention 
Outcome Study was set up; to prospectively collect data that could be used to assess local 
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clinical outcomes against national and international outcomes, to assess markers of 
performance, and also to be able to determine novel factors that could be associated with 
outcomes in contemporary PPCI. In comparison with national databases such as the BCIS or 
MINAP database, the use of a regional registry (with the involvement of dedicated research 
nurses prospectively collecting outcome data beyond just mortality and in-hospital 
complications) facilitates the undertaking of more in-depth analyses that include 30-day 
bleeding, and 30-day and 12-month re-infarction and repeat coronary revascularisation 
procedures that would not be picked up with the use of nationally collected data. 
 
2.6. Limitations of the WY-PPCI registry data 
This observational study was undertaken in a single centre, and therefore the outcomes 
observed in this study may not reflect those observed in other regions or countries. Patients 
were unmatched in this observational study, but multivariable analysis was undertaken to 
adjust for potential confounders. Regional differences in the management of STEMI have 
been reported, despite the national framework for STEMI treatment. However, in England 
and Wales, at present time, >98% of patients with a first diagnosis of STEMI receive PPCI 
rather than thrombolysis or no treatment. Patients presenting with out-of-hospital cardiac 
arrest, who due to haemodynamic instability are taken to the nearest Emergency 
Department for emergency treatment, may not all be referred for PPCI as they may not 
have been determined as stable or suitable for transfer, and depending on clinical findings 
and the patient background, referrers may take a view of futility in some of this patients. 
This could have potentially introduced an element of bias to the population seen in this 
study, as theoretically, patients who were more unwell or unstable may never have been 
referred for PPCI. This could not be explored further in this study as the data for this were 
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unavailable. Killip class and left ventricular systolic function could not be corrected for in this 
study, as these data were not collected in the registry. However, as this is an “all-comers” 
registry, differences in Pre-PPCI LV function and Killip class were likely to be attributable to 
delays to reperfusion, which was adjusted for in specific analyses. This study also only 
included patients presenting between 2009 and 2013. Since then, heparin, rather than 
Bivalirudin, is now the procedural anticoagulant of choice and ticagrelor, rather than 
clopidogrel or prasugrel is now the P2Y12 inhibitor of choice in our centre. Transradial PPCI 
is now the most common access route for PPCI, and patients are more likely to receive DES 
(specifically everolimus-eluting stents (EES)) implantation during PPCI at present time. 
Therefore, temporal changes in outcomes may be present, but unaccounted for. Although 
significant effort was put into the accurate documentation of events, it is possible that some 
patients could have undergone repeat coronary revascularisation at hospitals that are 
outside of our region, and these events could therefore have been missed. This could have 
led to under-reporting of MACE. Limitations specific to each analysis are described in the 
relevant chapters. 
2.7. Data entry 
The data used for research purposes are anonymised at the point of data download. All 
patients have a unique database ID. Date of birth and gender are recorded in the database 
to allow for identification of age. Although research ethical approval and local NHS approval 
from Caldicott guardians (for the collection of data for performance assessment) in each 
regional hospital were obtained, the remit of this study falls within Section 251 of the NHS 
Health Service Act 2006, and therefore, informed consent from all patients for data 
collection for research purposes in this instance was not necessary; as the window for 
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repatriation to their relevant regional hospitals made this impractical for most patients. The 
Data Protection Act of 1998 was complied with at all times. 
 
The baseline data that were collected were: date of birth, gender, ethnicity, previous MI, 
previous PCI, previous CABG, hypertension (pre-existing or new in-hospital diagnosis prior to 
discharge), hypercholesterolaemia (pre-existing or new in-hospital diagnosis prior to 
discharge), diabetes mellitus (pre-existing or new in-hospital diagnosis prior to discharge – 
mode of control: diet, oral hypoglycaemic agents, insulin), atrial fibrillation (pre-existing or 
new in-hospital diagnosis prior to discharge), peripheral vascular disease (pre-existing or 
new in-hospital diagnosis prior to discharge), cerebrovascular disease (pre-existing only – 
previous TIA or strokes), renal insufficiency including dialysis (pre-existing), cigarette-
smoking (never, ex- or current-smoker). These were obtained by interrogating admission 
notes and discharge summaries for the relevant variables. Where the variables above were 
diagnosed in hospital prior to discharge, it was assumed that they were done according to 
appropriate criteria at the time of diagnosis. 
 
The clinical data that were recorded were: date and time of symptom-onset, date and time 
of call for help, date and time of arrival to hospital (either LGI or other regional hospitals), 
discharging hospital, discharge date from LGI (for patients from other regional centres who 
were re-patriated to their local CCU, this was their date of transfer from LGI), discharge date 
from regional hospitals (if applicable), date of death, cardiac or non-cardiac cause of death 
(part 1 of certificate confirming death), heart rate (in beats per minute), systolic blood 
pressure (in mmHg as recorded in cardiac catheter laboratory electronic records), weight in 
kilogram, procedure status (emergency), procedure indication (by default, STEMI), 
84 
 
presentation with cardiogenic shock, ST-segment elevation, type of ST-segment elevation, 
left-bundle branch block morphology, cardiac rhythm at presentation, pre-procedural 
aspirin dose, pre-procedural P2Y12-receptor inhibitor and dose of each drug, first operator 
name, second operator name, time of first interventional device, choice of anticoagulant, 
GPI use, percentage stenosis in each vessel, arterial access site(s), size of arterial sheath (in 
French), type of haemostasis, radiation time, radiation dose, post-PPCI complications, 
baseline and post-PPCI blood tests, discharge aspirin, P2Y12-receptor inhibitor therapy, ACE-
inhibitor, beta-blocker, statin, angiotensin receptor blocker. 
 
Procedural data that were recorded into the database were: vessel name, percentage 
stenosis, TIMI flow pre-PPCI, type of lesion (de novo, in-stent restenosis, stent thrombosis), 
aspiration and/or mechanical thrombectomy, distal protection device, stent fitted (yes/no; 
BMS or DES), use of inotropic agents, use of intravascular ultrasound (IVUS), post-PPCI TIMI 
flow, post-PPCI percentage of stenosis, and procedural complications (as a binary variable – 
if a complication (aortic dissection, cardiac arrest, contrast medium reaction, 
cerebrovascular accident, coronary dissection, coronary perforation, cardiac tamponade, 
vascular complications, or death) was logged in the cardiac catheter laboratory electronic 
records or in the patient notes). 
2.7.1. Identifying missing data 
Patients whose outcome data were not collected or unavailable were not included in 
analyses. Of the remaining patients, the level of baseline, procedural and post-procedural 
non-outcome data that were unavailable were identified by ascertaining percentages of 
missing values. Data completeness for the variables in the data download were as follows: 
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Table 2.1: Variables collected and their completeness in percentages. 
Variable Percentage completeness (%) 
Age in years 100.0 
Death 100.0 
Date of death 100.0 
Gender* 100.0 
Ethnicity* 94.8 
Symptom onset date 99.8 
Symptom onset time 100.0 
Call for help date 99.6 
Call for help time 99.0 
Arrival at LGI datea 100.0 
Arrival at LGI time 100.0 
Date of first interventional device 100.0 
Time of first interventional device 99.9 
Discharge date from LGI 100.0 
Discharge date from district hospitals 68.9 
Previous MI*b 99.6 
Previous PCI* c 99.6 
Previous CABG* d 99.6 
Hypertension* 99.6 
Hypercholesterolaemia* 99.5 
Diabetes mellitus* 98.8 
Peripheral vascular disease* 99.5 
Cerebrovascular disease* 99.5 
Renal insufficiency* 99.5 
Smoking status* 94.2 
Location of ST-segment elevation 99.7 
Rhythm 86.2 
Aspirin dose 99.9 
P2Y12 receptor inhibitor loading dose 99.6 
First operator 100.0 
Consultant 100.0 
Heparin dose 2.4 
LMS stenosis e 99.0 
LAD proximal stenosis f 98.4 
LAD other stenosis 97.8 
RCA stenosis g 98.4 
Circumflex artery stenosis 97.8 
LIMA stenosis h 94.7 
Vein graft stenosis 96.2 
Arterial access 1 100 
Arterial access 2 99.5 
Largest French size 100.0 
Femoral venous access 99.9 
Haemostasis 99.5 
Fluoroscopy time 94.6 
Radiation dose 94.6 
Complication – cardiogenic shock 99.9 
Complication – ventilation 99.9 
Complication – bradycardia requiring pacing 99.7 
Complication – intra-aortic balloon pump 99.9 
LGI baseline haemoglobin 95.9 
LGI baseline platelet count 95.4 
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LGI baseline creatinine kinase 89.9 
LGI baseline troponin 88.7 
LGI baseline creatinine 96.8 
LGI baseline estimated glomerular filtration rate (eGFR) i 45.7 
DGH baseline haemoglobin 85.6 
DGH baseline platelet 58.5 
DGH baseline creatinine 30.6 
DGH baseline troponin 40.0 
DGH baseline creatinine 59.8 
DGH baseline eGFR 25.4 
LGI peak creatinine kinase 54.3 
LGI lowest haemoglobin 52.4 
LGI peak plasma glucose 56.8 
LGI lowest platelet count 50.8 
LGI total serum cholesterol 53.3 
LGI peak creatinine 59.1 
DGH peak creatinine kinase 19.5 
DGH lowest haemoglobin 48.5 
DGH peak plasma glucose 47.0 
DGH lowest platelet count 41.8 
DGH peak troponin 21.0 
DGH total serum cholesterol 50.7 
DGH peak creatinine 50.1 
Discharge Aspirin 95.6 
Discharge ACE-inhibitor j 92.3 
Discharge statin 92.4 
Discharge beta adrenergic receptor blocker 92.5 
Discharge angiotensin receptor blocker 91.0 
Aspirin at 30 days 82.9 
P2Y12-receptor inhibitor at 30 days 81.9 
Type of P2Y12 receptor inhibitor at 30 days 74.1 
Angina at 30 days 73.7 
Blood transfusion at 30 days 91.5 
30-day major bleeding 94.6 
30-day re-infarction 100.0 
30-day unplanned coronary revascularisation 100.0 
30-day planned coronary revascularisation 99.4 
30-day stent thrombosis 99.8 
30-day stroke 92.7 
30-day contrast-induced nephropathy 90.7 
Aspirin at 12 months 97.1 
P2Y12 receptor inhibitor at 12 months 60.2 
Type of P2Y12 receptor inhibitor at 12 months 39.1 
Angina at 12 months 64.0 
12-month re-infarction 100.0 
12-month unplanned coronary revascularisation 100.0 
12-month planned coronary revascularisation 99.0 
12-month stent thrombosis 99.7 
12-month stroke 89.6 
Infarct-related artery (IRA) k 100.0 
IRA percent stenosis 99.0 
IRA pre-PPCI TIMI flow l 99.2 
IRA presentation with stent thrombosis 99.8 
Failed PCI of IRA 99.8 
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IRA aspiration thrombectomy 99.9 
IRA mechanical thrombectomy 99.9 
IRA distal protection device 99.7 
IRA inotropes 99.8 
IRA intravascular ultrasound (IVUS)m 99.8 
IRA Post-PPCI TIMI flow 98.1 
IRA post-PPCI IRA 97.7 
Door-to-balloon (DTB) time n 99.2 
Call-to-balloon (CTB) time o 99.0 
Type of stent (BMS/DES) p,q 100.0 
*Variables ascertained on admission/discharge according patient self-reporting. a LGI: Leeds 
General Infirmary; b MI: myocardial infarction; c PCI: percutaneous coronary intervention; d 
CABG: coronary artery bypass grafting; e LMS: left main stem; f LAD: Left anterior 
descending; g RCA: right coronary artery; h LIMA: left internal mammary artery; i eGFR: 
estimated glomerular filtration rate; j ACE: Angiotensin-converting enzyme; k IRA: infarct-
related artery; l TIMI: thrombolysis in myocardial infarction; m IVUS: intravascular 




Major-bleeding: HORIZONS-AMI major bleeding. 
MI: Defined according to the Universal Definition of Myocardial Infarction. 
Unplanned coronary revascularisation: Both percutaneous and surgical revascularisation 
procedures not planned or staged prior to discharge from hospital following index 
admission. 
Planned coronary revascularisation: Planned up to the point of discharge from hospital 
following index admission. 
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Stent thrombosis: Definite/probable/possible – according to the Academic Research 
Consortium criteria165. 
Post-PPCI stroke: Clinically and radiologically confirmed stroke of any aetiology. 
Contrast-induced nephropathy: Defined as an increase in serum creatinine of >25%, or a 
decrease of eGFR of > 25%, within 72 hours of radio-opaque contrast use. 
2.7.2. Analysing missing data 
Data completeness for the variables (the rationale for the use of selected variables are 
described in more detail in the description of each survival analysis in their relevant 
chapters) that were used in each regression was above 80% (specifically 99.07%). Missing 
data were assumed to have been missing at random. To avoid exclusion of cases (and 
consequently introducing bias) in the regression models due to missing data, outcome 
analyses that were undertaken in Chapters 5-7 were undertaken following multiple 
imputation by chained equations method, generating five imputed datasets in IBM SPSS 
(version 23.0.0.2)166–168. Predictive mean matching was utilised for the imputation of 
continuous variables (in this thesis, age was analysed as a continuous variable in chapters 6 
and 7)169. Categorical variables in the regression models were analysed as binary variables, 
and were imputed using logistic regression. The pooled analyses from imputed datasets 
using Rubin’s rules informed the final results presented in Chapters 5-7. In Chapters 3 and 4, 
11 observations were deleted by the R statistical package due to missing data, as complete 




2.8. Statistical analyses 
For all analyses, differences in baseline and procedural characteristics were analysed in IBM 
SPSS (version 23.0.0.2). Continuous variables were reported as medians with their 
corresponding interquartile ranges (IQR) and categorical variables were reported as 
frequencies with their corresponding percentages (n (%)). Categorical variables were 
compared with Chi-square tests for all analyses. Continuous variables in the analyses of the 
association between gender and ethnicity and clinical outcomes, the association between 
P2Y12-receptor inhibitor and outcomes and the association between GPI-use and outcomes 
according to arterial access site, were compared with Independent samples Student’s t-tests 
and Mann-Whitney u-tests, as appropriate. In the analysis of the association between 
operator volume and outcome, one-way analysis of variance was used to compare continuous 
variables of three groups. Continuous variables in the sub-analysis of outcomes according to 
operator status was undertaken using Independent samples Student’s t-tests and Mann-
Whitney u-tests. A two-sided p-value of ≤0.05 was considered statistically significant. 

























3.1. Analysis of the association between gender and ethnicity and outcomes 
The first analyses undertaken were the investigation of the association between gender and 
ethnicity on clinical outcomes following PPCI. As described in section 1.6, given the 
differences noted in outcomes between genders, even in contemporary studies, it was felt 
that this was an association that should be re-evaluated, especially in a contemporary UK all-
comers cohort. There were little published data examining the association between South 
Asian ethnicity and outcomes following PPCI. Therefore, the investigation of the association 
of this baseline characteristic was justified.  
 
3.1.1. Clinical endpoints 
For the analyses of the association of both gender and ethnicity and outcomes, the primary 
endpoints were major adverse cardiovascular events (MACE), within 30 days and 12 months 
of index PPCI, defined as all-cause mortality, recurrent MI, and repeat target and non-target 







3.1.2. Survival analyses 
For this analysis, survival analyses were performed in R (version 3.2.1) by the study statistical 
team (Claire Keeble, PhD, Paul Baxter, PhD)170. Only patients presenting between 01-01-2009 
and 31-12-2011 (3 calendar years) were included in this analyses as data collection for the 
period of 01-01-2013 until 31-12-2013 were not completed at the time of analysis. Cox 
proportional hazards models were fitted to the data (for the variables current or previous 
history of cigarette smoking, diabetes mellitus, hypertension, hypercholesterolemia, prior 
revascularization, prior MI, peripheral vascular disease or cerebrovascular disease, age 
category, gender, ethnicity and cardiogenic shock – known predictors of poor outcomes and 
therefore clinically justified variables (besides gender and ethnicity that were the variables 
investigated) and outcomes (all-cause mortality and MACE) of interest (using the ‘survival’ 
package). Further variables were not included to avoid “overfitting” of the models. All 
assumptions, including the proportional hazards assumption, were verified. Age tertiles  (<60 
years – Group 1, 60 to 79 years – Group 2 and ≥80 years – Group 3) rather than continuous 
age were used throughout to satisfy the proportional hazards assumptions required where a 
MACE event (censored for first event) was the outcome of interest. Kaplan-Meier curves were 
produced to illustrate each unadjusted outcome of interest for age, ethnicity and gender. In 
the analysis of the association between gender and clinical outcomes, the male gender was 
used as the reference category. In the analysis of the association between ethnicity and 
clinical outcomes, white patients were used as the reference category. Hazard ratios were 







3049 patients presented between 01-01-2009 and 31-12-2011, and were included in the 
analyses. Data for MACE at 12 months were available for 3028 (99.3%) patients. 
Baseline and procedural characteristics according to gender are listed in Table 3.1. A total of 
2223 (72.9%) men and 826 (27.1%) women underwent PPCI during this period. Statistically 
significant differences in patient and procedural characteristics were observed between 
men and women. Men were younger at presentation, had a higher prevalence of current or 
ex-smoking, previous MI and prior coronary revascularisation. Women had a higher 
prevalence of hypertension, less transradial PPCI, had lower use of Glycoprotein IIb/IIIa 
antagonists and aspiration thrombectomy, had fewer DES implantations, and importantly, 
had longer call-to-balloon (CTB) times. 
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Table 3.1: Baseline and procedural characteristics according to gender. 





Age in years, median(IQR) 69 (20) 60 (19) <0.01 
Diabetes mellitus n (%) 119 (14.4) 278 (12.5) 0.51 
Current/Ex-smoker n (%) 492 (59.6) 1565 (70.4) <0.01 
Hypertension n (%) 389 (47.1) 781 (35.1) <0.01 
Hypercholesterolaemia n (%) 253 (30.6) 679 (30.5) 0.95 
Renal insufficiency n (%) 21 (2.5) 56 (2.5) 0.81 
Previous MI n (%)* 83 (10.0) 300 (13.5) 0.02 
Previous revascularisation n (%) 59 (7.1) 256 (11.5) <0.01 
Peripheral vascular disease n (%) 17 (2.1) 63 (2.8) 0.43 
Cerebrovascular disease n (%) 54 (6.5) 117 (5.3) 0.23 
Anterior MI n (%) 328 (39.7) 946 (42.6) 0.15 
Pre-procedure cardiogenic shock n (%) 37 (4.5) 86 (3.9) 0.45 
Pre-procedure cardiac arrest n (%) 63  (7.6) 206 (9.3) 0.25 
Call-to-balloon time in minutes median (IQR) 138 (72) 130 (64) <0.01 
Door-to-balloon time in minutes median (IQR) 52 (33) 51 (31) 0.10 
Radial access n (%) 463 (56.1) 1450 (65.2) <0.01 
Infarct-related artery 
Left main stem n (%) 7 (0.8) 26 (1.2) 0.44 
Left anterior descending n (%) 337 (40.8) 951 (42.8) 0.31 
Circumflex n (%) 95 (11.5) 321 (14.4) 0.03 
Right coronary n (%) 377 (45.6) 875 (39.4) <0.01 
Bypass graft n (%) 8 (1.0) 43 (1.9) 0.06 
Multivessel PCI n (%)† 59 (7.1) 216 (9.7) 0.03 
Drug-eluting stents n (%) 411 (49.8) 1221 (54.9) 0.03 
Pre-procedural Aspirin n (%) 819 (99.2) 2199 (98.9) 0.57 
Pre-procedural Clopidogrel n (%) 495 (59.9) 1205 (54.2) <0.01 
Pre-procedural Prasugrel n (%) 322 (39.0) 994 (44.7) <0.01 
Glycoprotein IIb/IIIa antagonist n (%) 115 (13.9) 412 (18.5) <0.01 
Heparin n (%) 33 (4.0) 112 (5.0) 0.23 
Bivalirudin n (%) 787 (95.3) 2095 (94.2) 0.26 
Aspiration thrombectomy n (%) 532 (64.4) 1536 (69.1) 0.05 
Mechanical thrombectomy n (%) 8 (1.0) 43 (1.9) 0.17 
Pre-procedural TIMI 0 flow n (%)‡ 543 (65.7) 1556 (70.0) 0.05 
Post-procedural TIMI 3 flow n (%)‡ 718 (86.9) 1929 (86.8) 0.91 
Data are expressed as median (IQR), or number (%);*MI: Myocardial Infarction; †PCI: 





Advancing age was adversely associated with clinical outcomes. Higher rates of mortality (HR 
4.17 (95% CI 2.86-6.09)) and MACE (HR 2.03 (95% CI 1.60-2.57)) at 12 months were observed 
in age group 2 (60-79 years) compared to age group 1 (<60 years). Age group 3 (≥80 years) 
was associated with the highest rates of mortality (HR 10.53 (95% CI 7.07-15.67) and MACE 
(HR 3.93 (95% CI 2.99-5.17)) when compared to age group 1 (Figure 3.1). 
 
Figure 3.1: Kaplan-Meier survival curves illustrating unadjusted mortality (A) and MACE (B) 
in the three age tertiles. 
 
In univariable analyses, women had significantly higher mortality (HR 1.48 (95% CI 1.15-1.90)) 
and MACE (HR 1.40 (95% CI 1.14-1.72)) at 12 months compared to men (Table 3.2; Figures 
2A&B) for both first adjudicated MACE and all MACE. However, age-stratification alone by 
categorising into age groups 1-3 eliminated the excess risk of mortality and MACE in women 
(Figures 3.2C&D). When adjustment for potential confounders (including age) was carried out 
by multivariable analysis, once again, no statistically significant differences in MACE (HR 1.10 
(95% CI 0.89-1.37)) or mortality (HR 0.99 (95% CI 0.76-1.30)) in women compared to men. 
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Table 3.2: Clinical outcomes at 12 months according to gender. 





MACE* (n=427) 284 (13) 143 (17) <0.01 
Mortality (n=247) 159 (7) 88 (11) <0.01 
MI† (n=118) 77 (3) 41 (5) 0.06 
Revascularisation (n=62) 48 (2) 14 (2) 0.42 
All MACE MACE* (615) 18.4 24.9 <0.01 
Mortality (n=269) 7.9 11.4 <0.01 
MI† (n=203) 6.0 8.4 0.02 
Revascularisation (n=143) 4.5 5.2 0.41 
Data for first adjudicated MACE are expressed as n (%). Data for all MACE are expressed per 






Figure 3.2: Kaplan-Meier survival curves comparing crude mortality and MACE in men and 







Our analysis of real-world data from truly consecutive patients undergoing PPCI at a very 
large heart attack centre provides important insights into the association between gender 
and clinical outcomes following PPCI. Women had significantly higher rates of mortality and 
MACE compared to men in univariable analysis. However, age-stratification alone 
eliminated this excess risk. Multivariable analysis for adjustment for risk factors (including 
age) showed that female gender per se is not associated with adverse clinical outcomes. The 
difference in outcomes between genders is driven by age. 
 
Important differences between men and women in terms of baseline characteristics and 
procedural variables in a population of patients in the “contemporary” PPCI era were 
observed in this study. Previous studies had also observed these differences in 
chracteristics60,67–70,76. Previous studies have shown that women have higher rates of MACE 
despite correction for age and risk factors60,61,68,70,75. However, as described in Section 1.4.1.2, 
there has been increasing evidence in recent studies that female gender per se is does not 
independently predict poor clinical outcomes following PPCI and rather, adverse risk factor 
profile and patient delays contributed to poorer outcomes in women74. Our analysis has 
shown that the difference in age and baseline characteristics at the time of PPCI contributed 
to the differences in clinical outcomes between men and women, as suggested in previous 
studies63,67,71,73,74,78,79. However, importantly, we have shown that adjustment for age alone 
eliminates this excess risk, suggesting that age is the strongest determinant of clinical 




Delays to reperfusion have been identified in previous studies as potential explanations for 
poorer outcomes following PPCI in women66,70,79. In this study, statistically significantly 
longer CTB times were observed in women compared to men. However, In contrast to these 
studies statistically significant differences in door-to-balloon (DTB) times between men and 
women were not observed, and the DTB times in both genders in this study were 
comparable to these studies. Clinical outcomes in women could potentially be improved 
further by minimising pre-hospital delays. 
 
In this study, radial access for PPCI which is independently associated with improved clinical 
outcomes compared to femoral access, was significantly lower in women compared to men. 
Transradial PPCI was not included in the Cox-regression model, as reduced rates of radial 
access could be due to size-mismatch between 6-French arterial sheaths and the diameter 
of the radial artery, or increased incidence of radial artery spasm in women171. Therefore 
differences in transradial PPCI, rather than being a confounder, is likely to be due to 
anatomical and physiological differences between genders. However, with the development 
of sheath-less guide catheter and hydrophilic sheaths, along with newer techniques such as 
balloon-tracking, the differences noted between genders in transradial PPCI could be 
improved further with time. 
3.4. Limitations 
In addition to the limitations described in Chapter 2, in the female < 60 years group, the lack 
of statistical significance in outcomes compared to men could be to the relatively smaller 
number of patients (compared to women aged 61-79 years) in this group, as it has been 
suggested in the literature that younger women may have more adverse outcomes 
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compared to younger men. However, it is important to recognise that a larger population 
may not have necessarily revealed differences in outcomes. Complete case analyses rather 
than multiple imputation analyses were undertaken, as the number of cases with missing 
data were only 11 (0.36%). Despite the very small number of cases excluded with complete 


















A total of 2570 (84.3%) White patients and 297 (9.7%) South Asian patients underwent PPCI 
between 01-01-2009 and 31-12-2011 (Table 4.1). Multiple statistically significant differences 
in baseline and procedural characteristics between South Asian and White patients were 
observed. Although South Asian patients presented with STEMI at a younger age, their 
prevalence of other established risk factors (diabetes mellitus, systemic hypertension, 
hypercholesterolaemia and pre-existing coronary disease) were higher compared to White 
patients. 
 
There was no statistically significant difference in mortality (HR 0.97 (95% CI 0.64-1.47)) or 
MACE (HR 1.21 (95% CI 0.89-1.64)) between South Asian and White patients in univariable 
analysis of first adjudicated MACE (Figure 4.1). However, when individual components of 
MACE (mortality, MI, and coronary revascularisation) were considered separately, a higher 
incidence of MI was observed in South Asian patients (Table 4.2). Multivariable analysis 
confirmed that South Asian patients do not have statistically significant difference in MACE 





Table 4.1: Baseline and procedural characteristics according to ethnicity. 
Baseline and procedural characteristics White (n=2570) South Asian (n=297) p value 
Age in years, median (IQR) 64 (20) 56 (21) <0.01 
Diabetes mellitus n (%) 277 (10.8) 94 (31.6) <0.01 
Current/Ex-smoker n (%) 1783 (69.4) 151 (50.8) <0.01 
Hypertension n (%) 971 (37.8) 134 (45.1) 0.02 
Hypercholesterolaemia n (%) 753 (29.3) 121 (40.7) <0.01 
Renal insufficiency n (%) 66 (2.6) 10 (3.4) 0.51 
Previous MI n (%)* 318 (12.4) 49 (16.5) 0.07 
Previous revascularisation n (%) 250 (9.7) 45 (15.2) <0.01 
Peripheral vascular disease n (%) 70 (2.7) 3 (1.0) 0.21 
Cerebrovascular disease n (%) 153 (6.0) 14 (4.7) 0.54 
Anterior MI n (%) 1044 (40.6) 147 (49.5) <0.01 
Pre-procedure cardiogenic shock n (%) 103 (4.0) 11 (3.7) 0.82 
Pre-procedure cardiac arrest n (%) 220 (8.6) 20 (6.7) 0.49 
Call-to-balloon time in minutes median (IQR) 139 (64) 131 (68) 0.06 
Door-to-balloon time in minutes median (IQR) 51 (32) 52 (35) 0.53 
Radial access n (%) 1610 (62.6) 185 (62.3) 0.72 
Infarct-related artery  
Left main stem n (%) 26 (1.0) 1 (0.3) 0.25 
Left anterior descending n (%) 1062 (41.3) 149 (50.2) <0.01 
Circumflex n (%) 357 (13.9) 36 (12.1) 0.40 
Right coronary n (%) 1081 (42.1) 105 (35.4) 0.03 
Bypass graft n (%) 42 (1.6) 5 (1.7) 0.95 
Multivessel PCI n (%) † 230 (8.9) 24 (8.1) 0.62 
Drug-eluting stents n (%) 1336 (52.0) 195 (65.7) <0.01 
Pre-procedural Aspirin n (%) 2546 (99.1) 293 (98.7) 0.49 
Pre-procedural Clopidogrel n (%) 1425 (55.4) 184 (62.0) 0.03 
Pre-procedural Prasugrel n (%) 1121 (43.6) 109 (36.7) 0.02 
Glycoprotein IIb/IIIa antagonist n (%) 440 (17.1) 51 (17.2) 0.94 
Heparin n (%) 119 (4.6) 20 (6.7) 0.11 
Bivalirudin n (%) 2438 (94.9) 276 (92.9) 0.34 
Aspiration thrombectomy n (%) 1752 (68.2) 198 (66.7) 0.88 
Mechanical thrombectomy n (%) 45 (1.8) 4 (1.3) 0.28 
Pre-procedural TIMI 0 flow n (%) ‡ 1769 (68.8) 201 (67.7) 0.90 
Post-procedural TIMI 3 flow n (%)‡ 2235 (87.0) 258 (86.9) 0.96 
Data are expressed as median (IQR), or number (%); *MI: Myocardial Infarction; †PCI: 





Figure 4.1: Kaplan-Meier survival curve illustrating 12-month unadjusted mortality (A) and 
MACE (B) in South Asian and White patients. 
 
Table 4.2: Clinical outcomes at 12 months according to ethnicity. 
Event White 
(n=2570) 





MACE* (n=427) 354 (14) 48 (16) 0.26 
Mortality (n=247) 207 (8) 19 (6) 0.32 
MI† (n=118) 93 (4) 22 (7) <0.01 
Revascularisation (n=62) 54 (2) 7 (2) 0.77 
All MACE MACE* (615) 19.3 27.9 <0.01 
Mortality (n=269) 8.7 8.4 0.88 
MI† (n=203) 6.3 12.1 <0.01 
Revascularisation (n=143) 4.4 7.4 0.02 
Data for first adjudicated MACE are expressed as n (%). Data for all MACE are expressed per 





This is the first study to assess the association between South Asian ethnicity and outcomes 
in the contemporary era of PPCI. No statistically significant difference in mortality or MACE 
was observed in univariable and multivariable analysis comparing clinical outcomes of South 
Asian patients with those of White patients. However, South Asian patients had higher 
incidence of recurrent MI within 12 months of index PPCI. 
 
There are limited published data assessing clinical outcomes in South Asian individuals 
undergoing PPCI in the contemporary era. Multiple statistically significant differences in 
baseline characteristics were found between South Asian and White patients: higher 
prevalence of diabetes mellitus, hypertension, hypercholesterolaemia and pre-existing 
coronary artery disease in South Asian patients despite their younger age at presentation. 
These were consistent with previous studies2,104,105,109–111. Metabolic syndromes (including 
insulin resistance and diabetes mellitus) and altered levels of adipokines and inflammatory 
mediators have been shown to contribute to the younger age of onset of CAD and poorer 
clinical outcomes following coronary events in South Asian individuals compared to White 
individuals98–108.  Multiple statistically significant differences in procedural variables between 
South Asian and White patients were observed in this study. Importantly, South Asian patients 
were statistically significantly more likely to present with anterior MIs, with the left anterior 
descending (LAD) artery being the infarct-related artery. This is associated with adverse 
clinical outcomes and a greater risk of  in-stent restenosis172,173. 
 
The statistically significant difference in the prevalence of risk factors, particularly the 
prevalence of diabetes mellitus in South Asian patients, which in our cohort was three times 
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higher than in White patients, is likely to contribute to the higher incidence of recurrent MIs 
in South Asian patients. Despite their higher rates of recurrent MIs, when only first 
adjudicated events were analysed, South Asian patients did not have higher mortality or 
MACE. Younger age at presentation and some patients experiencing multiple events, with 
subsequent events not being included when censored for first adjudicated event, could 
explain this difference. 
 
4.3. Limitations 
Although a large number of South Asian patients were included in this study, distinguishing 
those born in the UK from those born outside the UK and immigrated to the UK in later life 
was not possible. This is potentially an important factor to recognise, as standardized 
mortality ratios from CAD are higher in South Asian countries compared to the UK. It is 
therefore possible that South Asian patients who had emigrated to the UK may have higher 
risk of adverse events from CAD compared to those who were born in the UK174. Finally, 
determination of continuation of secondary prevention medication at 12 months, which may 
have been different between genders and ethnicities, was not possible. However, this is 
unlikely to be different between the ethnicities, and if there were differences, compliance 






Chapter 5: Oral P2Y12-




5.1. Analysis of the association between oral P2Y12-receptor inhibitors and outcomes 
There are limited available data reporting the association between the choice of oral P2Y12 
receptor inhibitors and outcomes following PPCI. Data comparing prasugrel with ticagrelor 
are limited to two studies (one trial that was terminated early and one observational study 
that may have been confounded by differences in arterial access site that were not presented) 
as described in Chapter 1. This association therefore warranted investigation from this 
registry. 
 
5.1.1. Clinical endpoints 
The primary efficacy endpoints were 30-day and 12-month MACE. The secondary efficacy 
endpoints were 30-day and 12-month all-cause mortality. The primary safety endpoint was 
30-day major bleeding according to HORIZONS criteria (bleeding from an intracranial or 
intraocular source; arterial access site bleeding measuring ≥5cm, or intervention for bleeding; 
a haemoglobin-reduction of ≥4g/dL with no overt source of bleeding, or a haemoglobin-
reduction of ≥3g/dL with an identifiable source of bleeding; red cell transfusion; bleeding 
requiring re-operation) 177. 
 
5.1.2. Survival analyses 
Logistic regression analyses were undertaken in IBM SPSS (version 23.0.0.2) by AK, to evaluate 
outcomes adjusted for confounding variables. Patients presenting between 01-01-2009 and 
31-12-2011, and between 01-01-2013 and 31-12-2013 were included in this analysis, and all 
subsequent survival analyses. The pre-procedural P2Y12-receptor inhibitor therapy was used 
to define choice of P2Y12-receptor inhibitor. Confounders were identified in exploratory 
analyses of variables that were known in scientific literature to contribute positively or 
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negatively to outcomes, and were included on the logistic regression models if there were 
differences within groups with P≤0.10. Exploratory analyses revealed the following variables 
with P≤0.10: Age over 65 years, radial artery access, P2Y12-receptor inhibitor therapy, 
hypertension, hypercholesterolaemia, diabetes mellitus, renal dysfunction, anterior STEMI, 
prior MI, pre-existing peripheral vascular disease or cerebrovascular disease, CTB > 120 
minutes, GPI-use, cardiogenic shock at presentation, year PPCI was performed (adjusting for 
temporal advances in PPCI that were otherwise not identified or recorded, such as 
advancement in secondary prevention, rise in primary prevention ICD devices142), and DES 
implantation. Year of PPCI was assessed in exploratory analyses due to the strong temporal 
trend in the choice of P2Y12-receptor inhibitor (Figure 5.1). As with the analysis of the 
association between gender and ethnicity and outcomes, although there are more known 
predictors of poor outcomes following PPCI, the variables that were assessed were only those 
that were recorded in the database. Further variables, even if recorded in the database, were 
not included in the regression models to avoid “overfitting” of the models. In the comparison 
of prasugrel and ticagrelor against clopidogrel, the reference category was clopidogrel. In the 
comparison of prasugrel with ticagrelor, the reference category was ticagrelor. All odds ratios 






Between 01-01-2009 and 31-12-2011, and between 01-01-2013 and 31-12-2013 (four 
calendar-year period), 4056 patients underwent PPCI, of whom 3703 (91.3%) were followed 
up to a minimum of 12 months, all of whom had data for 30-day and 12-month mortality and 
MI collected at follow-up. These patients were therefore included in the analysis. Follow-up 
data for 30-day HORIZONS-major bleeding were available for 3449 (93.1%) of the 3703 
patients who were included in this analysis. 
 
The breakdown of the choice of P2Y12-receptor inhibitor were as follows: 1648 (44.5%) 
patients received clopidogrel, 1244 (33.6%) patients received prasugrel and 811 (21.9%) 
patients received ticagrelor. Comparison of baseline and procedural variables revealed 
multiple statistically significant differences amongst the patients receiving each P2Y12-
receptor inhibitor (Table 5.1). This is likely to be due to the temporal trend of use of each 
P2Y12-receptor inhibitor over the recruitment period, which is illustrated in Figure 5.1. 
Unadjusted and adjusted 30-day and 12-month mortality and recurrent MI, and 30-day 




Table 5.1: Baseline and procedural details according to procedural P2Y12-receptor inhibitor.  
Data are expressed as median (IQR), or number (%); 1 MI: Myocardial Infarction; 2 PCI: Percutaneous coronary intervention; 3 TIMI: 
Thrombolysis in Myocardial Infarction. These are hypothesis-generating analyses and therefore, p-values should be interpreted with caution. 
  













Age in years, median (IQR) 61 (17) 63 (19) <0.01 65 (21) 61 (17) <0.01 63 (19) 65 (21) <0.01 
Male n (%) 941 (75.6) 587 (72.4) 0.10 1178 (71.5) 941 (75.6) 0.01 587 (72.4) 1178 (71.5) 0.64 
White n (%) 1061 (85.3) 707 (87.2) 0.23 1388 (84.2) 1061 (85.3) 0.43 707 (87.2) 1388 (84.2) 0.05 
Diabetes mellitus n (%) 152 (12.2) 133 (16.4) <0.01 235 (14.3) 152 (12.2) 0.05 133 (16.4) 235 (14.3) 0.37 
Current/Ex-smoker n (%) 885 (71.1) 510 (62.9) <0.01 1070 (64.9) 885 (71.1) <0.01 510 (62.9) 1070 (64.9) 0.54 
Hypertension n (%) 424 (34.1) 317 (39.1) <0.01 688 (41.7) 424 (34.1) <0.01 317 (39.1) 688 (41.7) <0.01 
Hypercholesterolaemia n (%) 365 (29.3) 269 (33.2) <0.01 524 (31.8) 365 (29.3) 0.15 269 (33.2) 524 (31.8) <0.01 
Renal insufficiency n (%) 15 (1.2) 16 (2.0) <0.01 66 (4.0) 15 (1.2) <0.01 16 (2.0) 66 (4.0) <0.01 
Previous MI n (%)1 122 (9.8) 101 (12.5) <0.01 237 (14.4) 122 (9.8) <0.01 101 (12.5) 237 (14.4) 0.02 
Peripheral/Cerebrovascular disease n (%) 53 (4.3) 54 (6.7) <0.01 180 (10.9) 53 (4.3) <0.01 54 (6.7) 180 (10.9) <0.01 
Cardiogenic shock n (%) 36 (2.9) 59 (7.3) <0.01 75 (4.6) 36 (2.9) 0.02 59 (7.3) 75 (4.6) <0.01 
Anterior ST-Elevation MI n (%) 542 (43.6) 320 (39.5) 0.07 673 (40.8) 542 (43.6) 0.14 320 (39.5) 673 (40.8) 0.51 
Call-to-balloon time in minutes median (IQR) 122 (43) 125 (52) 0.02 142 (79) 122 (43) <0.01 125 (52) 142 (79) <0.01 
Door-to-balloon time in minutes median (IQR) 51 (30) 48 (28) <0.01 51 (33) 51 (30) 0.83 48 (28) 51 (33) <0.01 
Radial access n (%) 876 (70.4) 663 (81.8) <0.01 843 (51.2) 876 (70.4) <0.01 663 (81.8) 843 (51.2) <0.01 
Multivessel PCI n (%)2 100 (8.0) 63 (7.8) 0.83 160 (9.7) 100 (8.0) 0.12 63 (7.8) 160 (9.7) 0.12 
Drug-eluting stents n (%) 785 (63.1) 669 (82.5) <0.01 773 (46.9) 785 (63.1) <0.01 669 (82.5) 773 (46.9) <0.01 
Glycoprotein IIb/IIIa antagonist n (%) 197 (15.8) 88 (10.9) <0.01 302 (18.3) 197 (15.8) 0.08 88 (10.9) 302 (18.3) <0.01 
Bivalirudin n (%) 1202 (96.6) 771 (95.1) 0.08 1532 (93.0) 1202 (96.6) <0.01 771 (95.1) 1532 (93.0) 0.04 
Aspiration thrombectomy n (%) 917 (73.7) 621 (76.8) 0.23 1053 (63.9) 917 (73.7) <0.01 621 (76.8) 1053 (63.9) <0.01 
Post-procedural TIMI 3 flow n (%)3 1121 (90.1) 737 (90.9) 0.24 1410 (85.6) 1121 (90.1) <0.01 737 (90.9) 1410 (85.6) <0.01 
112 
 
Table 5.2: Clinical outcomes according to P2Y12-receptor inhibitor therapy. 
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Prasugrel vs ticagrelor 
Statistically significant differences in both unadjusted and adjusted 30-day mortality were 
observed in the comparison of prasugrel with ticagrelor, with patients receiving prasugrel 
observed to have lower mortality. Multivariable analysis revealed no statistically significant 
difference in adjusted 12-month mortality between patients receiving prasugrel and 
patients receiving ticagrelor, although unadjusted 12-month mortality was significantly 
higher in patients receiving ticagrelor. Neither univariate nor multivariable analysis revealed 
a significant difference in 30-day bleeding between the two groups (Table 5.2).  
 
Prasugrel vs clopidogrel 
Thirty-day and 12-month mortality were significantly less likely in patients receiving prasugrel 
compared to patients receiving clopidogrel, in both unadjusted and adjusted analyses. In 
addition, unadjusted and adjusted 30-day MI, and adjusted 12-month MI were also 
statistically significantly lower in patients receiving prasugrel compared to clopidogrel. There 
were no statistically significant difference in 30-day major bleeding between the two groups 
(Table 5.2). 
 
Ticagrelor vs clopidogrel 
There were no significant differences in unadjusted and adjusted 30-day and 12-month 
mortality, or 30-day major bleeding between patients receiving ticagrelor and patients 
receiving clopidogrel. However, patients receiving ticagrelor had lower unadjusted and 





This analysis of contemporary real-world data from a large consecutive patient series has 
provided an important direct comparison of clinical outcomes between patients treated 
with prasugrel and ticagrelor in the setting of PPCI for STEMI, with the first direct 
comparison of bleeding between ticagrelor and prasugrel. Prasugrel and ticagrelor were also 
individually compared with clopidogrel. Patients treated with prasugrel were observed to 
have statistically significantly lower adjusted mortality at both 30 days and 12 months, 
compared to patients treated with clopidogrel. This finding was not observed in patients 
receiving ticagrelor in comparison with patients receiving clopidogrel. Crucially, for the first 
time, patients receiving prasugrel have been shown to have lower risk-adjusted 30-day 
mortality compared to those receiving ticagrelor. This finding approached, but did not reach 
statistical significance at 12 months (P=0.06). Repeat MI were lower in both third-
generation P2Y12-reecptor inhibitor therapies, compared to clopidogrel, with the difference 
observed with ticagrelor being statistically significantly different at both 30-days and 12-
months. No differences in major bleeding were observed amongst the three drugs. 
In comparison to the analysis by Gosling et al140, reduction in mortality were not observed in 
patients treated with ticagrelor compared to clopidogrel. Prasugrel, however, was associated 
with reduced mortality at 30 days and 12 months compared to clopidogrel, and at 
importantly, 30 days compared to ticagrelor, which was partly in keeping with their findings. 
Key differences in statistical analyses might account for the differences in findings. Gosling et 
al did not present or adjust for arterial access site, which could have been different between 
the groups if there was a temporal trend in the use of relevant P2Y12-receptor antagonist, 
which was also not presented and if necessary, adjusted for. Radial artery access was included 
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in the regression models in this study, and was found to be independently associated with 
lower adjusted 30-day (OR 0.28 (95% CI 0.19-0.40)) and 12-month (OR 0.50 (95% CI 0.38-
0.66)) mortality, and 30-day bleeding (OR 0.40 (95% CI 0.28-0.56)) compared to femoral artery 
access. Year of presentation was also corrected for in this study, to minimise the effect of 
potentially unrecorded confounders such as progress with DES platforms and non-
pharmacological secondary prevention. The key finding of this study that in the real-world, 
the third-generation P2Y12-receptor inhibitors were associated with better outcomes 
compared to clopidogrel was in keeping with their study. 
 
There were several differences between the findings of this study and that of TRITON-TIMI 
38. In this study, lower 30-day and 12-month mortality, and lower MI within 30 days of index 
PPCI were observed in patients treated with prasugrel compared to clopidogrel. We also 
observed lower rates of recurrent MI within 30-days in patients receiving prasugrel compared 
to clopidogrel, which was in keeping with TRITON TIMI 38. Differences in outcomes between 
this study and the PPCI subgroup of TRITON TIMI 38 could be explained by differences in 
baseline and procedural characteristics. The patients in this study appeared older (median 
age 62 vs 59), had higher prevalence of tobacco use (67.5 % vs 45.0 %), lower prevalence of 
diabetes mellitus (14.3% vs 16.8%), hypertension (38.0% vs 48.7%) and 
hypercholesterolaemia (32.1% vs 37.6%), compared to those undergoing PPCI in TRITON TIMI 
38. The patients included in this study were also more likely to receive DES (60.1% vs 28.5%), 
were mostly anticoagulated with bivalirudin (95.5% vs 1.0%) and were less likely to receive 
GPI (85.3% vs 66.2%) compared to patients in the PPCI subgroup of TRITON TIMI 38. Patients 
in this study also mostly underwent transradial PPCI (59.4% in the prasugrel and clopidogrel 
group), whereas in TRITON TIMI 38, arterial access site was not presented and was likely to 
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be femoral artery. Analysis of 30-day bleeding in this cohort of patients was in keeping with 
TRITON TIMI 38, which also found no statistically significant difference in bleeding at 30 days. 
 
Koshy et al137 compared prasugrel with clopidogrel for 12-month mortality, and reported that 
patients receiving prasugrel had lower adjusted 12-month mortality compared to patients 
receiving clopidogrel, which was similar to the results observed in this study. However, in 
contrast with this study, choice of arterial access site was not included in their multivariable 
analysis, despite a higher proportion of patients in their prasugrel subgroup undergoing 
transradial PPCI, compared to their clopidogrel subgroup. Post-procedural TIMI 3 flow was 
also included in their Cox model. This was not included in the regression model of this study 
as it was plausible post-PPCI microvascular function could be influenced by the choice of 
P2Y12 receptor inhibitor, and therefore, differences in TIMI flow should not be considered a 
confounding factor178. Age of patient at presentation and DTB times also appeared different 
between this study and that of Koshy et al, and higher rates of use of GPI were observed in 
their study compared to this study. In this study, as described earlier, given the significant 
temporal trends in the use of each P2Y12 receptor inhibitor, year of PPCI was included in the 
regression models. Importantly, despite the difference in statistical analysis, along with 
differences in baseline and procedural characteristics, a similar association between 
treatment with prasugrel and survival, in comparison with clopidogrel, was observed in both 
studies. Additionally, an inverse association between prasugrel and recurrent MI within 12 
months of index PPCI was observed in our analysis. 
 
The PPCI subgroup analysis from the PLATO investigators 179 revealed a reduction in all-cause 
mortality in patients treated with ticagrelor compared to patients treated with clopidogrel 
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that approached statistical significance (p=0.05) at 12 months. This finding was not observed 
in this study. In this study, patients treated with ticagrelor had lower rates of recurrent MI at 
30 days and at 12 months compared to patients treated with clopidogrel. Patients treated 
with ticagrelor did not have a higher risk of bleeding compared to patients treated with 
clopidogrel, which was in keeping with the PLATO sub-study analysis. There were, however, 
important differences in clinical characteristics between the PLATO sub-study and the study 
population for this study that could account for the differences observed. In the PLATO sub-
study, patients who received open-label clopidogrel pre-randomization were then given an 
additional 600mg loading dose of clopidogrel upon randomization (if randomized to 
clopidogrel). The majority of their patients received BMS instead of DES, which if reversed, 
may have reduced recurrent ischaemic events. Procedural anticoagulation in PLATO was 
achieved with unfractionated heparin rather than bivalirudin in most patients, with higher 
use of GPI in comparison with this study. 
 
Significant differences in baseline and procedural characteristics between the three groups 
of patients were observed in this study. As illustrated in Figure 1, in 2009, most patients 
undergoing PPCI in LGI received clopidogrel, with the rest receiving prasugrel. In 2010 and 
2011 however, the majority of patients received prasugrel rather than clopidogrel, and in 
the final year of recruitment (2013), the majority of patients received ticagrelor. Over the 
course of recruitment, there were significant changes in the rates of transradial PPCI (39.6% 
in 2009 vs 81.8% in 2013) and the use of DES (41.3% in 2009 vs 82.2% in 2013). A higher 
proportion of patients in the ticagrelor cohort underwent PPCI for cardiogenic shock, which 
is traditionally regarded as a marker of poor prognosis180. This is likely to be due to a gradual 
reduction in the threshold for accepting patients for PPCI. There were also advances in 
119 
 
secondary prevention over the study period, including an increased rate of implantation of 
primary-prevention ICDs following MI142. These and other confounders such as changes in 
clinical practice, improvements in operator proficiency, particularly in transradial PPCI, and 
improvements in the PPCI pathway could have all contributed to the differences in 
unadjusted outcomes. However, multivariable analysis, including adjustment for year of 
PPCI to adjust for unquantifiable time-dependent confounders, was undertaken to correct 
for major confounding factors. 
 
5.4. Limitations 
As described previously, temporal advances in PPCI could have introduced unidentified or 
unquantified confounders to the results of this study. However, this was addressed and 
corrected for by adjusting for year of admission. Continuation and/or switching of P2Y12-
receptor inhibitors following discharge could not be adequately determined. However,  this 
limitation was also present in the only other comparable real-world studies137,140. Switching 
from ticagrelor was noted in PLATO due to dyspnoea, but also perhaps due to compliance 
with its twice-daily administration. However, in this study, differences in outcomes were 
observed in all three comparisons of P2Y12-receptor inhibitors, which should not have been 
observed if switching of P2Y12-receptor inhibitor therapy contributed to differences in 
outcomes. Event rates in this study were low compared to PLATO or TRITON-TIMI 38 that 
involved larger numbers of patients, as under-reporting of adverse events is more likely in 
observational studies compared to RCTs. Therefore play of chance could not be excluded. 
Details of other changes to secondary prevention that could also be of prognostic value 
(aspirin, beta-adrenergic receptor blockers, ACE-inhibitors, statins) at 30-days and 12-months 
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could not be determined. However, differences across the groups were unlikely as all patients 
in this study received guideline-indicated care. Multiple comparisons of baseline and 
procedural characteristics were undertaken (Table 5.1). However, as with other comparisons 
of baseline and procedural characteristics in this study (Tables 3.1, 4.1, 5.1, 6.1, and 7.1), p-
values presented in in Table 5.1 were not adjusted for multiple testing. This is because the p-
values presented were descriptive rather than inferential, and were therefore, uncorrected. 
Finally, the findings of this study should be considered hypothesis-generating. Interrogation 
of larger national databases would facilitate larger-scale propensity-matched comparisons 
between P2Y12-receptor inhibitors that may inform future guideline-recommendations 





Chapter 6. Individual operator 




6.1. Analysis of the association between individual operator annual PPCI volumes and 
outcomes 
The current international guideline recommendation of >11PPCI per year as adequate 
operator volume was informed by two non-contemporary studies undertaken in the USA, 
where the practice of PPCI, particularly operator volume, does not necessarily reflect that in 
the UK. As described by Fanaroff et al, there is a significant geographical variability in operator 
volumes in the USA143. Therefore, the association between annual operator PPCI volume and 
outcomes in contemporary PPCI was an important study to undertake. 
 
6.1.1. Calculation of annual operator PPCI volumes 
PPCI in LGI is undertaken by internal operators who are primarily employed by Leeds 
Teaching Hospitals NHS Trust undertaking in-hours PPCI (Monday to Friday from 0800 hours 
to 1800 hours) and out-of-hours PPCI (Monday to Friday 1800 hours to 0800 hours, all day 
Saturday and all day Sunday) PPCI only at LGI, or external or visiting operators who are 
primarily employed by other regional hospitals, performing predominantly out-of-hours 
PPCI only at LGI. 
Annual operator PPCI volumes were then calculated by deriving the mean number of PPCI 
undertaken by each operator over the time they were on the PPCI rota in LGI, which varied 
between 6 months and 4 years. The 33rd (55.5 PPCI per year) and 67th (110.3 PPCI per year) 
centiles of annual operator PPCI volumes were then calculated based on all PPCI performed 
over the four-year recruitment period. These centiles were then used to define operator 
volume tertiles, which were 1-54 PPCI per year (low-volume tertile), 55-109 PPCI per year 
(intermediate-volume tertile), and ≥110 PPCI per year (high-volume tertile).  
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6.1.2. Clinical endpoints 
For this analysis, the primary endpoints were 30-day and 12-month mortality. 
6.1.3. Survival analyses 
Multivariable analyses were undertaken by AK using Cox proportional hazards regression 
analyses in IBM SPSS (version 23.0.0.2), to adjust for confounding variables. The proportional 
hazards assumptions were verified both graphically with log-minus-log curves, and with time-
dependent covariate analyses. The variables included in the Cox models were: individual 
operator volume tertile, patient age (as a continuous variable), prior MI, 
hypercholesterolaemia, hypertension, pre-existing peripheral vascular disease or 
cerebrovascular disease, diabetes mellitus, current or previous history of cigarette-smoking, 
left main coronary artery IRA, out-of-hours PPCI (as defined above), DTB of ≥ 90 minutes (a 
combination of known predictors of poor outcomes following PPCI and variables that differed 
between groups with P<0.10. The high-volume tertile was used as the reference category for 
survival analyses when comparing clinical outcomes of low-volume and intermediate-volume 
operators against those of high-volume operators. In the comparison of low-volume 
operators and intermediate-volume operators, the reference category was intermediate-
volume operator. The Cox regression analyses were then repeated to compare 30-day and 
12-month mortality between PPCI performed by internal operators and PPCI performed by 
visiting operators, by substituting operator volumes with the categorical variable “internal 
operator”, using internal operator as the reference category for survival analyses. All hazard 
ratios in this study were obtained from the Cox regression models, and were quoted with 





During the study period (01-01-2009 and 31-12-2011, and between 01-01-2013 and 31-12-
2013 (four calendar-years)), a total of 4056 patients underwent PPCI in LGI, of whom 3703 
(91.3%) patients were followed up to a minimum of 12 months. All patients who were 
followed up were included in this analysis. Thirty-day and 12-month mortality data were 
available for all patients included in this analysis. Of the 3703 procedures, 1122 PPCI were 
performed by 23 low-volume operators, 1284 PPCI were performed by five intermediate-
volume operators, and 1297 PPCI were performed by three high-volume operators. Baseline 




Table 6.1: Baseline and procedural details according to annual operator PPCI volume. 
  
Data are expressed as median (interquartile range), or number (%) as described; *MI: Myocardial 
Infarction; †PCI: Percutaneous coronary intervention; ‡TIMI: Thrombolysis in Myocardial Infarction; § 
IRA: Infarct-related artery.
Clinical characteristics Operator volume 
Low (n=1122) Intermediate (n=1284) High (n=1297) P 
Number of PPCI per year, median (IQR)† 27 (9) 100 (24) 113 (9) <0.01 
Out-of-hours PPCI n (%)† 767 (68.4) 733 (57.1) 657 (50.7) <0.01 
Age in years, median (IQR) 63 (19) 63 (20) 63 (20) 0.88 
Male n (%) 828 (73.8) 950 (74.0) 928 (71.5) 0.31 
Diabetes mellitus n (%) 165 (14.7) 160 (12.5) 195 (15.0) 0.38 
Current/Ex-smoker n (%) 744 (66.3) 857 (66.7) 864 (66.6) 0.99 
Hypertension n (%) 451 (40.2) 488 (38.0) 490 (37.8) 0.44 
Hypercholesterolemia n (%) 351 (31.3) 398 (31.0) 409 (31.5) 0.90 
Renal insufficiency n (%) 26 (2.3) 33 (2.6) 38 (2.9) 0.76 
Previous MI n (%)* 137 (12.2) 162 (12.6) 161 (12.4) 0.78 
Peripheral/Cerebrovascular disease n (%) 82 (7.3) 95 (7.4) 110 (8.5) 0.62 
Cardiac arrest n (%) 92 (8.2) 134 (10.4) 128 (9.9) 0.16 
Door-to-balloon time in minutes median (IQR) 51 (29) 47 (30) 53 (31) <0.01 
Radial access n (%) 694 (61.9) 822 (64.0) 866 (66.8) 0.04 
Multivessel PCI n (%)† 110 (9.8) 104 (8.1) 109 (8.4) 0.30 
Stent implantation n (%) 1029 (91.7) 1206 (93.9) 1232 (95.0) <0.01 
Third generation P2Y12-receptor inhibitor n (%) 628 (56.0) 747 (58.2) 680 (52.4) 0.01 
Glycoprotein IIb/IIIa antagonist n (%) 215 (19.2) 156 (12.1) 216 (16.7) <0.01 
Bivalirudin n (%) 1065 (94.9) 1221 (95.1) 1219 (94.0) 0.41 
Aspiration thrombectomy n (%) 759 (67.7) 982 (76.5) 850 (65.6) <0.01 
Post-procedural TIMI 3 flow in IRA n (%)§ 956 (88.3) 1155 (92.7) 1157 (92.0) <0.01 
126 
 
Patient baseline characteristics did not significantly differ between the three tertiles. However, 
there were statistically significant differences in procedural characteristics; proportion of out-of-
hours PPCI, choice of pre-procedural P2Y12-receptor inhibitor therapy, radial artery access for 
PPCI, glycoprotein IIb/IIIa antagonist use, the use of thrombus aspiration catheters, rates of stent 
implantation, CTB and DTB times, and post-procedural TIMI 3 flow in the IRA were significantly 
different across the tertiles (Table 6.1).  
In the low-volume tertile, 30-day mortality was observed in 76 (6.8%) patients, in comparison 
with 71 (5.5%) patients in the intermediate-volume tertile, and 66 (5.1%) patients in the high-
volume tertile (Chi-square p-value = 0.19). Twelve-month mortality was recorded in 112 (10.0%) 
patients in the low-volume tertile, 116 (9.0%) patients in the intermediate-volume tertile, and 
110 (8.5%) of patients in the high-volume tertile (Chi-square p-value = 0.44). After adjusting for 
potential confounding factors, a statistically significant difference in 30-day mortality (HR 1.48 
(95% CI 1.05-2.08); p=0.02) was observed in PPCI performed by low-volume operators compared 
to high-volume operators. However, the difference in 12-month mortality approached, but did 
not reach statistical significance (HR 1.26 (95% CI 0.96-1.65); p=0.09). When PPCI performed by 
intermediate operators were compared to those performed by high-volume operators, no 
statistically significant difference in adjusted rates of 30-day (HR 1.29 (95% CI 0.91-1.81); p=0.15) 
and 12-month mortality (HR 1.21 (95% CI 0.93-1.58); p=0.15) (Table 6.2, Figures 6.1 & 6.2) were 
observed. Thirty-day (HR 1.15 (95% CI 0.83-1.60); p=0.40) and 12-month (HR 1.04 (95% CI 0.80-
1.35); p=0.78) adjusted mortality between PPCI performed by low and intermediate-volume 
operators were also not statistically significantly different. 
When analyses were repeated with operator status rather than operator volumes, PPCI 
performed by visiting operators (n=22) was not associated with higher 30-day (HR 1.18 (95% CI 
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0.88-1.56)) and 12-month (HR 1.12 (95% CI 0.89-1.40)) mortality compared to internal operators 
(n=9). 
Other factors that were independently associated with mortality in the Cox regression models 
were advancing age, prior MI, pre-existing peripheral vascular disease or cerebrovascular 
disease, diabetes mellitus, left-main coronary artery as the IRA, and DTB time of ≥90 minutes 
(Table 6.2). Left-main coronary artery as the IRA was most strongly associated with 30-day and 
12-month mortality in this analysis. 
Table 6.2: Adjusted 30-day and 12-month mortality for all variables included in Cox proportional 
hazards models analysing operator volumes and potential confounders. 
Factors 30-day mortality 
Adjusted HR (95% CI) † 
12-month mortality 
Adjusted HR (95% CI) † 
Low-volume operators 1.48 (95% CI 1.05-2.08)* 1.26 (95% CI 0.96-1.65) 
Intermediate-volume operators 1.29 (95% CI 0.91-1.81) 1.21 (95% CI 0.93-1.58) 
Out-of-hours presentation 1.02 (95% CI 0.77-1.35) 1.12 (95% CI 0.89-1.39) 
Previous myocardial infarction 1.48 (95% CI 1.02-2.14)* 1.51 (95% CI 1.13-2.00)* 
Hypertension 1.09 (95% CI 0.80-1.49) 1.14 (95% CI 0.90-1.46) 
Hypercholesterolemia 0.79 (95% CI 0.56-1.11) 0.79 (95% CI 0.61-1.03) 
Diabetes mellitus  1.54 (95% CI 1.07-2.22)* 1.64 (95% CI 1.24-2.17)* 
Peripheral / cerebral vascular disease 1.44 (95% CI 0.96-2.17) 1.92 (95% CI 1.43-2.57)* 
Current / Ex-smoker 0.79 (95% CI 0.57-1.10) 0.91 (95% CI 0.70-1.17) 
Left main coronary artery culprit vessel 7.27 (95% CI 4.11-12.85)* 5.00 (95% CI 2.93-8.52)* 
Advancing age (per year) 1.05 (95% CI 1.04-1.07)* 1.06 (95% CI 1.05-1.08)* 
Door-to-balloon time ≥ 90 minutes 1.46 (95% CI 1.05-2.03)* 1.52 (95% CI 1.17-1.97)* 
The reference category for operator volume is high-volume operators; †HR: Hazard ratio; CI: 
Confidence intervals; * p-value ≤ 0.05. All hazard ratios were obtained from Cox models used to 




Figure 6.1: Kaplan-Meier curves illustrating adjusted 30-day mortality according to operator 




Figure 6.2: Kaplan-Meier curves illustrating adjusted 12-month mortality according to 





In this study, annual operator volume of PPCI for STEMI has been shown to be 
independently and inversely associated with 30-day mortality following the index-PPCI. PPCI 
performed by low volume operators (<55 PPCI per year) were associated with statistically 
significantly higher adjusted 30-day mortality than those performed by high-volume 
operators (≥110 PPCI per year). This suggests that an operator volume-outcome relationship 
specific to PPCI exists at a threshold far higher than those quoted current AHA guideline 
recommendation of ≥11 PPCI per year per individual operator181.  
Vakili et al demonstrated that in a cohort of patients who underwent PPCI in 1995, PPCI 
performed by high-volume operators (defined as ≥11 PPCI per operator per year) in high-
volume centres (≥57 PPCI per centre per year) was associated with significantly lower in-
hospital mortality compared to low-volume operators in low-volume centres144. However, 
contradictory to the findings of this study, this difference was not observed when comparing 
low-volume operators with high-volume operators in high-volume centres. The difference 
between their study and this study might be explained by the advances in PPCI between 
1995 and 2009 in procedural techniques (radial artery access, smaller arterial sheaths), stent 
implantation (only 18% of patients received stents in their study, compared to 93.6% of 
patients in our study), pharmacotherapy (their study population predated the DAPT-era), 
and general trends in the acceptance of PPCI as the gold-standard reperfusion strategy in 
STEMI, following the landmark meta-analysis by Keeley et al in 200319. Importantly, this 
study has shown a difference in mortality at 30 days (compared to just in-hospital outcomes 
in their study). Although their study was important in  informing the AHA Guideline 
recommendation pertaining to operator volumes of PPCI, its relevance in contemporary 
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PPCI is not clear, as the uptake of PPCI, evolution of techniques, technology and the 
evolution of secondary prevention since 1995 has been significant. 
In comparison with the analysis by Srinivas et al148, this study has shown that operator-
volume-outcome relationship exists at a threshold higher than previously found. This could 
be due to a few factors. Their period of recruitment was between 2000 and 2002, which 
predated the routine utilisation of DAPT and transradial PPCI, both of which have been 
shown to be associated with outcomes, and the latter of which has a significant learning 
curve, which may be a marker of operator skill and experience. The principal finding of this 
study is that within a single high-volume institution, annual PPCI operator volume was 
independently and inversely associated with mortality at a higher operator-volume 
threshold, and after a longer follow-up period than previously reported. This is the first 
study to show that a difference in 30-day mortality according to operator PPCI volume in a 
high-volume centre, in a “contemporary era” of PPCI. This is also the first study outside USA 
to assess this association. 
In this study, differences in outcomes according to operator characteristics has been shown 
to be driven by annual operator PPCI volume, rather than operator status (internal vs 
external). Differences in procedural characteristics were identified that could potentially 
contribute to the differences observed in adjusted mortality. In the low-volume tertile, 
lower rates of radial access for PPCI, which is independently associated with improved 
outcomes in PPCI, was observed when compared with the intermediate-volume and high-
volume tertiles24,36,39,182. Higher proportion of patients with post-procedural TIMI 3 flow in 
the IRA were also noted in the high-volume operator tertile compared to the low-volume 
operator tertile, which, in addition to radial artery access, may be a reflection of operator 
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skill and experience. PPCI is also believed to involve clinical and procedural skills not usually 
seen in elective or urgent PCI, such as the use of thrombus aspiration, adjunct 
pharmacotherapy to manage slow/no-reflow, and the ability to safely perform PCI in the 
setting of active cardiac ischemia, cardiogenic shock or refractory cardiac arrest. Therefore, 
development and maintenance of these skills, along with familiarity with institutional staff 
and equipment could also explain the volume-outcome relationship, although these factors 
are difficult to objectively quantify. There were also differences in the proportion of PPCI 
undertaken out-of-hours. As described in previous sections, the low-volume operators 
undertake more out-of-hours PPCI compared to the intermediate and high-volume 
operators. However, there may not necessarily be an association between time of admission 
and outcomes in a 24/7 tertiary referral centre183,184. 
Although institutional PCI volumes have been shown to not be associated with clinical 
outcomes185, the finding of this study that PPCI performed by operators undertaking <55 
PPCI per year is associated with significantly higher risk-adjusted 30-day mortality compared 
to PPCI performed by high-volume operators, suggests the need to re-examine the AHA 
recommendation that ≥11 PPCI per year per operator (which was derived from old-non-
contemporary studies) is recommended for the safe provision of PPCI. 
 
6.4. Limitations 
As with other observational studies, despite data being prospectively collected, it is possible 
that some confounders remain unadjusted for. However, this was observed in prior analyses 
of operator volumes, and is likely to be the case with future analyses of operator volumes 
and outcomes, as data for this particular scientific question is likely to be derived only from 
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registry data. In this study, the difference between median annual PPCI volumes between 
intermediate-volume operators and high-volume operators was not numerically large. 
However, the difference in mean operator volumes in these two groups was strongly 
statistically significant (P<0.01). Clinically, dividing these groups may not be relevant or even 
appropriate. However, in this study, and any other study examining annual operator 
volumes of procedures, this was an expected finding due to the right-skewed distribution of 
operator-volume. Therefore, the use of operator volume tertiles based on institutional 
operator-volumes was statistically justified. Some visiting operators may have undertaken 
in-hours PPCI in their own regional hospitals. However, according data form to the British 
Cardiovascular Intervention Society database, between 2012 and 2014 (3 calendar years), 
only 25 PPCI procedures (less than 1% of total PPCI volumes undertaken in West Yorkshire 
during this period) were undertaken in four regional hospitals by 13 of the 21 visiting 
operators. This only adds approximately 0.6 PPCI per year per operator. Therefore, the PPCI 
undertaken by visiting cardiologists in Leeds General Infirmary is likely to be representative 
of their actual annual PPCI volume. Although play of chance could not be excluded with 
observational data, the findings of this study are scientifically plausible as transradial PPCI 
and post-procedural TIMI 3 flow in IRA, both of which are associated with improved 
outcomes following PPCI, were noted to be more likely in PPCI undertaken by high-volume 
operators compared to low-volume operators. Another potential source of bias is the 8% 
loss to follow up at 12 months. However, as these patients were distributed randomly 
across the volume tertiles, the population included in the analyses should be representative 
of the total PPCI population. The high-volume tertile was populated by three high-volume 
operators. This is significantly fewer than the other tertiles, as expected following a division 
by the number of cases done. The difference in outcomes observed in the high-volume 
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group could potentially be due to individual practice and technique, rather than case 
volume. Although outcomes in this study were analysed according to volume tertiles, as 
were the two prior studies examining this association, future studies could analyse the 
association between operator volumes and outcomes as a continuous variable, rather than 
volume tertiles. As with prior chapters, although multiple comparisons were shown in the 
comparison of baseline and clinical characteristics (Table 6.1), these comparisons were not 
corrected for multiple testing as the p-values shown were only descriptive. Although PPCI 
undertaken by low-volume operators was associated with higher risk-adjusted mortality, the 
benefit of this life-saving procedure, regardless of operator volume, has to be weighed 
against that of thrombolysis, which has been shown to be significantly less efficacious and 
more risky compared to PPCI. The results of this study therefore should be considered 
hypothesis-generating, and examination of larger national/international datasets should be 
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7.1. Analysis of the association between the use of GPI and outcomes, according to arterial 
access site 
The evidence surrounding the use of GPI in PPCI is based on studies that were undertaken 
prior to the routine utilisation of radial artery access for PPCI, the use of third-generation 
P2Y12-receptor inhibitors, and the acceptance of PPCI as the default treatment strategy for 
STEMI in the UK. The progress with all of these factors could have led to a change in 
outcomes observed in patients undergoing PPCI, particularly in those undergoing 
transfemoral PPCI (the less-favoured and consequently less-utilised access site). 
7.1.1. Study population 
As described in section 2.3, GPI was typically used as a bail-out drug, most commonly in 
patients with significant thrombus burden, or slow or no-reflow phenomenon following PTCA 
or deployment of stent. Therefore, these patients, by default, had more adverse angiographic 
findings compared to patients in whom GPI was not used. Therefore, prior to any further 
adjustment, only patients with pre-PPCI TIMI flow (TIMI 0 in IRA) and post-PPCI TIMI flow 





7.1.2. Clinical endpoints 
The co-primary endpoints in this study were 30-day and 12-month mortality, and 30-day 
major bleeding according to HORIZONS criteria. The secondary endpoints were arterial access 
site and non-access site bleeding within 30 days of index PPCI. 
 
7.1.3. Survival analyses 
Cox proportional hazards regression models, performed by AK in IBM SPSS (Version 23.0.0.2) 
were used for survival analyses. All proportional hazards assumptions were verified visually 
with log-minus-log curves, and with time-dependent covariate analyses. Multivariable 
analyses were undertaken to adjust for potential confounding factors. Separate analyses were 
undertaken for based on arterial access site (Figure 7.1). In the analysis of mortality and 
bleeding, the variables included in the regression models were: GPI use, patient age at the 
time of index PPCI, gender, prior MI, prior coronary revascularisation (either PCI or CABG), 
diabetes mellitus, systolic blood pressure of less than 90mmHg (defined as a binary 
categorical variable), use of third-generation P2Y12-receptor inhibitors (prasugrel or 
ticagrelor), use of bivalirudin, and CTB time of > 120 minutes. In the analysis of access-site 
bleeding, variables included in the Cox models were: use of GPI, procedural bivalirudin and 
use of third generation P2Y12-receptor blockers. Further variables were not included to avoid 
overfitting of the models, based on the number of events observed. All hazard ratios quoted 
in this analysis were obtained from the Cox proportional hazards models, and were presented 




During the period 01-01-2009 and 31-12-2011, and between 01-01-2013 and 31-12-2013 
(four calendar-years), a total of 4056 patients underwent PPCI, of whom 12-month follow-
up was completed for 3703 (91.3%) patients. A total of 2369 (64.0%) of the 3703 patient 
satisfied the inclusion criteria (pre-procedural TIMI 0 flow and post-procedural TIMI 3 flow 
in IRA), and were therefore included in the final analyses (Figure 7.1).  
 




Of these patients, 1548 (65.3%) underwent transradial PPCI, 179 (11.6%) of whom received 
GPI (abciximab: n=176 (98.3%); tirofiban: n=3 (1.7%)). The remaining 821 (34.7%) patients 
who underwent transfemoral PPCI, 169 (20.6%) of whom received GPI (abciximab: n=166 
(98.2%); tirofiban: n=2(1.2%); eptifipatide: n=1 (0.6%)). Comparison of baseline and 
procedural characteristics are detailed in Table 7.1. Comparison of clinical outcomes are 
shown in Table 7.2. In both groups of patients (transfemoral PPCI and transradial PPCI), 
statistically significant differences in baseline and procedural characteristics were observed 




















Data are expressed as median (IQR), or number (%) as described; *MI: Myocardial Infarction. 
Characteristics Transradial PPCI Transfemoral PPCI 













Age in years median (IQR) 61 (18) 59 (18) 0.01 63 (21) 62 (21) 0.10 
Male n (%) 1053 (76.9) 147 (82.1) 0.12 444 (68.1) 125 (74.0) 0.14 
Diabetes mellitus n (%) 171 (12.5) 23 (12.8) 0.98 90 (13.8) 25 (14.8) 0.62 
Cigarette smoking (current/ex-) n (%) 961 (70.2) 123 (68.7) 0.85 431 (66.1) 106 (62.7) 0.44 
Hypertension n (%) 484 (35.4) 64 (35.8) 0.82 248 (38.0) 70 (41.4) 0.34 
Previous MI n (%)* 127 (9.3) 21 (11.7) 0.45 72 (11.0) 40 (23.7) <0.01 
Previous CABG 5 (0.4) 0 (0.0) 0.59 25 (3.8) 13 (7.7) <0.01 
Previous revascularisation (percutaneous 
and surgical) n (%) 
104 (7.6) 19 (10.6) 0.16 66 (10.1) 39 (23.1) <0.01 
Renal insufficiency n (%) 20 (1.4) 3 (1.6) 0.82 22 (3.3) 7 (4.2) 0.58 
Systolic blood pressure < 90mmHg n (%) 55 (4.0) 8 (4.5) 0.77 51 (7.8) 18 (10.7) 0.24 
Anterior MI n (%)* 512 (37.4) 70 (39.1) 0.66 271 (41.6) 74 (43.8) 0.60 
Aspiration thrombectomy n (%) 1163 (85.0) 146 (81.6) 0.24 484 (74.3) 124 (73.4) 0.80 
Third-generation P2Y12 inhibitors n (%) 910 (66.5) 121 (67.6) 0.76 294 (45.1) 54 (32.0) <0.01 
Drug-eluting stents n (%) 903 (66.0) 111 (62.0) 0.30 393 (60.3) 98 (58.0) 0.59 
Call-to-balloon time median (IQR) 123 (55) 129 (46) 0.17 131 (66) 135 (67) 0.58 
Bivalirudin n (%) 1348 (98.5) 149 (83.2) <0.01 648 (99.4) 105 (62.1) <0.01 
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Data are expressed as n (%); † HR: Hazard ratio; ‡ CI: Confidence interval; *p-value ≤ 0.05.
 Transfemoral PPCI Transradial PPCI 
No GP IIb/IIIa inhibitor 
n=652 
GP IIb/IIIa inhibitor 
n=169 
No GP IIb/IIIa inhibitor 
n=1369 
GP IIb/IIIa inhibitor 
n=179 
30-day mortality n (%) 








1.27 (95% CI 0.39-4.16) 
12-month mortality n (%) 








1.21 (95% CI 0.58-2.51) 
30-day total bleeding n (%) 








1.93 (95% CI 0.73-4.76) 
30-day arterial access site bleeding n (%) 












In patients undergoing transfemoral PPCI, patients receiving GPI were statistically 
significantly more likely to have had prior MI, prior coronary revascularisation, received 
clopidogrel rather than prasugrel or ticagrelor, and received heparin rather than bivalirudin 
compared to patients who did not receive GPI (Table 7.1). Other variables were not 
statistically significantly different between patients who received GPI and patients who did 
not receive GPI. 
Unadjusted analyses revealed no statistically significant differences in 30-day and 12-month 
mortality in patients receiving GPI compared to patients who did not receive GPI (Table 7.2; 
Figure 7.2). However, after adjustment for confounding factors, GPI use in transfemoral PPCI 
was independently associated with increased 30-day mortality, but not 12-month mortality 
in patients receiving GPI (Table 7.2; Figure 7.3 (A) & (B)). 
Thirty-day major bleeding was significantly higher in patients receiving GPI in both 
unadjusted and adjusted analyses (Table 7.2; Figures 7.2 & 7.3(C)). Importantly, higher 
adjusted (for P2Y12-receptor inhibitor therapy and procedural anticoagulant therapy) 
arterial access-site related bleeding (HR 2.71 (95% CI 1.00-7.37); p=0.05)), but not non-
access-site bleeding (HR 1.65 (95% CI 0.78-3.48); p=0.19), was observed in patients treated 






Figure 7.2: Unadjusted outcomes according to arterial access site and use of glycoprotein IIb/IIIa inhibitor therapy. 
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Figures 7.3 (A)-(C): Kaplan-Meier curves illustrating GPI use and adjusted 30-day survival, 12-






In the transradial PPCI cohort, patients receiving GPI were likely to be younger and were 
more likely to receive intra-procedural heparin rather than bivalirudin compared to patients 
who did not receive GPI (Table 7.1). No other statistically significant differences in baseline 
or procedural characteristics were noted.  
Unadjusted 30-day and 12-month mortality were not statistically significantly higher in 
patients receiving GPI (Table 7.2; Figure 7.1). Multivariable analysis confirmed no significant 
difference in adjusted 30-day and 12-month mortality in patients receiving GPI compared to 
patients not receiving GPI (Table 7.2; Figures 7.4 (A) & (B)). 
Analysis of unadjusted 30-day bleeding showed that total bleeding, arterial access-site 
bleeding, and non-access-site bleeding were not significantly higher in patients who 
received GPI (Table 2; Figure 2). Multivariable analysis confirmed no statistically significant 
difference in adjusted total bleeding in patients receiving GPI (HR 1.93 (95% CI 0.73-4.76); 
p=0.16) (Figure 7.4 (C)). When procedural anticoagulation and P2Y12-receptor inhibitor 
were adjusted for, non-access-site bleeding was not statistically significantly higher in 
patients treated with GPI (HR 1.60 (95% CI 0.67-3.83); p=0.29). Multivariable analysis of 
arterial access site bleeding in patients undergoing transradial PPCI was not undertaken due 






Figures 7.4 (A)-(C): Kaplan-Meier curves illustrating GPI use and adjusted 30-day survival, 12-






This analysis of patients undergoing PPCI in the “contemporary” era has revealed GPI use in 
patients undergoing transfemoral PPCI in the real-world was independently associated with 
increased 30-day mortality and 30-day bleeding, in particular arterial access-site bleeding. 
However, in patients undergoing transradial PPCI, GPI use was not associated with increased 
unadjusted or risk-adjusted mortality or bleeding. 
Heer et al published real-world data collected between 2000 and 2002 from the German 
Acute Coronary Syndrome (ACOS) database, showing that treatment with abciximab was 
associated with improved mid-term mortality (HR 0.65 (95% CI 0.49-0.95)), with increased 
bleeding events noted in patients over 75 years of age155. However, in-hospital mortality 
was not significantly different. In contrast to their study, this study has shown an early 
divergence in risk-adjusted survival, which makes attributing adverse events with GPI-
treatment more plausible. Patients treated with abciximab in their analysis were also more 
likely to have received aspirin (95% vs 89.3%; p<0.01) and were also 10% more likely to 
receive P2Y12-receptor inhibitor therapy. Patients receiving abciximab in their study were 
also younger, with fewer co-morbidities at presentation. In comparison, only one patient in 
this study did not receive aspirin due to allergy, and all patients received P2Y12-receptor 
inhibitors (a significant proportion of whom received the more potent third-generation 
P2Y12-receptor inhibitors), with a loading dose prior to PPCI. It is possible that patients who 
received abciximab in their study may have had lower bleeding risk, reflected in the 
difference in use of aspirin and clopidogrel, and may have been less frail compared to those 
who did not receive abciximab. In contrast, patients who received GPI in this study were 
mainly prescribed it as a “bailout”, and therefore had a more adverse angiographic and 
clinical profile compared to patients who did not receive GPI, which may account for the 
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differences in outcomes between the two studies. Perhaps most importantly, the adjusted 
survival analysis in their study revealed a divergence in survival from approximately day 20, 
which should not be attributable to GPI therapy, whereas in this study, divergence is noted 
earlier. This suggests the more plausible possibility that other factors, such as frailty and 
differences in secondary prevention, particularly aspirin and clopidogrel, may have 
contributed to differences in survival in their study. 
In comparison with the study by Iversen et al, this study was a comparison of GPI use 
according to arterial access site, and their study was a comparison of GPI use according to 
lesion complexity. In comparison with our study, arterial access site was not presented in 
this study, which could potentially have included both patients whom underwent 
transfemoral PPCI and transradial PPCI, particularly towards to latter years of recruitment. 
The principal finding of both this study and that of Iversen et al’s was that in a real-world 
setting, treatment with abciximab was associated with improved clinical outcomes in a 
specific cohort of patients, and conversely, was associated with adverse clinical outcomes in 
the opposite cohort, which was in contrast with RCT data. Although our findings are not 
comparable to their study, due to differences in analyses, it is important to acknowledge 
that in keeping with our study, their real-world data pertaining to GPI use were not 
reflective of RCT data. 
In terms of RCTs, the ADMIRAL and CADILLAC trials both demonstrated a benefit in the use 
of abciximab, driven by reduced target vessel revascularisation151,152. This was offset by 
higher rates of TIMI-minor bleeding in ADMIRAL, and higher rates of thrombocytopenia and 
blood transfusion in CADILLAC. Abciximab use was not associated with improvement in 
mortality in both trials. Arterial access site was not presented in either study, but they were 
both likely to have included patients who mainly underwent transfemoral PPCI, based on 
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the recruitment timeline. There were important differences in the patients recruited to 
ADMIRAL and CADILLAC in comparison to this study. Patients receiving GPI in this study 
appeared older (mean age 62 years-old vs 60 years-old). Only patients with pre-PPCI 
anterograde flow in IRA of TIMI 0 and post-PPCI anterograde flow in IRA of TIMI 3 were 
included in this study, to adjust for potential differences in thrombus-burden, and to adjust 
for final angiographic findings. Patients in ADMIRAL and CADILLAC received ticlopidine as 
their P2Y12-receptor inhibitor, compared to the newer and more potent clopidogrel, 
prasugrel and ticagrelor used in this study. They also received intraprocedural heparin 
rather than bivalirudin, which was the intraprocedural anticoagulant of choice in this. In 
ADMIRAL, abciximab was administered prior to arrival at the cardiac catheter laboratory, 
and possibly as a consequence, patients receiving abciximab had were less likely to have 
pre-procedural TIMI 0 flow (67.0% vs 81.5%; p=0.02), and were more likely to have post-
procedural TIMI 3 flow (95.1% vs 86.7%; p=0.04) in their IRA, which could have in turn 
affected post-MI left-ventricular ejection fraction. In contrast, in this study and in current 
practice for STEMI, GPI is not routinely administered prior to arrival at the cardiac catheter 
laboratory. In the CADILLAC trial, patients who received GPI were less likely to have had 
prior MI (14.5% vs 23.7%), prior coronary revascularisation (14.2% vs 23.1%) or presented 
with ST-segment elevation or presumed new-onset left-bundle-branch-block (88.0% vs 
100%) compared to this study. Patients receiving GPI in CADILLAC were less likely to have 
had their LAD as the IRA (34.6%vs 38.9%; p=0.04). In contrast to our study and to ADMIRAL, 
patients with cardiogenic shock were excluded from this trial. Both trials were undertaken 
at a time when transfemoral PPCI was the standard of treatment, in comparison to the era 
of transradial PPCI, with the femoral artery typically used as the second-choice arterial 
access site for most operators. Differences in patient characteristics, advances in 
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pharmacological therapy and PPCI technique and access site utilisation might account for 
the differences observed between this study and the RCTs. 
More recently, the BRAVE-3 investigators compared abciximab with placebo in 800 patients 
undergoing PPCI between June 2003 and January 2008, showing no statistically significant 
difference in infarct size, mortality or major bleeding between the two groups154. However, 
there were several important differences between their study and ours. In BRAVE-3, all 
patients received clopidogrel as their P2Y12-receptor inhibitor. In contrast, only 990 (41.8%) 
of patients included in our study received clopidogrel, the remainder of whom received the 
more potent prasugrel (n=831 (35.1%)) and ticagrelor (n=548 (23.1%)). Maintenance dose of 
aspirin was also lower in our study (75mg/day vs 200mg/day). There were also several 
important exclusion criteria in BRAVE-3: thrombolytic therapy, previous stroke, bleeding 
diathesis or bleeding, major surgery or trauma within one month of PPCI, treatment with 
oral anticoagulant therapy within 7 days of PPCI, use of GPI within 14 days of PPCI, systolic 
blood pressure > 180mmHg, resistant to therapy, haematological abnormalities, cardiogenic 
shock, prolonged cardiopulmonary resuscitation (CPR), age >80 or <18, known or suspected 
pregnancy and allergy to study drugs. In contrast, the only patients excluded in our analysis, 
in addition to those whose follow-up data were unavailable, were patients who had pre-
procedural TIMI flow > 0 and post-procedural TIMI flow < 3. Arterial access site was not 
presented in BRAVE-3, and it is possible that their study population included patients who 
underwent transradial PPCI as well as patients who underwent transfemoral PPCI. 
Therefore, assessing the association between GPI use and outcomes according to arterial 
access site was not possible. In our study, 1505 (63.5%) patients received DES, compared to 
44% in BRAVE-3. These differences, in addition to potential patient-selection bias that can 
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be present in RCTs as a result of stringent inclusion criteria, could account for the 
differences in outcomes between BRAVE-3 and our study. 
There is a widely reported association between transfemoral PPCI and adverse outcomes, in 
comparison to transradial PPCI39,186,187. As a result, the radial artery is the preferred access 
site for PPCI, with the femoral artery utilized as a “backup” arterial access site, and there has 
been a steady temporal trend in the uptake of transradial PCI in the UK157. In our study, 
65.3% of patients underwent transradial PPCI. However, only 11.6% of patients who 
underwent transradial PPCI received GPI, compared to 20.6% of patients receiving GPI in the 
transfemoral PPCI cohort. This could be due to clinician approach towards GPI, which has 
evolved from routine use to bail-out use over the course of this study, which has also seen a 
parallel temporal rise in transradial PPCI. In the transfemoral cohort, patients receiving GPI 
were more likely to have had previous coronary revascularisation (both PCI and CABG), and 
were less likely to have received third-generation P2Y12 receptor inhibitors compared to 
patients who did not receive GPI. Although these differences could have contributed to 
higher unadjusted mortality in patients receiving GPI in the transfemoral PPCI cohort, 
correcting for them using multivariable analysis did not eliminate excess mortality observed 
at 30 days following index PPCI. The significant difference in adjusted mortality is likely to be 
due to increased arterial access site bleeding observed in patients receiving GPI during 
transfemoral PPCI, a finding which has been previously reported177,188–191. In patients 
undergoing transradial PPCI, there was no difference in adjusted mortality or bleeding in 
patients receiving GPI, as access site bleeding is rare in transradial PPCI compared to 




Although current guidelines provide a Class II indication for the use of GPI in PPCI, the 
findings of this study should prompt interrogation of larger databases to clarify the 
association between GPI use and outcomes in transfemoral PPCI in a “real-world” setting, 
which could in turn inform future guideline recommendations pertaining to GPI use161,193. 
7.4. Limitations 
As with single-centre observational studies, outcomes observed in this study may not 
represent outcomes in other regions or centres. However, as our STEMI-management 
model is the default model in the UK, we are confident that our findings are representative 
of PPCI in the UK. As with most observational studies, it was not possible to correct for all 
potential confounding factors. This is especially important as the use of GPI has evolved 
from routine use to “bail-out” use, and therefore patients receiving GPI were possibly 
“selected” based on adverse angiographic findings, particularly thrombus burden. However, 
we attempted to attenuate the possible selection bias by matching patients according to 
pre-PPCI and post-PPCI TIMI flow, and then conducting multivariable analysis to adjust for 
remaining confounders. Nevertheless, it remains possible that some confounders may not 
have been corrected for. However, it is important to acknowledge that any further studies 
published pertaining to GPI use in transfemoral PPCI are likely to be derived from 
observational registry data, as there may be ethical issues with conducting RCTs assessing 
the impact of GPI in transfemoral PPCI, as it would involve routine use of GPI rather than the 
currently-accepted bail-out usage, and it may involve assignment to transfemoral PPCI, 
which is associated with adverse outcomes compared to transradial PPCI. We were also 
unable to determine details of changes to secondary prevention therapy following discharge 
from hospital. Therefore, changes to antiplatelet therapy, which in turn could have led to 
ischaemic or bleeding events, although unlikely to be different between the cohorts, could 
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not be excluded. Although mortality data were available for all patients in this analysis, 
under-reporting of bleeding events following discharge from hospital could not be excluded. 
However, this was unlikely to have been different across the groups of patients, and 
importantly, post-discharge (>72 hours) bleeding may not necessarily be due to intra-














The five studies undertaken from this large “all-comers” registry have provided important 
outcome information in regard to contemporary PPCI. Three of these studies (Chapters 3, 4 
and 6) examined patient and operator variables associated with clinical outcomes following 
PPCI, whilst the other two (Chapters 5 and 7) examined the association between treatment 
received and clinical outcomes following PPCI. Although the populations in each study were 
unmatched, multivariable analyses were undertaken to correct for confounding factors. 
Some of the findings in these studies were not in keeping with RCT data. This discrepancy is 
common in observational “real-world” datasets, as there is less control over patients 
included in these registries. The findings of these studies may need to be further validated 
with interrogation of larger datasets, such as the UK British Cardiovascular Intervention 
Society database, the Swedish Coronary Angiography and Angioplasty Register database, or 
the New York PCI database, as the results of single-centre studies may not necessarily 
reflect the results obtained in other centres or regions. However, whilst the number of 
patients from these larger databases may be significantly higher compared to the WY-PPCI 
registry, with this being a single-centre prospectively recruited study, obtaining data 
pertaining to events that did not occur in the same hospital that PPCI was undertaken, such 
as bleeding and recurrent MI, was possible in this study. This advantage was particularly 
notable as a balanced comparison of therapies, namely P2Y12-receptor inhibitors and GPI 




The key conclusions from each study are summarised as follows: 
8.1. The association between gender and ethnicity and outcomes following PPCI 
The female gender is not an independent predictor of poor clinical outcomes. Instead, the 
difference in age at presentation is the strongest predictor of clinical outcomes in the 
comparison between men and women. Improvements in service provision, particularly 
minimising delays in women, and in transradial PPCI, could further improve outcomes in 
women following PPCI. 
Despite experiencing higher rates of recurrent MI, univariable and multivariable analysis 
showed that South Asian patients did not have statistically significantly higher rates of 
mortality or MACE compared to White patients. The significantly higher rate of recurrent MI 
in South Asian patients is likely to be due to their higher prevalence of diabetes mellitus 
compared to white patients. 
 
8.2. Clinical outcomes in PPCI according to P2Y12-receptor inhibitor 
This study has shown that in patients undergoing PPCI, treatment with prasugrel was 
independently associated with lower adjusted 30-day and 12-month mortality, and 12-
month MI when compared with clopidogrel. Importantly, for the first time, treatment with 
prasugrel has been shown to be independently associated with lower adjusted 30-day 
mortality compared to ticagrelor in PPCI. Recurrent MI within 30 days and 12 months 
following index PPCI were lower in patients treated with ticagrelor compared to clopidogrel. 
However, there were no significant differences in 30-day and 12-month mortality between 
patients treated with ticagrelor and clopidogrel. Overall, both prasugrel and ticagrelor were 
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associated with lower adverse events compared to clopidogrel, with no associated excess 
bleeding within 30 days. 
 
8.3. The association between individual operator annual PPCI volume and outcomes 
Low operator-volume in PPCI for STEMI was independently associated with higher 30-day 
mortality compared to high operator-volume, suggesting an operator volume-outcome 
relationship exists at a threshold significantly higher than current guideline 
recommendations. If confirmed, annual recommended operator volumes for PPCI in national 
and international guidelines may need to be re-defined to ensure optimal patient outcomes 
following PPCI. 
 
8.4. The association between GPI use and outcomes in PPCI according to arterial access site 
In patients undergoing transfemoral PPCI, GPI use was independently and directly 
associated with increased 30-day mortality and 30-day bleeding, which was driven by 
increased arterial access-site bleeding, findings that were not observed in patients 
undergoing transradial PPCI. If confirmed in larger studies, clarification of guideline-
recommendations for GPI use in transfemoral PPCI may be necessary. 
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Appendix 1: Patient information leaflet for prospective recruitment into WY-PPCI 




Cardiology & Respiratory Directorate 
G Floor 
Jubilee Wing 
Leeds General Infirmary 
Great George Street 
Leeds LS1 3EX 
   
                                     
Study information Sheet 
 
West Yorkshire Primary Percutaneous Coronary Intervention Outcome  
Study 
(WY-PPCI Outcome Study) 
Patient Information Sheet A 




You are being invited to take part in this study. Before you decide it is important for you to 
understand why the study is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends and relatives if you wish.  Please do 
ask if there is anything that is not clear or if you would like more information.  
 
 
WHY HAVE I BEEN CHOSEN? 
We are inviting all patients who have suffered a heart attack and had a stent put into their 
heart artery (PCI) to take part.  This study is looking at people like you who were admitted to 





WHAT IS THE PURPOSE OF THE STUDY? 
The purpose of this study is to look at what the main factors are which influence the health of 
patients who have been treated with Primary Percutaneous Coronary Intervention (PPCI) as 
the first treatment for a heart attack.  We are therefore aiming to undertake the follow up of 
all patients who have been treated with PPCI in West Yorkshire. This requires us to contact 
you by telephone after 30 days and again after one year.  The aim of contacting you is to ask 
you for up-to-date information about your on-going health.  All the information you give us 
will be confidential.  
 
 
DO I HAVE TO TAKE PART? 
It is up to you to decide whether or not to take part. If you decide not to take part, your 
clinical details will still be held on the NHS database, as this is normal clinical practice. We 
will however not be telephoning you for further follow-up or be obtaining any blood or saliva 
samples from you. 
If you do decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to withdraw at any time and 




WHAT WILL HAPPEN TO ME IF I TAKE PART? 
As you are currently under our care and have been treated with a primary PCI for your heart 
attack, we already have your details on the NHS clinical databases.  We are asking you if 
you would consent to being contacted by a research nurse by telephone. We would in 
addition like to ask your consent for a blood sample (9 mls or approximately 2 teaspoonfuls) 
or a saliva sample (approximately 5 mls) to be used for genetic testing for genes that relate 
to heart disease. The type of sample to be collected can be chosen by you. If you agree then 
we will collect the sample whilst you are still in hospital. Any results obtained will not be 
made available to individual participants, as these tests are designed to give us information 
that might be relevant to groups of future heart patients rather than individuals. 
 
Any sample you give us will be securely stored within the University of Leeds Integrated 
Molecular Cardiology laboratories. Your sample may be used in future research projects that 
have been approved by an NHS Research Ethics Committee.  
 
To enable us to study how well patients do after a heart attack in the longer term, we would 







WHAT ARE THE RISKS AND DISCOMFORTS? 
There are no foreseeable risks to you in this study. If you have consented to giving your blood, 
you may experience minor discomfort or bruising at the needle site when that is performed but 
we will minimise any inconvenience to you. 
 
 
BENEFITS TO YOU 
There is no direct personal benefit to you.  However, the information gained from this study 
may help us in evaluating the most appropriate treatment for patients in the future 
 
 
WILL MY TAKING PART BE KEPT CONFIDENTIAL? 
All information collected about you during the course of the study will be kept strictly 
confidential. This information will be securely stored, electronically on the Leeds General 
Infirmary secure server, and on paper, under the provisions of the 1998 Data Protection Act. 
You will not be identified in any publication that may result from this research.  
 
We may contact the NHS Information Service at a later stage for information which they hold 
on your health status. This means some of your personal data will be shared with the NHS 
Information Service. Any information exchanged between us and the NHS Information Service 
will be subject to strict data protection regulations. 
 
With your permission, your data may also provide a resource for future studies. If any 
information from this study is used to develop new research, data protection regulations will 
be observed and strict confidentiality maintained. Ethical approval will be obtained for any 
future studies involving your data. You will not be identified in the results of any future studies.  
 
If you withdraw consent from further study follow-up, your data will remain on file and will be 
included in the final study analysis. You may withdraw your samples if you so wish. 
 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE ON-GOING STUDY? 
At different stages of the study, results will be presented at local and regional audit and clinical 
governance meetings. In addition, results may be published in medical journals, but no 







If you are harmed as a direct result of taking part in this study, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then you may 
have grounds to a legal action. Regardless of this, if you have any cause to complain about any 
aspect of the way you have been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are available to you. 
 
 
WHO IS ORGANISING AND FUNDING THE STUDY? 
This study is part of a whole range of studies into heart disease conducted by Cardiovascular 




WHO HAS REVIEWED THE STUDY? 
The study has been reviewed and approved by York NHS Research Ethics Committee 
 
For further information please contact:      
 
Dr John P Greenwood 
Consultant Cardiologist 
Academic Unit of Cardiovascular Medicine 
‘G’ Floor, Jubilee Wing 









Academic Unit of Cardiovascular Medicine 
‘G’ Floor, Jubilee Wing 
Leeds General Infirmary 
LS1 3EX 






Cardiology & Respiratory Directorate 
G Floor 
Jubilee Wing 
Leeds General Infirmary 
Great George Street 
Leeds LS1 3EX 
 
 
      Consent for follow-up only. 
 
                       WY-PPCI Outcome Study 
 West Yorkshire Primary Percutaneous Coronary Intervention 
Outcome Study 
 
 Patient Study Number: ………………..  Date of Birth:……………… 
 
Hospital Number: …………………….             Initials: ……………………….. 
 
                                                                                                                                              
    
 1. I have read the Patient Information Sheet dated May 2012 (Version 1.5) for the 
above study and I have had the opportunity to ask questions and discuss the 
research study and I am satisfied with the answers to my questions. 
            
 2. I have received enough information about this study. 
 
 3. I understand that my participation is voluntary and that I am free to withdraw 
from the study at any time without giving a reason and without this affecting my 
future care. 
 
 4. I understand that information held by the NHS and records maintained by the 
NHS Information Centre, the NHS Central Register and by my General 
Practitioner may be used to contact me and provide information about my health 
                                                                                                                              




status. I give permission for this information to be obtained from the NHS 
Information Centre, the NHS Central Register and/or my GP if necessary. 
 
 5. I agree that my medical data maybe used to help develop future research 
studies and I understand that my identity will remain anonymous. 
 
 6. I understand that if I were to lose capacity, the information collected will be 
kept and used for the purposes of the study. 
 
7. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from the study team or from regulatory authorities 
where it is relevant to my taking part in research. I give permission for these 
individuals to have access to my records. 
 





 Name (block capitals)............................................................ Date................ 
  
 Signature of witness........................................................................................ 
 








Cardiology & Respiratory Directorate 
G Floor 
Jubilee Wing 
Leeds General Infirmary 
Great George Street 
Leeds LS1 3EX 
 
 
Study information Sheet 
 
West Yorkshire Primary Percutaneous Coronary Intervention Outcome 
Study 
(WY-PPCI Outcome Study) 
Patient Information Sheet B 




You are being invited to take part in this study. Before you decide it is important for you to 
understand why the study is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends and relatives if you wish.  Please do 
ask if there is anything that is not clear or if you would like more information.  
 
 
WHY HAVE I BEEN CHOSEN? 
We are inviting all patients who have suffered a heart attack and had a stent put into their 
heart artery (PCI) to take part.  This study is looking at people like you who were admitted to 





WHAT IS THE PURPOSE OF THE STUDY? 
The purpose of this study is to look at what the main factors are which influence the health of 
patients who have been treated with Primary Percutaneous Coronary Intervention (PPCI) as 
the first treatment for a heart attack.  We are therefore aiming to undertake the follow up of 
all patients who have been treated with PPCI in West Yorkshire. This requires us to contact 
you.  It may be that you have been discharged and are no longer under our routine clinical 
follow-up.  The aim of contacting you is to ask you for up-to-date information about your on-
going health.  All the information you give us will be confidential.  
 
 
DO I HAVE TO TAKE PART? 
It is up to you to decide whether or not to take part. If you decide not to take part, your 
clinical details will still be held on the NHS database, as this is normal clinical practice. We 
will however not be contacting you for further follow-up or be obtaining any blood or saliva 
samples from you. 
If you do decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to withdraw at any time and 
without giving a reason. This will not affect the standard of care you would receive should you 




WHAT WILL HAPPEN TO ME IF I TAKE PART? 
As you have previously been under our care and were treated with a primary PCI for your 
heart attack, we already have your details on the NHS clinical databases.  We are writing to 
you to ask if you would consent to being contacted by a research nurse by telephone. 
We would in addition like to ask your consent for a blood sample (9 mls or approximately 2 
teaspoonfuls) or a saliva sample (approximately 5 mls) to be used for genetic testing for 
genes that relate to heart disease. The type of sample to be collected can be chosen by you. 
We will make all the necessary arrangements (including postage paid envelopes for saliva 
samples), and any costs you might incur will be reimbursed by us. Any results obtained will 
not be made available to individual participants, as these tests are designed to give us 
information that might be relevant to groups of future heart patients rather than individuals. 
 
Any sample you give us will be securely stored within the University of Leeds Integrated 
Molecular Cardiology laboratories. Your sample may be used in future research projects that 
have been approved by an NHS Research Ethics Committee.  
 
To enable us to study how well patients do after a heart attack in the longer term, we would 






WHAT ARE THE RISKS AND DISCOMFORTS? 
There are no foreseeable risks to you in this study. If you have consented to giving your blood, 
you may experience minor discomfort or bruising at the needle site when that is performed but 
we will minimise any inconvenience to you. 
 
 
BENEFITS TO YOU 
There is no direct personal benefit to you.  However, the information gained from this study 
may help us in evaluating the most appropriate treatment for patients in the future 
 
 
WILL MY TAKING PART BE KEPT CONFIDENTIAL? 
All information collected about you during the course of the study will be kept strictly 
confidential. This information will be securely stored at the Leeds General Infirmary secure 
server electronically and on paper, under the provisions of the 1998 Data Protection Act. You 
will not be identified in any publication that may result from this research.  
 
We may contact the NHS Information Service at a later stage for information which they hold 
on your health status. This means some of your personal data will be shared with the NHS 
Information Service. Any information exchanged between us and the NHS Information Service 
will be subject to strict data protection regulations. 
 
With your permission, your data may also provide a resource for future studies. If any 
information from this study is used to develop new research, data protection regulations will 
be observed and strict confidentiality maintained. Ethical approval will be obtained for any 
future studies involving your data. You will not be identified in the results of any future studies.  
 
If you withdraw consent from further study follow-up, your data will remain on file and will be 
included in the final study analysis. You may withdraw your samples if you so wish. 
 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE ON-GOING STUDY? 
At different stages of the study, results will be presented at local and regional audit and clinical 
governance meetings. In addition, results may be published in medical journals, but no 







If you are harmed as a direct result of taking part in this study, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then you may 
have grounds to a legal action. Regardless of this, if you have any cause to complain about any 
aspect of the way you have been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are available to you. 
 
 
WHO IS ORGANISING AND FUNDING THE STUDY? 
This study is part of a whole range of studies into heart disease conducted by Cardiovascular 




WHO HAS REVIEWED THE STUDY? 
The study has been reviewed and approved by York NHS Research Ethics Committee 
 
For further information please contact:      
 
Dr John P Greenwood 
Consultant Cardiologist 
Academic Unit of Cardiovascular Medicine 
‘G’ Floor, Jubilee Wing 









Academic Unit of Cardiovascular Medicine 
‘G’ Floor, Jubilee Wing 
Leeds General Infirmary 
LS1 3EX 
Tel. no. 0113 39 28483  
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Cardiology & Respiratory Directorate 
G Floor 
Jubilee Wing 
Leeds General Infirmary 
Great George Street 
Leeds LS1 3EX 
  Consent for follow-up only. 
 
                       WY-PPCI Outcome Study 
 West Yorkshire Primary Percutaneous Coronary Intervention 
Outcome Study 
 
 Patient Study Number: ……………….. Date of Birth: ………………… 
 
Hospital Number: …………………….    Initials: ……………………….. 
 
                                                                                                                                             
    
1. I have read the Patient Information Sheet dated May 2012 (Version 1.5) 
for the above study and I have had the opportunity to ask questions and 
discuss the research study and I am satisfied with the answers to my 
questions. 
 
 2. I have received enough information about this study. 
 
 3. I understand that my participation is voluntary and that I am free to 
withdraw from the study at any time without giving a reason and without this 
affecting my future care. 
 
 4. I understand that information held by the NHS and records maintained by 
the NHS Information Centre, the NHS Central Register and by my General 
Practitioner may be used to contact me and provide information about my 
health status. I give permission for this information to be obtained from the 
                                                                                                                              




NHS Information Centre, the NHS Central Register and/or my GP if 
necessary. 
 
5. I agree that my medical data maybe used to help develop future research 
studies and I understand that my identity will remain anonymous. 
 
 6. I understand that if I were to lose capacity, the information collected 
will be kept and used for the purposes of the study. 
 
7. I understand that sections of any of my medical notes may be looked 
at by responsible individuals from the study team or from regulatory 
authorities where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records. 
 






 Name (block capitals)............................................................ Date................ 
 
 
 Signature of witness........................................................................................ 
 








CLINICAL AUDIT PROPOSAL/TOOLKIT 
WY-PPCI Outcome project 
 
Name of Auditor:   Prof John Greenwood / Dr Daniel Blackman 
Audit supervisor:   Prof John Greenwood / Dr Daniel Blackman 
Specialty:    Cardiology 
Proposed audit start date: 01/01/2009 




There is now an overwhelming evidence base in support of primary percutaneous coronary 
intervention (PPCI) for the treatment of ST segment elevation myocardial infarction (STEMI). Currently 
in excess of 1000 patients per year in West Yorkshire suffer a STEMI (heart attack).  These patients are 
transferred immediately (24/7) to the Leeds General Infirmary (LGI) for PPCI as the first line treatment.  
 
Leeds is currently the largest provider of PPCI in the UK. Routinely the clinical details of all patients 
undergoing PPCI in West Yorkshire are entered and stored into NHS clinical databases. Information 
obtained from these databases is used (in a non-identifiable format) for audit, service evaluation 
(clinical governance) and for improving/developing clinical care via monitoring of trends and 
outcomes. This information may be used locally, regionally as well as nationally for these purposes.  
Some of this information is in the public domain, e.g. ‘Treatment of heart attack national guidance: 
final report of the National Infarct Angioplasty Project (NIAP)’ published on October 20th 2008 by the 
Department of Health. 
 
This audit will attempt to quantify the characteristics of patients undergoing PPCI at LTHT, 
identifying trends and comparing outcomes against the changes in practice that have occurred since 
01/01/2009. These service adjustments have occurred due to changes in the evidence base and best 
practice guidelines. The PPCI service at LTHT is growing, and therefore there is a need to audit past 






What will the audit tell us? Specify the main objective(s) 
 
E.g. To ensure patients with X condition are being managed in accordance with Trust guidelines 
 
The aim of the West Yorkshire Primary Percutaneous Intervention Outcome project (WY-PPCI 
Outcome project) is to characterize a population of unselected, consecutive patients undergoing 
percutaneous coronary intervention in an acute setting in terms of outcomes of clinical care. Because 
angioplasty technology is constantly changing and developing, as are the drugs available to treat heart 
disease, it is important to evaluate these changes in clinical practice in a large unselected patient 
population, to understand how change impacts on clinical outcomes and patient survival. If we are to 
assess the long-term effectiveness of this intervention we require long-term surveillance in the format 
of an unselected consecutive registry. The establishment of the WY-PPCI Outcome project will enable 
us to examine the changing trends both locally and regionally. 
 
In addition to studying survival following a heart attack, we want to examine other important 
cardiovascular outcomes such as the need for further revascularisation i.e. Angioplasty or Bypass 




3. STANDARDS/EVIDENCE BASE 
 
Practice will be compared against NICE guidelines 





 Sample size 
 
We aim to collect data on all patients in Yorkshire that have received PPCI in Leeds.  Currently, this is 
approximately 1,000 patients per year.  Therefore our total sample size will be approximately 4000 
patients. 
 





All patients undergoing Primary Percutaneous Coronary Intervention at the Leeds General Infirmary 
are potentially eligible for inclusion.  
 
Exclusion Criteria 
Patients less than 18 years of age 
There are no further exclusion criteria  
 
 How will the data be obtained 
 
Data on all patients treated by PPCI at the LGI will be collected from local and regional sources, 
including: 
 Electronic clinical information systems 
o Cardiobase 




 Patient notes 
 Records kept by local departments 
o E.g. transfusion records 
 
(Please note that the above systems refer to those at LTHT - the district hospitals are expected to have equivalent systems) 
 
The audit will require the collation of existing information only. No primary data collection will be 
conducted. Data will be entered into a secure bespoke database held within LTHT. 
Patients will be identified by experienced nurses working within the Cardiovascular Research 
department, using the Cardiobase system.  
 
For those patient who are referred for PPCI treatment from a district general hospital (or bypass 
their local hospital and are brought directly to LTHT), it may be necessary to obtain data from their 
local hospital - up to 12 months post procedure. This will allow us to capture outcomes data on all 
patients undergoing intervention. Although it is anticipated that this will be a demanding task, a high 
proportion of patients fall into this category - and therefore must be included to make this audit 
robust. We will therefore require access to clinical systems and/or patient notes at the following 
locations: 
 Calderdale & Hudderfield NHS Foundation Trust 
 Airedale NHS foundation Trust 
 Bradford Teaching Hospitals NHS Foundation Trust 
 York Teaching Hospitals NHS Foundation Trust 
 Harrogate and District NHS Foundation Trust 




Please see Appendix A for a list of data items that will be required for all patients. Patient identifiers 
will be kept - to allow us to link the various pieces of information obtained from different sources. 
Data will be anonymised before it is released to the analysis team. 
 
 
Description of methodology should be sufficient to allow the clinical audit to be replicated by 
someone who had no previous involvement or knowledge of it. 
 
The WY-PPCI Outcome project will compare the clinical outcomes of patients undergoing PPCI up to 
12 months post procedure. Data to be collected include death, hospital admissions including any 
further cardiac events and/or revascularization, and current medication. All data will be sourced from 
routine medical records. The patient will not be contacted. We intend to interrogate Cardiobase, PAS, 
the Results Service, and transfusion records. 
 
As LTHT is a regional provider of the PPCI service, patients from the districts are treated at LTHT and 
repatriated to their local hospital circa 6 hours post procedure. In order for us to capture a full picture 
of the outcomes of our patients – we will require access to patient records at these surrounding 
centres. Approximately 60% of the patients treated at Leeds are repatriated to a District General 
Hospital – and therefore it is very important for us to capture this data. Honorary contracts / letters 
of access will be sought, to enable us to collect key information from these sources. It is also hoped 




Appendix 4: Data items to be collected 
 















Symptom onset date 
Symptom onset time 
Call for help date 
Call for help time 
Arrival hospital 1 
Arrival hospital 1 date 
Arrival hospital 1 time 
Arrive LGI date 
Arrive LGI time 
Discharge hospital 
Discharge date LGI 
Discharge date DGH 










Non Cardiac History 



























First balloon / device date 














Vein graft 1 
Vein graft 2 
Vein graft 3 
Other 
Arterial access 
Arterial access 2 
French size 








TIMI flow pre 
Stent thrombosis 








TIMI flow post 
208 
 
% stenosis post 



























LGI - Post precedure bloods - peak / lowest value 
Peak CK 
Lowest Hb 










% rise creatinine 
DGH - Post precedure bloods - peak / lowest value 
Peak CK 
Lowest Hb 
















Discharge drugs notes 
Outcomes (up to 12 months post procedure) 
Medication 
Aspirin 
Aspirin reasons why not 
Antiplatelet 
Antiplatelet type 











Major bleeding date 
Intracranial haemorrage 
Hb drop >=4g no source 
Intraocular 
>=5cm haematoma 
Access site requiring intervention 
Retroperationeal bleed 
Hb drop >=3g with source 
Re-operation for bleed 
Diagnosis procedure for bleeding 
Surgical intervention for bleeding 
Reinfarction 
Number of re-infarctions 
Reinfarction STEMI (1) 
Re-infarction date (1) 
Reinfarction STEMI (2) 
Re-infarction date (2) 
Unscheduled revascularisation 
Number of CABG 
CABG target vessel date 
CABG non target vessel date 
Repeat PCI - target vessel date 
Repeat PCI - non target vessel date 
Planned revascularisation 
CABG target vessel Date 
CABG non target vessel Date 
PCI - target vessel date 





Stent thrombosis date 














Appendix 6: Documents confirming NHS National Research Ethics Committee approval. 
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